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General Introduction
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I.I. Selective tumour targeting and imaging:
background
1.1.1. General
The development of cancers involves a complex growth cascade of various cell
types, both genetically and phcnotypically. The expansion of clonal cell populations
that are characterized by a proliferation and survival difference over normal cells
defines the evolution of cancer in the body. The change of normal cells into malignant
ones is due to (he accumulation of several genetic changes that influence cell cycle
control; oncogenes such as cyclin Dl, tumour suppressor genes such as the
rctinoblastoma gene, and/or inactivation of p53 gene and DNA repair (e.g. [1,2] and
reviews 13, 4J). A catalogue of specific chromosome aberrations to correlate with
some particular tumour types is presently becoming available.
Because of the acquired genetic instability, tumours may become both genetically and
phenotypically more heterogeneous during evolution (see e.g. [5]). A considerable
variety in cellular architecture is by definition related to intra-tumoural functional
differences (such as degree of hypoxia, acidity). This heterogeneity changes
continuously in area and time during phases of tumour growth (e.g. [6]). It could for
example translate into cell populations with different metastatic capacity and
resistance to treatment.
On the other hand, in the absence of angiogenesis, most tumours would not grow
beyond 1-2 mm' [7, 8). Induction of angiogenesis is mediated by changes in the
balance of positive and negative regulatory molecules released by tumour cells and
also host cells (e.g. [9]). The initial events are local degradation of the basement
membrane and cndothelial cell invasion of the surrounding stroma in the direction of
the angiogenic signalling. This migration step is followed by endothclial cell
proliferation, and subsequently a three-dimensional organization to form vascular
tubes. The quality and functionality of these newly formed tumoural vessels is
different from the normal tissue vessels. This includes differences in cellular
composition, growth regulation and permeability, but also geometrical distribution as
the most obvious characteristics [10-12]. To quote the author of a review: "...
ma/zg/ki/if /umours »Wuce a verifaft/e Afe</«ja's /iea<i o/ vessel jupp/v/ng fAe
growing core o/ma/ignarif ce//5".
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For many tumours a mixture of viable cells is present close to these irregular vascular
structures, with necrotic cells beyond an adequate oxygen gradient from the blood
vessels, and cells in sub-optimal condition in-between. As such the vascular system
dictates the distribution of viable dividing cells, potentially viable cells, and dying
necrotic cells (see Figure 1.1).
Anoxk Nfcrotic Cell«
Chronically Hypoxie
Viable (ells
Figure I.I: Car/oon /mficaf/>i£ f/ie sfringen/ rWa/io/u/wp frf/ween r/i^  /?r««flcf a*
f/ie/unc/iona/ <7iW/ry o/Wood VMJWJ ant/ f/ie ojrvgf/tafi^n sf«/M.v «//uw««r cW/.v,
o//r>/>aWa, a/iau'a am/ ce// dear/i (redVavwi/ro/n
Solid tumours thus reveal chronic hypoxic areas that arc heterogeneously distributed
within well-perfused areas, and which can reside even within a distance of about 120
urn from a vessel with sufficient blood flow. Of at least equal importance is, due to
temporally closing and opening of blood vessels, the presence of cells that are thus
acutely hypoxic, eventually up to several hours.
The strategy of the presently available 'conventional' cancer therapies (with the
exception of surgery), such as radio- and chemotherapy, is related in a major way to
the increased proliferation rate of the malignant cells as compared with their normal
counterpart. These treatment modalities, although effective for a broad range of
tumours, have however been shown not to be cancer cell selective. Regarding
radiotherapy, it is the locally surrounding normal tissue structures that limits the total
dose to the tumour. With chemotherapy the drug dose limitation is dictated by the
rapidly dividing stem cells of the gastrointestinal epithelium and bone marrow, or by
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organ-specific toxicity related to drug accumulation and metabolism (e.g. liver
toxicity with 5-fluorouracyl anti-cancer treatment).
Of equal importance is the increased expression of multi-drug resistance genes, that is
metabolic adaptation to inactivate drugs (e.g. review [13]). Recent insights into
tumour biology reveal an increasingly complex picture of cell and molecular
processes that interplay with their micro-environment. Various strategies are under
investigation to exploit the differences between the malignant and the normal cells at
the molecular level (such as pS3 status, tumor suppressor genes, signal transduction
pathways) as well as differences in the tissue physiology (e.g. oxygenation status).
Furthermore, the possibility to use these differential characteristics may show certain
advantages for treatment [14, IS]).
These intermingling yet complex characteristics of tumour growth, parallel vascular
expansion and measurements of hypoxia are related to the present thesis and are
explained in detail in the next sections. A concise outline of the investigations is given
just after the references to this introduction (on pages 55-57).
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The improvement of methods and technologies in laboratory and clinical cancer
practice has allowed researchers to again tackle observations that were made and
questions that were posed in the first half of the 20'* century and to assess in depth
several anti-cancer treatment modalities based selectively on tumour micro-
environment characteristics.
To recount in brief, some major questions relate to
(1) the pathway of blood vessel recruitment and expansion that allows further
tumour growth.
(2) the distinct differences in structural morphology and functionality of tumour
vessels as compared with normal tissue blood vessels.
(3) the relationship between the aberrant intra-lumoural veneU and the
heterogeneous condition of tumour oxygenation and cellular metabolism,
(4) hypoxia as a potential target for adjuvant therapy in individualized anti-cancer
strategics,
(5) the appreciation of these tumour micro-environmental pathways using
molecular immunohistochemistry and the introduction of non-invasive
imaging techniques.
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1.1.2. Tumour vascular status
The development of blood vessels from an existing vascular network, defined as
angiogenesis, plays an important role in embryonic life and physiological repair
processes. Angiogenesis is also a major part in the development of various diseases
such as diabetic retinopathy, but more so during growth of neoplastic tissue.
Otherwise, in fully developed normal tissues and organs, vascular expansion is
unnecessary and therefore endothelial cells divide rarely [16]. The biology of
angiogenesis still remains incompletely understood. A variety of methods have
contributed to our current understanding of angiogenesis and allowed the
identification of several factors that control its regulation (reviewed by [17-19]).
Among the vascular mediators arc the well known polypeptides acidic and basic
fihroblast growth factor, the family of vascular endothelial growth factors, angiostatin
and endostatin, as well as angiogenic cytokines. Expression of some of these
angiogenic growth factors is mediated by the transcription factor hypoxia inducible
factor 1, a hctcrodimcr in which the alpha subunit is unstable in the presence of
oxygen [20]. The release of diffusible angiogenic factors, i.e. the switch to an
angiogenic phenotype [9, 21-23], stimulates endothelial migration and proliferation
with the subsequent growth of capillary tubes in vivo. Vascular maturation, namely
the recruitment of pcricytes or smooth muscle cells, is the final process in the blood
vessel development, yet to a major extent absent in malignancies. Again, this final
vessel remodelling that should result in a mature and functionally stable capillary, has
become an area of additional research [24],
To acquire the trigger for the angiogenic process, oncogenes and tumour-suppressor
genes in conjunction with the development of hypoxia play an important role next to
cell-cell and cell-matrix interactions, involving members of the integrin family as for
example Oyß.i ( rg. [25-27]). Finally also macrophages, recruited through the tumour
cells' production of chemotactic factors, seem involved with the initial part of the
angiogenic process.
This formation of new blood vessels seems, together with branching, crucial for the
growth and persistence of primary solid tumours and for the initiation and survival of
their eventual metastasis at distant sites [28, 29]. Support for this important
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observation has been offered in the seventies/eighties by various research teams using
different in v/vo tumour models and techniques, such as with tumours implanted on
the chorioallantoic membrane of the chicken egg. in the rabbit eye (cornea or anterior
chamber) or in transgenic mice (subcutaneous, or orthotopic for example in the
pancreatic islets). Also in human tumours, both (a) the pre-vascular phase that defines
poor or no angiogenic activity with inherent very slow or no tumour growth and (b)
the neo-vascularization phase during which rapid tumour growth and increased
probability of metastasis are evident, has been documented, for example with 1/1 .W/M
carcinoma of the cervix [30] or with cutaneous melanoma [31 ].
The fact that the vascular network of tumours is known to differ from that in
normal tissues (see for instance the elegant work of Koncrding f/ a/. (II) and
references therein, and [32]) highlights the potential therapeutic benefit that should be
obtainable from such an anti-cancer treatment approach. Tumour Mood vessels are
more tortuous, show artcrio-venous anastomoses and blunt ends; tumours have
vascular plexuses with vessels having 'capillary wall' structure with however a wide
diameter and large inter-capillary distances (Figure 1.2, illustrating some of these
features in for example a colon carcinoma).
Figure 1.2: Sca/winj? efcefron microjccyrv o /a corrosion cos/ o//ne wwcM/ar .Jfrittrfu/r
o /a co/on carcinoma: arrow-Zita^r j>u/ica/? WM/M «ufo; /n* variai/7/ry in </uim£fer «
a n j arrow*
Growing capillaries are furthermore characterized by fragmented basement
membranes and therefore they are leaky [33, 34]. Additionally, the assessment of
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cndothelial cell proliferation in various experimental and human tumours
demonstrated a large difference in proliferation as compared with endothelium in
adult normal tissue vessels [16, 35, 36]. The potential doubling time is less than a
week for tumour blood vessels, but months or even years for normal tissue vessel
expansion; Denekamp and Hobson [16, 37] showed a huge increase in labelling index
of cndothelial cells in tumour vessels.
Conceptually, the blood vessel-based approaches should be applicable to numerous, if
not all, types of solid tumours because they rely on vascular expansion for continuous
growth. Yet, it should be kept in mind that there is not a 'tumour-type-specific'
structural vascular system, either in the morphological and functional aspect
(discussed by e.g. [11]). Neither is there a standard cndothelial labelling index, not
within a single type of tumour, nor within tumours of different histology; and neither
docs a correlation exist between the proliferation index of the capillary endothelium
and the growth rate of the tumours [35].
A) NORMAL TISSUE
BLOOD VESSEL
anglogcncsl*
Inhibition
B) TUMOUR
BLOOD VESSEL
MgtogrMtb
Inklbllloii
VASCULAR TARGETING
Figure 1.3: Tutu cartoon (/virf/v
<in'fy-c/iirrfrt/ jf/w/rjfv in <jnfi-<.'a
/rvr/ o/( /) rrfracW/u/cir mflfn.v </ig?.tfion. (2
/ JS/) i7/i«fra/M f/i* fcroadVr Ay/x>fArrica/
n j f - < . ' a / i f ? r f r v < i / m ? n f . L f / f p u r / : i n / i i 7 > f / i o n / r ä
« / / migrarion and"/jro/i/<rra/ion,
The impact and the conditions of the angiogenesis process during solid tumour
growth have given rise to a major interest in these tumour vessels to serve as a direct
target. This idea has been elaborated by the respective pioneers to propose anti-
angiogenesis [29] and vascular targeting [37], as illustrated in Figure 1.3. An arrest
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of vessel growth or a deliberate and permanent occlusion of existing tumour vessels,
respectively, will induce tumour growth arrest and an avalanche of tumour cell death.
/.7.2.6.
The rapid intra-tumoural cndothclial proliferation however, that has never
been identified in any unstimulatcd mature normal vessel, has obviously triggered
various anti-angiogenic strategies (reviewed by [ 18, 39, 401).
Some of the more promising agents for clinical testing are :
a) naturally occurring inhibitors of angiogencsis, ?.#.
thrombospondin, endostatin, angioslatin, bactcricidal/pcnncubilily-
increasing protein;
b) neutralizing angiogcnic peptides, or those binding their receptors,
r.;. antibodies to fibroblast growth factor (FGF) or vascular
endothelial growth factor (VEGF), suramin;
c) agents that interfere with the extracellular matrix, e.g. matrix
metalloprotease inhibitors;
d) anti-adhesion molecules, e.g. anti-intcgrin oußi;
or cytokines, e.g. intcrleukin 12, tumor necrosis factor alpha
(TNFa);
e) specific inhibitors of endothelial cell proliferation and migration,
e.g. the fumagillin analogue TNP-470, thalidomide.
Various natural inhibitors, such as the multimodular protein thrombospondin-1, were
shown to turn off the angiogenic activity when over-expressed and to reduce tumour
growth (e.g. [41]). The administration of the more potent endogenous vessel growth
inhibitors angiostatin and endostatin not only suppressed the growth of the primary
tumours but also their metastases, as shown with xenografted human tumours in mice
[42-44]. Other compounds with angiogencsis inhibitory characteristics (interfering at
different levels of blood vessel formation) have been synthesized during the last
decade. For example, SU5416, selectively binding tyrosine kinase receptors (blocks
the phosphorylation of Flk-I induced by VEGF) was shown to specifically inhibit
sprouting through endothelial cell apoptosis and to influence growth of various
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tumour types (e.g. [45, 46J). The use of anti-VEGF antibodies (Avastin) or inhibitors
of FGF-2 expression and activity has been demonstrated to substantially impair
angiogencsis and reduce the tumour growth rate [47, 48]. Saturation of the integrin
Gtvßj-receptor with the use of the monoclonal antibody (Vitaxin) inhibits angiogenesis
by inducing endothclial cell apoptosis [49]. Novel inhibitors, displaying a
simultaneous interference with several steps of the blood vessel formation (such as the
recently developed peptide Anginex), or endogenous proteins with strong anti-
angiogenic activity at dose levels without the occurrence of systemic toxicity, are
currently under investigation [50, 51 ].
The well-known TNP-470 (AGM1470), a synthetic derivative of fumagillin, strongly
interferes with cndothelial cell growth and inhibits vessel expansion. This occurs
seemingly ihrough the inactivation of type 2 methioninc aminopeptidase activity [52,
531, and inhibition of cyclin-dcpcndent kinascs [54]. Others demonstrated the
cytostatic activity of TNP-470 to be related with a specific late G| cell cycle arrest
[55, 56]. /« vifro data showed inhibition of both proliferation and migration of
endothclial cells; and in v/vo activity was appreciated as significant growth delay in
several tumour types [57-60]. Importantly, not only did TNP-470 inhibit growth of the
primary tumour but also to some extent metastasis development [61, 62].
To resume, based on these //» v/Vo studies it became obvious (i) that angiogenesis
inhibitors can be very active as a selective anti-tumour agent, (ii) that their use
eventually may result in sustained tumour growth inhibition (characterized by a
balance between proliferation and apoptosis of tumour cells), if a continuous drug
presence can be obtained, (iii) that anti-angiogenic compounds seemingly do not
induce drug resistance, as registered during repeated treatment [63-65].
Accepting (hat continuous tumour growth inherently requires additional blood vessel
formation, it is of interest to evaluate the efficacy of an angiogencsis inhibitor at
various defined tumour sizes. This aspect has been assessed in the present thesis
research.
Based on the fact that a relatively high rate of endothclial cell division exists in
the tumour and that several chcmothcrapeutics act on cycling cells only (interference
with DNA replication), it may be appropriate to consider an anti-angiogenic action of
such drugs. Effects on tumour blood flow have been described by Murray and
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colleagues, when melphalan was used in the treatment of a mouse sarcoma [66]. An
anti-angiogenic effect was observed during the treatment of mouse Lewis lung
carcinoma or LI210 leukemia with cyclophosphamidc. applied as a repeat-dosing
schedule without interruption; an efficacy that was further improved through the
combination with TNP-470 (67). Similarly. Klcment and colleagues demonstrated the
capacity of 'metronomic' drug dosing with xenografted human neuroblastoma und
low-dose vinblastine [68].
The prc-clinical studies indicated that most of these anti-angiogenic compounds
are active at doses not associated with treatment-limiting side-effects in the hculthy
tissues, as is most often the case with classical chctnothcrapcutic drugs. This tact,
together with the selectivity towards tumour cndothclium has emerged into their
testing in phase III clinical studies (see review [69]). The variable success that has
been obtained so far is likely related to the much broader variation, and sometimes a
low level, of the angiogenesis status in human tumours as compared with the rodent
tumours [70]. Also the large variability of the process (both molecular and
morphological) within tumours of the same type, and the fact that in phasc-I-II large
tumours inherently are evaluated, may add to the lack of overall benefits from anti-
angiogenic treatments. However, their main clinical future, certainly as a single
agent, will probably not lie in massive tumour cell kill and regression, but rather in
preventing expansion of small-sized tumours and eventually inhibiting the metastasis
formation. Combination treatments involving angiogenesis inhibitors and for example
radiotherapy or vascular targeting agents should be at the forefront. To some extent,
this aspect is part of the present thesis research.
/./.2.C. Vascu/flr tariert/ig
In contrast with the anti-angiogenesis strategies that aim to arrest new vessel
growth, the vascular targeting concept in its 'pure definition' consists attacking the
existing intra-tumoural neovasculature. Given the existence of an aberrant and
immature vascular system in tumours, it is obvious to introduce strategies that take
advantage of these aberrations (some examples are lined-up in Table I.a).
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Table I. a
Vascular targeting :
e.g. - compounds such as tubulin interfering agents (combretastatin A-4,
ZD6126,...)
• hyperthermia
- photodynamic therapy
Encapsulated drug delivery :
*•£• " cytotoxic drug-containing (Stealth™) liposomes
Receptor-based gene therapy :
e.£. - a, ßj integrin
• Flk-1
The aberrant morphology, and likely also the altered functionality of the tumour
vessels, render them more susceptible to the vascular targeting agents. The endothelial
cells are directly accessible to the circulating vascular targeting agents. Since several
thousands of tumour cells rely on a single capillary for their oxygen and nutrient
supply, even a limited damage and reduction of the vascular structures will result in
an avalanche of tumour cell death.
From the late seventies onwards, the at-that-time-period novel anti-cancer
therapy, /ly/vrfArrmia that aims to deliver localized heat, was shown to affect tumours
by damaging differentially newly formed vessels as opposed to normal vessels [71].
This tumour vessel damage may be appreciated by endothelial cell lethality, increased
vascular permeability and reduced blood flow. Although a therapeutic window could
be set forward, at least for some tumour locations, the broad use of hyperthermia was
and still is hampered in clinical practice by the lack of methods to administer and
monitor deep heat without critical normal tissue damage.
In parallel with hyperthermia, the activation of a systemically administered non-
toxic compound by visible light to release cell-killing activated oxygen species,
termed /»/wftx/ymimir f/ifrap.v (PDT), was investigated for its anti-tumour activity.
Similar to hyperthermia, endothelial cell damage (separate from direct tumour cell
kill) with subsequent vessel permeability changes as well as blood flow alterations.
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were documented in various tumour models (see r/j. |72. 731). Various cellular
targets for photodynamic activity have been described, with disruption of
mitochondria! integrity as the most important one [741. In (he broad context of tumour
vascular targeting, it is of interest to mention the impact of nitric oxide inhibition in
the PDT-induced vessel damage and subsequent anti-tumour efficacy [75]. Until now,
the use of PDT remains restricted to the external treatment of superficial tumours or
as an intra-operative therapy of tumour remnants after tumour resection (<•./?. (75]).
Prc-clinical research in PDT is ongoing to broaden the therapeutic potential bused on
an improved differential efficacy towards (he tumour versus the normal tissues at risk,
with the use of more selective and potent photosensiti/ers [76. 77].
More recently, "c/wm^ra/jv" has been discussed as being active against
tumours by affecting the intra-tumoural vasculaturc to some extent. More evidence of
a combined direct but also indirect (vascular damage-mediated) tumour cell kill from
the use of cytoloxic drugs was presented by the Auckland-New Zealand research team
[78]. They documented the vessel damaging capacity of vinblastinc and colchicine in
a mouse colon adenocarcinoma, by describing the rapidly induced extensive
haemorrhagic necrosis that is the consequence of acute blood vessel collapse.
Reductions in blood flow of rodent tumours from the administration of vinca alkaloids
and flavone acetic acid (FAA) have been confirmed in parallel studies (r/j. [79, 80)).
Regarding colchicine, already as early as the thirties, vessel-mediated anti-tumour
activities were strongly suggested (not really 'proven') in various rodent tumour
models (nicely reviewed by Ludford [81]). These clear-cut experiments demonstrated
a highly similar vascular damage-mediated anti-tumour activity to the one observed in
more recent experiments with FAA and TNF-a [82]. Specifically, the publication of
the latter group, that involved a rodent subcutaneous colon adenocarcinoma and the
intramuscular EMT-6/Ak mammary carcinoma, did add conclusive information about
the involvement of reduced blood flow and vessel perfusion, respectively 15 minutes
or 3 hours after a single FAA injection [83]. Seemingly, activity may be dependent on
tumour type (tumour site?) in that study, because the poorly vascularized EMT-6/Ak
spheroids implanted in the peritoneal space were in that study shown to be much less
responsive.
Notwithstanding the various promising /« v«Vo rodent tumour investigations,
these compounds were not at all equally successful in clinical trials [84, 85], and
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analogues with an improved therapeutic ratio were searched for (e.g. [85]). Regarding
FAA for example, a structural analogue 5,6-dimethylxanthenone 4-acetic acid
(DMXAA) has been synthesized, with increased anti-tumour activity in rodent tumour
models [86, 87]. The activity of the acetic acid compounds seems, apart from
involved immunomodulation, mediated mainly by TNF-a [82, 88]. With the use of
DMXAA (as opposed to FAA), TNFa seems however differentially expressed in
favour of tumour tissues as compared with normal tissues [88, 89]. Separate from any
possible pharmacokinetic explanation, activity was shown for most if not all
experimental tumours at drug dosages that were very near the maximum tolerable
dose (MTD) for the tumour-host systems under investigation. Regarding the taxoids,
research has demonstrated inhibition of endothelial cell motility during tumour-
induced angiogencsis through microtubule stabilization and induction of apoptosis,
which was observed independent from cytotoxic tumour cell activity, (e.g. [90]).
However, apart from the potent anti-cancer properties, these drugs also exhibit
treatment-limiting side effects. Novel, second-generation compounds are being
developed (e.g. [91]).
Separate, but within the same time-frame as the DMXAA studies, tubulin-
binding compounds of the combretastatin family, isolated from the Com/wtam
caj^ runi tree [92], have been introduced and tested for activity [93-95]. Combretastatin
is a compound with two phenyl rings linked by a two-carbon bridge. The cis-form of
combretastatin A-4 (see Figure 1.4) was found most potent //i v/fro and was
synthesized for further pre-clinical research, after being phosphated to enable better
water solubility and improved in vivo administration. Anti-mitotic activity was found
with various tumour cell lines, such as P388 leukemia, colon and lung cancer [94, 95].
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The combretastatin A-4 shows a structural similarity to colchicincs [94, 96], hut
possesses a higher affinity for the binding site on tubulin and causes a catastrophic
microtubule disruption [92]. Colchicine affects proliferating endothclial cells in
growing capillaries and shuts down the blood flow in experimental tumours, but only
at systemic toxic doses. Several in wfro studies showing different characteristics of
combrelastatin A-4 phosphate (combreAp) are published. Damaging effects from
combreAp are seen only in proliferating endothclial cells and not in the quiescent
population [97]; condensation of tubulin and rounding-up of the endothclial cells arc
documented [98]. Another important morphological change induced by the drug
includes reorganization of the actin skeleton and the formation of actin stress fibres
[99].
The /« VJVO plasma half-life of combreAp is of the order of 4-9 minutes; but the dc-
phosphorylated active combretastatin A-4 shows two plasma half-lives, with an initial
one of about 15 minutes and a terminal one of 1-2 hours up to 9.4 hours [1(X)J. A
single intraperitoneal (i.p.) injected combreAp dose of 1 /10*** to 1/4"" of the MTD
(being about 1.000 mg/kg in mice) resulted in an early and major blood vessel damage
in small mouse tumours, reflected by decreased blood flow and perfusion as well as
haemorrhagic necrosis typical for a vascular mode of action of the drug (*.#. [97, 101,
102]). The blood flow rate of a subcutaneous (s.c.) transplanted P22 carcinosarcoma
rat tumour was reduced to a nearly undetectable level in less than 6 hours following
26 Chapter I
the injection of 30 mg/kg combrcAp i.p. [103]. With a window chamber study using
the rat P22 tumour model, vascular shutdown and reduced red blood cell velocity
were observed even as rapid as 10-20 minutes after the combreAp injection [97, 98].
Much less and only very transient blood flow reductions were seen in normal tissues
and organs of rats [103]. The mean oxygen partial pressure was largely reduced
throughout the tumour, as measured in C3H mammary carcinoma of mice following
the drug administration [ 101 ].
Some potential mechanisms to explain the acute tumour blood flow and oxygenation
reduction have recently been put forward. Indirect and direct evidence for the nitric
oxide synthasc (NOS) pathway to be involved in the combreAp anti-tumour activity
has been deduced from increased efficacy of the drug when NOS inhibition is
introduced [104, 105]. The very rapid (10-20 minutes) changes in the proliferating
cndothclial cells' area and form [98] add strength to the acute increase in vascular
resistance and blood flow decrease. The increase in vessel wall permeability may
further add, through increased interstitial pressure, to the changes of these functional
vascular parameters. From 30 minutes post-treatment, an increased number of non-
functioning blood vessels was recorded following the combination with a NOS
inhibitor as compared with combreAp alone, an effect which seemed additive only;
the combreAp on its own induced a severe reduction over vehicle or NOS inhibitor.
Such a result involving the NO pathway correlates with the observation of stronger
anti-tumour activity from PDT (also vascular targeting, c^* supra) when NOS is
inhibited 1106].
Separate from the pre-clinical research involving locally growing solid tumour
models, a few rodent tumour studies also demonstrated a strong anti-metastatic action
from combrcAp. Using a Lewis lung carcinoma model; very few lung metastases
were seen after a fractionated drug injection as compared with untreated mice [107].
Grosios and colleagues observed combreAp-induced necrosis in metastatic deposits of
an orthotopically growing human colon tumour in mice [108].
Not only with syngeneic rodent tumours, but also with xenograft models were such
strong anti-vascular effects measured after combreAp treatments. This has for
example been illustrated in a non-Hodgkin lymphoma xenografted to severe
combined immune-defecicnt (SCID) mice [109]. Both single and fractionated
combreAp injections (always to the same total drug dose) resulted in substantial
growth delay as well as increased survival time. Yet, the total combreAp dose used in
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this tumour model was the MTD, making a straight comparison with other rodent
studies difficult.
Several other novel compounds with tubulin-intcrfcring activity have been entered
into pre-clinical research. A combreAp derivative, the serinc prodrug AC-7700
(cleaved by aminopeptidase to the active form) has been shown in v iw to exert very
significant activity against several rodent tumours as well as a human colon
adenocarcinoma [110, 111). Similar to the combreAp mechanism of anti-lumoural
action, a reduction of endothclial cell proliferation and blood flow with subsequent
hemorrhagic necrosis were demonstrated selectively in tumour tissue. The more
recent developments are towards r # . the oral administration of vascular targeting
compounds (for example BTO-956), displaying potentially stronger anti-tumour
activity as combreAp and obviously without the induction of systemic toxicity 1112|.
Since the vascular targeting compounds have been shown to tackle by
definition the developed vessel structures in the tumour and to induce vessel
shutdown with subsequent tumour cell kill through starvation (see cartoon Figure 1.5),
it is of great interest to investigate their activity in large sized tumours. All published
data concern small tumours (most often less than 0.5 cm'). Larger tumours however
inherently have more established immature vasculaturc than small ones, and the anti-
tumour efficacy of the drugs could be stronger. As these compounds are aimed at
killing indirectly the hypoxic tumour cells (resistant to classical therapy), a
broadening of the therapeutic benefit may be expected. This evaluation is a major
theme of the present thesis research.
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All of the /« vivo prc-clinical combreAp studies, as well as with other vascular
targeting agents (such as DMXAA and AC-7700) thus clearly demonstrate massive
necrosis, yet leaving a small but viable rim of tumour cells at the periphery. From this
peripheral tissue, the tumour continued growth if left untreated. Therefore it is
obviously necessary to combine the vascular targeting treatment with a conventional
cancer therapy in an optimal lime-sequence.
Various combination treatment approaches have been and still are being tested with
several rodent tumour models, aiming to broaden the therapeutic window. The
combination of vascular targeting with ionising radiations, with several types of
chemothcrapeutic drugs, and with hypcrthermia, were shown in those studies to
increase anti-tumour efficacy of vascular targeting to different extents. Indeed, a
larger reduction in clonogenic KHT sarcoma tumor cell survival has been published
by Li and colleagues, when combreAp was combined with a single dose irradiation
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[113-115]. A similar improved anti-tumour result has been obtained when DMXAA
was combined with irradiation [116]. Importantly, although until now only evaluated
using (he acute irradiation response in rodent skin (desquamation incidence) as the
endpoint. one report indicates the absence of enhanced epidennal irradiation reaction
when combreAp was added shortly after the single dose irradiation | I15 | . Other
studies involving a rat glioma model or mouse mammary carcinoma, combined (he
combreAp administration with hypcrthermia and indicated an enhancement of (he
heat-induced damage in the combination experiments [117, 118). Combining 5-
fluorouracyl (5-FU) or cis-platinum injections with the combrcAp treatment resulted
in a significantly larger growth delay as compared with cither agent alone 1119, 120).
The potential of an increased anti-tumoural effect from the combination of combrcAp
with irradiation or anti-angiogencsis is part of the present thesis research.
1.1.3. Tumour oxygenation status
Molecular oxygen is an essential requirement for the oxidative
phosphorylation that provides the cellular energy in the form of adenosinc
triphosphate in tissues. To make this provision possible in normal tissues, the macro-
and microvascular branching is in perfect balance thus assuring the necessary supply
of oxygen.
Solid tumours outgrow their blood supply, consequently the vasculature is unable to
meet the demands, and inherently hypoxic and anoxic areas develop.
The emergence of a hypoxia status in solid tumours is majorly the result of (1) the
reduced oxygen-binding capacity of hemoglobin, (2) an aberrant oxygen consumption
gradient, (3) an oxygen diffusion limitation (chronic), resulting from the increasing
distance between blood flow and tumour cells (likely related to some extent to the
interstitial fluid pressure increases), (4) intermittent perfusion-limiting vessel lumen
changes, defined as acute hypoxia and (5) a sluggish blood flow as the result of poorly
organized vasculature. The morphological, structural and functional deficiencies of
the intratumoural microcirculation thus provide an aberrant micro-environmental
condition regarding cellular responses and treatment efficacy (Figure 1.6).
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In the last 10-15 years, a remarkable progress has been made in the
understanding of intrinsic cellular properties that determine radio- and
chemorcsistance. Some of these have been set forward as major characteristics: such
as inherent radiation sensitivity [122, 123], multidrug resistance [124] and gene
amplification [125]. Realizing their importance, researchers have in parallel focussed
on the biochemical and physiological heterogeneity within tumours. These are aspects
that not only highlight the differential condition between tumour and normal tissues,
but moreover critically define the cells' reaction to treatment. Some of these micro-
environmental conditions are the oxygenation status (see in/ra for further description
in relation to treatment and imaging), the extracellular pH and glucose metabolism.
Tumour hypoxia and anoxia play a significant role in determining the
curability of most cancers for all treatment options available in overall-oncology
clinics at the present time.
General Introduction 31
Regarding the hypoxia-relatcd rcu/iafion-frcijtancr aspect. Gray and colleagues
demonstrated already in 1953 the important role of tissue oxygen concentrations prior
to and during the irradiation (126). Lower pO? values relate to a reduced relative
radiation-sensitivity, and thus inherently to a lesser cell kill. Hypoxic cells arc 2-3
times more resistant to ionising radiation than their well-oxygenated counterpart
1127). The absence of oxygen allows for instance a more adequate repair of the free
radicals in critical molecular cell structures such as DNA. which results in a higher
incidence of cell survival. During the last IS years, sufficient data have been
accumulated to underline the importance of the tumour oxygcnulion status. Tumour
oxygenation status has been shown to be an independent prognostic factor for
radiotherapy outcome (local control and discasc-frcc survival) of for example
advanced cervix cancer [128-130] or head and neck cancer [131, 132]. Stadler und
colleagues introduced the description of 'hypoxic sub-volume' in their head and neck
squamous cell carcinoma study, a parameter they consider of great radiobiologicul
value and which takes into account the total number of hypoxic cells [132]. Yet,
compared with the available data describing e.g. median pC>2, the hypoxic subvolume
factor merely confirms the known correlation with treatment outcome and disease
progression. Furthermore, the combination of hypoxic status and hemoglobin
concentration showed a positive relation with treatment outcome for cancer of the
uterine cervix [133].
But hypoxia is also influencing the response o/rwrnowrj fo c/iemo//iffap>>; since most
chemo-drugs target dividing cells, their activity is much reduced and even absent
because cells do poorly or not proliferate in a continuous hypoxic environment [ 134],
Moreover, drug delivery into hypoxic areas is hindered by the inherent (causal
relationship) ill-formed and non-functional intra-tumoural vascularity. Obviously, the
efficiency of radio- and chemotherapy is also influenced by several other biological
factors: such as the distribution of cells within their cell cycle, the mitotic activity and
the pH value (all parameters with potential impact prior during treatment).
The existence of a straight relationship between the severity of hypoxia and the
reduced success of j«rgjca/ rrea/men/ has been demonstrated with for example
advanced cervical cancer [ 135].
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Furthermore, evidence has been gathered on the contribution of hypoxia to
ma/igwanr /?rogr<>s.non, e.g. by influencing signal transduction pathways and the
regulation of various genes such as hypoxic inducible factor (HIF) - la , erythropoietin
(EPO) and p53 (e.g. review [ 136]). Graeber e/ a/ indicated that the hypoxic condition
does provide a selective pressure in tumours for the development of apoptosis-
deficient more malignant variants [137]. Various proto-oncogenes have been shown to
be up-regulated by hypoxia [138]. Increased invasiveness and metastatic potential, to
a major extent a result of loss in apoptotic ability and the switch to a pro-angiogenic
phenotype, arc being documented both in pre-clinical tumour models as well as with
patient studies [139-142].
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The presence of tissue-areas with a low oxygen status is, though not unique (as
for example with the ischemic heart), a major characteristic property of solid
mammalian malignancies beyond an early phase of their growth (e.g. [143, 144]).
The premise that hypoxia influences to a large extent the outcome of many cancer
treatment modalities introduced the necessity to measure these hypoxic cell
populations with retained viability. One of the initial approaches involved the use of
radiosensitizcr adducts such as misonidazole to mark the hypoxic cells (reviewed e.g.
by Chapman [ 145]). These results, and those obtained with other methodologies such
as oxygen electrode techniques, showed both in experimental and in human tumours
that tissue oxygenation is quite heterogeneous within the tumour volume. Areas with
high pOi, comparable with normal tissue, as well as areas with severe hypoxia can be
found; the latter being the result of an imbalance between the supply and the
consumption of oxygen. The fraction of pC>2 values < 5 mm Hg measured in
metastatic lesions is higher as compared with the hypoxic status of the related primary
lesion (e.g. illustrated by Vaupel era/. [146]).
The fact whether the degree of hypoxia rises with increasing tumour size is to some
extent still a matter of dispute, at least for some types of malignancies. For example,
in breast cancer, no such relationship was found by Vaupel er a/, in their small-scaled
patient study [143]. Yet, this 'controversial aspect' could result from inter-tumour
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variability (not the same tumours being followcd-up during growth) or from
insufficient representative intra-tumoural oxygen tension measurements for the
tumours at various phases of growth. It has been pointed out by Fyles and colleagues
that at least S micro-electrode tracks and a sufficient number of measurements per
track may be necessary to minimize the variation within tumours compared with the
heterogeneity between different tumours (130). The data of Vaupel « a/. |I43). as
well as those from Nordsmark and Ovcrgaard (147], contrast the more extensive
breast cancer patient investigation of Runkcl ?r a/. |I48| which shows a clear-cut
association between tumour size (stage T1-T2 versus T3-T4) and oxygen purtial
pressure: larger tumours present with an increased hypoxia level. The presence of an
association between (he hypoxic condition and the size of the tumour has also been
pointed at by Zhao and colleagues using the rat Dunning prostate R3327-H1
adenacarcinoma; their data showed higher pO? values in small tumours us opposed to
large ones [149]. One important consideration: tumour size has definitively been
shown to be highly significantly related to disease-free survival (*.#. 1130, 150-152)).
All these investigations highlight the necessity to incorporate tumour volume in the
analysis of therapy results, and point to the potential impact of the inherent
differences in hypoxic fraction on treatment choice and outcome.
It thus is very important to develop reliable methods for measuring the oxygen level
in tumours. Entire meetings have been dedicated to discussions on the methodologies
to measure hypoxia and the relation of such measurements with the efficacy of
various therapies (e.#. [153, 154]). Well-defined and established assays will provide
patient prognosis and identification of patients whose tumours would be most likely to
respond positively to treatment strategies targeted at hypoxic cells. These hypoxia
measurements are routinely divided into invasive and non-invasive approaches.
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One of the first clinical applicable attempts to measure tumour oxygenation
status m j/ru used polarographic oxygen electrodes (Eppendorf, Hamburg, Germany),
optimised to reduce measurement bias from tissue oxygen consumption at the probe
tip [155]. The evaluation of the apparatus, its validation in patients and the
reproducibility have initially been reported by Kallinowski and colleagues [156].
Since more than a decade, this methodology, be it invasive and necessitating optimal
calibration and multiple intra-tumoural positioning, has proven relatively successful
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for estimating the uxygenation status in several tumour types and tumour locations in
humans. More importantly, these electrode-based oxygenation measurements to some
extent allowed the prognosis of tumour treatment responsiveness, both in terms of
loco-regional tumour control as overall patient survival.
Recently a newly invented fibre-optic monitor "OxyLite" (Oxford company, Oxford,
United Kingdom) has been introduced in pre-clinical in v/'vo research. Light pulses
carried by an optical fibre induce fluorescent pulses of a luminophor incorporated into
a siliconc rubber polymer at the probe tip. The lifetime of the fluorescent pulse is
inversely proportional to the oxygen tension at the tip. A continuous read-out of pO2
can thus be obtained. Without doubt, at least two important advantages over the
Eppcndorf micro-electrode system have been defined. The luminescence-based probes
do not consume oxygen, allowing real-time evaluation of pOi changes at the same
inta-tumoural position, and they provide accurate oxygenation values well below a
pO2 of 5 mm Hg (true radiobiologic hypoxia). This instrument therefore carries a
larger clinical potential. Correlation with other hypoxia measurements, for example
with pimonidazole hypoxic cell labelling and with Eppcndorf electrode measurements
have been made in syngencic rodent and xenografted human tumours (e.g. [157,
158]). Bearing in mind that the two micro-probe devices can not be considered
exclusive on their own, results show that the fibre-optic instrument allows regions
with pOi values less than 5 mm Hg to be more accurately defined.
Other methodologies to estimate the hypoxic condition in tumours are the
biopsy-based immuno-histochemistry staining using bioreductive probes with their
respective antibodies, such as pimonidazole, 7-4'-2-nitroimidazole-l-butyl-
thcrophyline (NITP) and lluorinated etanidazole [ 159-161J. These 2-nitroimidazoles
arc metabolised as one-electron reduction by intracellular nitroreductases;
subsequently the nilro-radical is further reduced in oxygen-depleted environment and
identification of hypoxic cells through the bound metabolites can proceed with the
appropriate antibody. Various pre-clinical and clinical data-sets and peer-reviewed
publications support presently the utility of these staining procedures.
Further refinement to stain (he biopsies and surgical resection materials, frozen or
paraffinized, is ongoing. A recent retrospective cancer patient study combined vesscl-
cndothclial cell staining with a diffusion limited fraction (DLF) measurement
(translating chronic hypoxia at a fixed distance of 120 Jim) to estimate treatment
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outcome, thus aiming to avoid the necessity to inject a bioreductive stain (162). The
DLF measurements seemed to correlate to some extent with the pimonida/ole stained
areas in relation to the blood vessels, but the methodology needs further elaboration.
Begg and colleagues demonstrated with an t'/i vivo rodent tumour the potential to use
deoxyuridine labelling as a marker of pcrfusion-limitcd acute hypoxia |I63). Triple
staining for hypoxia simultaneously with vessel quantity and functionality has been
under investigation in pre-clinical laboratory research using xcnotranspluntcd human
tumours [164]. These data also indicated chronic hypoxia through NITP staining at
increasing distance from blood vessels (stained with 9FI), with not all vessels being
perfused (Hoechst dye uptake). The use of intrinsic markers, such as the hypoxia
inducible factors (HIF- l a and 2a), or the glucose transporters (Glut-1 and Glut-3) und
carbonic anhydrasc IX (CA-IX) both under transcriptional control of hypoxia, is ulso
under investigation both prc-clinical as with patient studies involving for example
head and neck squamous cell carcinoma and cervical carcinoma (r#. 1165-167)).
These results show potential for their application as 'surrogate' markers of hypoxia,
specifically because a significant correlation seems for example present between the
mean vessel density p/us the amount of necrosis and the CA-IX expression (peri-
necrotic staining). The fact however that overlap between the different staining
procedures (including pimonidazole) is not always seen, partly related to f.#.
differentiation between acute versus chronic hypoxia, highlights the need to continue
comparative investigation using various tumour types and sites of growth. All these
studies, for which the techniques appear feasible on their own, definitely point at the
broad intra- and inter-tumoural heterogeneity of pcrfusion and diffusion in relation
with oxygenation status, which seems independent of tumour type, size or location.
Such a heterogenous situation (as for example reflected in the pC>2
measurements) necessitates a correct characterisation of the descriptive parameters,
biological and statistical, as clearly discussed by Thews and Vaupel [168], and the
application of complementary methodologies. Of equal importance is to perform
repeated measurements, at best of the 'undisturbed' whole tumour rather than only
very small parts. The literature offers discussion on how many biopsies or micro-
electrode tracks are necessary to allow a representative evaluation of hypoxia for each
individual tumour. Regarding biopsies, at least 3-4 would be needed, whereas 5 tracks
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would be a necessary number to minimize the influence of variation within tumours
compared with heterogeneity between different tumours (e.g. (130, 169]). These
factors, specifically in view of repetition during treatment, together with the fact that
deep-seated tumours or those near critical structures cannot be assessed, introduce the
strong need of non-invasive methodologies.
/.7J.</.2. Aton-invasive Aypoxia measure/we/ifs
Several possibilities involving imaging techniques have been introduced and
tested for estimating parameters of the tumour micro-environment in a non-invasive
way, specifically related with positron emission tomography (PET) and single-photon
emission computed tomography (SPECT), computed tomography (CT) and magnetic
resonance imaging (MRI).
For example, '*F-fluoromisonidazolc (FMISO) and more recently '*F-
fluorocrythro-nitroimidazolc (FETNIM) and '*F-labeled nitroimidazol-acetamide
derivative (EF3) or '*F-2-fluoro-2-deoxyglucose (FDG) PET are becoming
established clinical imaging techniques to measure respectively tumour hypoxia and
glucose metabolism (e.g. (170-173]). These techniques, based on capturing
annihilation photons from positron-emitting tracers, thus provide information on the
metabolic activity and functional capacity of tumours as a whole as well as regions of
interest, with additionally the possibility to quantify changes in time. FDG PET
measurements of the glucose metabolism, translated as standard uptake value,
demonstrated the differential between tumour and normal tissues and indicated the
prognostic value of this approach (e.g. 1174]).
The use of FMISO and '"i-iodoazomycinarabinoside (IAZA) enable an indirect
(tracer uptake inversely proportional to intraccllular oxygen concentration) estimate of
tumour oxygenation (e.g. [175-177]). Among these tracers, FMISO has been most
extensively studied. The method allows to image approximately the whole tumour and
at the same time to estimate the heterogeneity within the individual tumour, as
indicated in a study concerning various types of malignancies (176]. Despite these
encouraging results, sub-optimal imaging properties have limited the routine use of
FMISO in clinical practice. Research is ongoing to further evaluate and validate the
existing azomycin-nucleosidc markers, to test novel hypoxic cell-specific chelates,
and to define the optimal timing of image-acquisition of maximal hypoxia signalling
(sce«.g. [170, 178]).
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Using contrast-based CT, the oxygenation condition of tumours can be appreciated
indirectly through the measurement of perfusion. This quantitative approach has been
demonstrated elegantly by Hermans and colleagues in head and neck squumous cell
carcinoma; a positive correlation between perfusion rate and local control after
radiotherapy was found [179].
Tumour oxygenation measurements, on the other hand, have also been performed by
using fluorine '*F magnetic resonance imaging (MRI) spectroscopy; they allowed the
evaluation of dynamic changes from baseline oxygenation status when applying
different hyperoxic gasses (r#. [149, 180, 181)). Other MRI spectroscopy methods
involve phosphorus "P and proton 'H (see r/?. review [I82|) which measure tumour
parameters that relate to oxygenation, such as pH. lactate or high energy phosphates
(ATP), with some results found to correlate relatively with Eppcndorf electrode and
fraction of radiobiological hypoxia evaluations in the same tumour model [ 183, 184).
The classical MRI provides the detection and delineation of tumours in the body
[185). The method is based on differences in signal intensity between tumours and
normal tissues related to the water content. Spatial information is obtained by changes
in magnetic Held gradients at specific times during and after radiofrcquency pulses.
MRI enables the use of each point (voxel) in each individual tumour as its own
control, thus providing a longitudinal statistically powerful test of the effects from
treatments. Contrast enhancement techniques have been entered to image the tumour
physiology and micro-environment, such as blood flow and hypoxia, more efficiently.
For example, evaluation of the rate of uptake of gadolinium-dicthylcnctriamincpenta-
acetic acid (Gd-DTPA) is extensively used to estimate tumour perfusion [186], In a
proof-of-principle evaluation involving locally advanced uterine cervix carcinoma, the
use of dynamic contrast enhanced MRI has been indicated to correlate relatively well
with the Eppendorf electrode measurements [187J.
Blood oxygen level dependent (BOLD) functional MRI is, compared to dynamic MRI
methods, an interesting non-invasive approach because no exogenous contrast agent is
necessary. The BOLD effect uses hemoglobulin as intrinsic contrast agent:
oxyhemoglobin has no magnetic properties, while deoxyhemoglobin is paramagnetic.
So, deoxyhemoglobin causes magnetic susceptibility effects that lower T2*-weighted
image intensity; improving blood oxygenation therefore results in T2*-weighted
image intensity increases. It has been extensively applied for the non-invasive
monitoring of cerebral activity upon exercise or external stimuli (e.g. [188-190]).
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Changes in the ratio oxy- to deoxyhemoglobin are translated into signal intensity
changes, and indicate changes in blood and tissue oxygenation.
Evidence that BOLD contrast in tumours is sensitive to changes in oxygen saturation
of blood caused by oxygenation treatment was demonstrated first by Karczmar and
colleagues with a rat mammary adenocarcinoma [191]. During inhalation of 100 %
oxygen or carbogen , large and reproducible changes in T2*-weighted images
occurred. The likely explanation of these changes was that increased oxygen delivery
decreases blood deoxyhemoglobin, resulting in an increase in signal intensity on Ti*-
weighted images. Increases in blood flow, oxyhemoglobin saturation and tissue pOj
are expected to be greatest in tumour regions where oxygen delivery was previously
inadequate to satisfy demand. The T2* changes during hyperoxic breathing were small
in surrounding muscle, providing support for the fact that oxygen-enriched gas is not
expected to significantly increase the oxy- to deoxyhemoglobin ratio in normal
tissues. Through literature screening it is evident that these signal intensity changes,
from the application of a hyperoxic gas, differ among tumour types (e.g. [182, 192,
193)). This observation was not only true for pre-clinical tumour evaluation, but in a
similar way when tumours in patients were evaluated with the MRI [194, 195]. The
methodologies altogether indicate potential predictive power in cancer therapy; they
allow us to estimate the level of hypoxia and its change during and after a specific
single or combined therapy (e.g. [194]).
The introduction of functional MRI in tumour imaging, using gradient echo
sequences, thus offered a major benefit; yet, due to the pulse sequence design, only
one slice through the tumour is measured.
The final part of the present thesis research is aimed to test the feasibility of applying
gradient echo functional MRI with an cchoplanar imaging (EPI) sequence to evaluate
the oxygenation condition of the tumours in total using multiple slices.
The hypoxic condition can be exploited or, on the other hand, can be reduced
to advance additional anti-cancer treatments. Various options (see Table I. b) can be
offered to use the presence of hypoxia and anoxia for the benefit of cancer treatment
and improved outcome.
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Table I. b
Hvpoxia-selective 'bioreduetive' drugs :
e.g. - nitroimidazoles, such as misonidazole and nimoratole
- tirapazamine
- AQ4N
Hvpoxia-based gene delivery :
e.g. • transfection of tumour cells with the HRK-CDasc gene
Hvpoxia/anoxia/necrosis-hased therapeutic protein transfer :
e.g. - anaerobe bacteria, such as nun-pathogenic C/os/rw/ium, with
incorporated CDase or TNFa
Reduction of hypoxia:
e.g. - erythropoictin
- hyperoxic gasses, such as hyperbaric oxygen and carbogen
The principle of using radiosentizing agents, such as misonidazole and etanida/.ole, is
that they mimic the effects of oxygen at the time of irradiation thereby enlarging the
DNA damage. Although proven efficient as sensitizcrs in laboratory tumour models,
their clinical application showed a very limited benefit because of unacceptable side-
effects. Nimorazole, a drug of the same family, but showing little systemic toxicity,
has been used more successfully in a randomised phase-Ill study [ 196|.
Extensively investigated in pre-clinical settings, are the class of hypoxia-activated
(bioreductive) prodrugs (see review [197, 198]). Such compounds require a metabolic
reduction (optimal at low oxygen levels in the tumour) to produce the cytotoxic
agents. Two novel compounds, tirapazamine (SR4233) [199J, which currently is
evaluated in clinical trials (e.g. [200, 201]) and alkylaminoanthraquinonc N-oxide
(AQ4N) [202] show great potential to increase cancer treatment efficacy. With
tirapazamine for example, the combination with either fractionated irradiation, or with
cisplatin, or the 'triplet'-combination resulted in an increased growth delay [203-205].
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With AQ4N, reduced to AQ4 that intercalates within DNA, an important
enhancement of chemo- and radiation-induced cell kill has been shown with rodent
tumours [206].
Recently, experiments have demonstrated several possibilities to use the
hypoxic environment for the transfer of therapeutic proteins selectively to the tumour.
One of these strategies involved the combination of a 'hypoxia responsive element
(HRE)' with the suicide gene cytosine deaminase (CDase), to transfect tumour cells
for a strictly on-site therapeutic activity [207]. Intra-tumoural cytotoxicity, through
the conversion of the systemically delivered prodrug 5-fluorocytosine (5-FC) to the
chemothcrapcutic 5-fluorouracil (5-FU) by the CDase, only occurred with cells in the
hypoxic condition. These data provided a first proof-of-principle of the possibility to
control the regulation of prodrug activation in a hypoxia-selective way. On the basis
of vascular cndothclial growth factor (VEGF) expression under hypoxia, Shibata and
colleagues developed a cytomegalovirus-driven hypoxia-responsive vector which may
allow for improved tumour-selective therapeutic gene expression [208].
In parallel, a bacteria-based methodology to transfer therapeutic proteins has
been investigated [209-211 ]. This idea has found its roots in the pioneering work of at
least two research teams in the fifties-sixties, using non-engineered apathogenic
C/osfnV/;um species [212, 213] and later research using combinations with
chemotherapy [214]. The use of anaerobic clostridia is based on the presence of areas
in tumours that lack oxygen, thus allowing the proliferation of these bacteria
exclusively intra-tumoural. This was not only shown for C/oj/ri<//um feMtyncum [215]
and C7o.vfri</ium .«jcc/iarojMTfcKfy/acerom'cuwt [210] and very recently for C7orfrü/ium
nov>>/-/VT[2l6], but is also well documented for ßi/ü/ofracterium /o/igu/n [217].
The data from our research group (Experimental Radiobiology and Bacteriology,
K.U.Lcuven) indicated absence of a major immune response as well as absence of any
toxicity. Although spores (mctabolically inactive) were detected in normal organs of
tumour-bearing rats, no germination occurred and the spores disappeared from all
organs within a few weeks. Using the C. novyi-WTstrain, devoid of toxin genes. Dang
and colleagues still recorded mortality in their mouse experiments, which they assume
to be related to the tumour lysis syndrome [216]. The application of an appropriate
antibiotic eradicates all bacteria from the rat body (part of this thesis).
Non-pathogenic recombinant clostridia may thus be used as highly tumour-
selective factories to locally produce an anti-tumoural component. There is no need
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for insertion of the gene coding for the therapeutic protein into the tumour cell
genome, and therefore problems involving genomic instability and insufficient
transduction efficiency are avoided. This has been demonstrated for C7<w/ri</iMm
atrfoftury/'ru"» DSM792 recombinant for cither the cylokinc tumor necrosis factor
alpha gene (TNFa) [2l8]or the suicide CDasc gene (part of this thesis: |2I9|). With
both TNFa and 5-FU. severe normal tissue toxicity is present when given
systemically at doses that cause tumour cell death. The bacterial transfer system
circumvents this problem, and. together with the pleiotropic ami-tumour effect of
TNFa (against tumour cells and vasculature) and the bystander effect of 5-FU |22O),
thus offers great potential in anti-cancer treatment combinations. Very recently,
another group presented an in vivo investigation on the use of C7oj/m//'ufn j/wrujfrncs
recombinant for CDase in combination with the prodrug 5-FC (2211. These data
illustrated the sufficient production of 5-FU through (he bacteria-based cn/.ymc-
prodrug system to induce a significant growth delay. The levels that have been
obtained with this system thus should be sufficient to obtain improvement of
irradiation treatments. The potential to find increased radiation efficacy from the 5-FU
presence has been indicated through a theoretical modelling of necessary 5-FU
concentrations [222]. The deduction and calculation, based on 5-FU literature data,
indicates radio-sensitization factors between 1.1-1.2 when bactcria-CDasc-based
conversion efficiency is as low as 1-3 %. The combination with radiotherapy could
improve anti-cancer results, next to the temporal control of therapeutic protein
expression through radiation-induciblc promoters, as elaborated by Nuyts and
colleagues at our research units [223, 224].
The combination of the anaerobe bacteria-based therapeutic gene transfer with
vascular targeting, based on the hypothesis to provide an inlra-tumoural environment
that increases the proliferation of the recombinant bacteria, has been evaluated by us
using combreAp (this thesis research). Dang and colleagues more recently combined
the non-rccombinant C7os/ru//u/n novyi-A/T with mitomycin C and dolastatin, and
showed a stronger 'bacterial' activity against two different tumour types as compared
with either agent alone [216].
More bacterial species are presently being evaluated for the use as selective anti-
cancer probes, either as such or as recombinant for a specific therapeutic protein (sec
brief review [225]). Also stronger promoters such as the glutaminc-synthcta.se gene
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from C. fr?f/er/>ic£(( could advance the expression and secretion of the inserted
therapeutic proteins [226].
Finally, agents that reduce the hypoxic status have been considered to improve
the tumour responses to radiotherapy. The alteration of oxygen delivery to the tumour
tissue has been assessed already in the eighties, including methods such as blood
transfusion or pcrfluorochcmicals administration (^.g. [227, 228]). Using the
pcrfluorocarbon Fluosol-DA, the oxygen-carying capacity of the blood could be
increased several fold. Radioscnsitization with the administration of
pcrfluorochcmicals has been documented (see £.g. review [229]).
Hemoglobin concentration is well known as a prognostic factor for local control in
e.g. radiotherapy of uterine cervix cancer [230, 231] as well as head and neck
carcinoma patients [232, 233]; low levels (<12-I3 g/dl) are positively correlated with
poor local control and overall survival in these and other tumour types.
Erythropoietin (EPO) is up-regulated in response to hypoxia, and stimulates red blood
cell production in the bone marrow, with consequently an improved oxygenation. This
has led to the introduction of recombinant EPO administrations to anaemic cancer
patients, data showing some beneficial effects (e.g. [234, 235]).
Another equally important strategy to improve tumour tissue oxygenation is
the application of hyperoxic gasses (see also section /./..?.d.2. on non-invasive
imaging). The use of hypcrbaric oxygen breathing has initially shown some benefit in
experimental rodent tumours and patients with head and neck cancer [236, 237]; yet,
no confirmation followed [238]. Hyperbaric oxygen was abandoned because of severe
side-effects that occured in some clinical trials (e.g. [239]) and it was time-
consuming, and also because apparently more appropriate hypoxic cell sensitizers
were being introduced.
A more recently tested approach combines the breathing of a mixture of oxygen and
carbon dioxide (classical carbogen = 95% O; + 5 * CO:) in combination with the
administration of nicotinamidc [240]. Its introduction along with radiotherapy was
specifically based on the hypothesis that carbogen and nicotinamidc would target the
chronic and the acute hypoxia respectively to increase tumour cell radiosensiiivity
(*.#. [241, 242]). The use of these agents simultaneously has subsequently been
shown to increase the radiation damaging effect in a variety of rodent tumour models
[154,243-246],
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Based on that demonstrated prc-clinical therapeutic advantage, the concept was
thereafter introduced in the clinic (e.g. (247-250)). An increased oxygenution of
tumours from the use of carbogen breathing with nicotinamidc has been demonstrated
in patients. The strategy of this "Accelerated Radiotherapy with CarbOgcn breathing
and Nicotinamidc" (ARCON) is logical and thoroughly described |I54|: briefly,
introducing a shorter overall radiation treatment time counteracts the rapid
proliferation of the tumour cells, whilst the carbogen-nicotinamide application
sensitises the hypoxic tumour cells. Very promising results have been obtained in
several, however, non-randomi/cd clinical studies using this combination in
conjunction with accelerated irradiation: treatment of stage T1-T4 squamous cell
carcinoma (SCC) tumours of the larynx |24K, 251 ], and patients presenting with large
bulky tumours of the hypopharynx and oropharynx [251] as well as bladder
carcinoma (250). These positive findings however were not confirmed by a phase I/II
study of the EORTC that involved head and neck SCC tumours of various
localizations and late stages [252]. Neither did the EORTC study involving non small
cell lung cancer [253], nor the EORTC trial with glioblastoma multiformc patients
[254], indicate a benefit from the use of ARCON. The selection of tumour type, but
certainly also the localization, has to be rigid to allow further clinical improvements
(c/r supra; and [251 ]). Pre-treatment measurements of the tumour oxygenation status
and response to modulators, specifically in a non-invasive manner, may further help
to sort the 'ideal' patients for ARCON-based treatment (c/r supra: part /./J.</.2.; as
well as for other hypoxia-related combination therapies.
1.1.4. Background-based conclusion
The studies reviewed in the present introductory notes do provide important
information about the intra-tumoural angiogenesis, established tumour vascularity,
and related treatment options (anti-angiogenesis and vascular targeting). They invite
us to broaden research and application in pre-clinical laboratory models to further
advance novel anti-cancer strategics.
Hypoxia-selective cancer therapy has been, based on molecular knowledge
and tools, broadened from the use of specific cytotoxins to the application of gene
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therapy and related methods. The best ways to continue the search for improvement
appear to include agents that increase hypoxia or combinations with irradiation and
anti-angiogenesis.
Generalizations about intra-tumoural oxygenation based on tumour size,
tumour stage, or any other stratification, are not possible. Therefore the need to
encompass the whole tumour volume when investigating the hypoxic status of an
individual tumour, rather than a few biopsies or a single slice, is a stringent necessity.
Nevertheless, complementary evaluations of hypoxia remain a priority as well in
laboratory animal as clinical cancer research to define the most optimal therapy for
eliminating tumours.
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1.2. Outline of the principal investigations
As may be obvious from the foregoing introductory notes, information on the
tumour micro-environment, and its changes during tumour growth, has accumulated
during the last 10-15 years.
Separate from the established anti-cancer treatments that directly target the
tumour cells, therapy has been broadened to additional strategics related (o aspects of
the tumour micro-environment. Among the latter are those (hat utilize compounds that
interfere with the angiogenesis process and those that are selectively directed at (he
hypoxic tumour cells. Novel therapies have been elaborated during the last decade.
Among these are the 'clinical potential' vascular targeting drugs (such as flavonoid
derivatives and (ubulin-binders). cither as a single agent, or more promisingly, as un
adjuvant to other treatments.
Also virus- and liposome-based gene therapy, targeting either tumour-specific
antigens (e.g. EGFr or c-kitr) or micro-environmental conditions (e.g. glucose
deprivation), has become a promising anti-cancer development. Alternatively,
engineered non-pathogenic bacteria are being investigated as a delivery system for
therapeutic proteins, such as the cytokine TNFa and the suicide protein CDasc, to the
solid tumour. Among these bacteria are non-pathogenic obligatory anaerobic
clostridia, shown to selectively localize and proliferate in severely hypoxic and
necrotic tumour areas.
In parallel, the need for a non-invasive visualisation of the metabolic and
proliferative quality of the tumour micro-environment, including deep-seated and
critically positioned malignancies, has evolved in the exploration of various imaging
techniques (such as CT, PET, MRI). Using these scanners to evaluate, not only the
morphology, but more importantly the functional quality of tumours before, during
and after treatment, may allow the selection and guidance of an optimised therapy.
The objectives of the present pre-clinical in vivo investigations involved the
use of tumour vascularity and hypoxic/anoxic status for the benefit of selective
therapy and for non-invasive diagnosis. The basis for the various hypotheses and
related questions is presented in a diagram (Figure 1.7)
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Hypothesis and questions that have been addressed specifically:
It is hypothesized that the efficacy of blood vessel-related treatments
may depend on the tumour volume at the time of application.
We therefore studied
a) the effect of anti-angiogenesis using TNP-470 in rhabdomyosarcoma
tumours of different sizes;
b) the potential of vascular targeting using combretastatin A-4
phosphate (combrcAp) to exert activity in tumours of different sizes;
with (wo related questions: (i) is it possible to evaluate the acute vessel
damage in a clinical applicable setting (radiological angiography)?; and
(ii) what would be the outcome of combreAp repeat-treatment in relation
to tumour size?
Based on the hypothesis that the tumour rim (not affected by combreAp
treatment because of the presence of peripheral mature host vasculature)
consists of well-oxygenated tumour cells, can a benefit be obtained from
combining combreAp vascular targeting with ionising radiation?
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Based on the hypothesis that tumours, regrowing utter the initial
combreAp treatment, will be characterized by blood vessel expansion,
we added the anti-angiogenesis TNP-470 treatment u( a prc-sclectcd
timing to evaluate the potential benefit?
With the knowledge that combreAp induces a major proportion of
necrosis, irrespective of the tumour volume at treatment, would its
combination with an anaerobe bacteria-based transfer of a therapeutic
gene selectively improve the tumour colonisation und the expression of
these proteins?
Considering the potential of magnetic resonance imaging in cancer
screening, we aimed to evaluate a non-invasive fast functional MR-
mcthodology (with an echo planar imaging sequence) for the assessment
of tumour oxygenation. This should enable tumours to be selected which
might be preferentially responsive to the above mentioned treatment
options.
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Summary ' '
Potential anti-cancer therapy with the fumagillin analog TNP-470 was investigated in the
present project using subcutaneously growing rhabdomyosarcomas in rats. Specifically,
influences of different tumor sizes at the start of treatment as well as dose/schedules were
evaluated. The results show a significant (pSO.Ol) reduction of the growth rate, even for
relatively large-sized (> 7 cm') tumors, when 50 mg/kg TNP-470 was used every other day
for up to 3 or 5 injections. With 30 mg/kg TNP-470 injections, effects were seen only with
tumors measuring less than 7 cm'. The histologic examinations demonstrate an increase in
necrosis, both in the centre and in the peripheral part of TNP-470-treated tumors.
Overall, both tumor volume and drug dose determine treatment outcome with the rat rhabdo-
myosarcoma. The results suggest that angiogencsis inhibitors could represent a valid
component in the treatment of progressive tumor growth.
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11.1.1. Introduction
To support cell survival and growth, a tumor relies on neovasculan/ation and
thus on endothelial cell proliferation | l ) . The consequent effect of angiogenesis on
tumor growth and the establishment of mctastascs is well documented. During ihc last
two decades much attention has focused on the development of anti-angiogenic
compounds. One such inhibitor of angiogenesis is the fumagillin analog TNP-470
(AGM-1470). The compound has shown in vivo anti-angiogenic effect in various
tumor models (rg. [2-5]) and is currently in phase I/II clinical trials for the treatment
of a variety of solid tumors. Although the full mechanism of the anti-angiogenic
activity has not yet been clarified, important inhibition of proliferation and migration
of endothelial cells and of capillary tube formation has been observed (r/j. (6,7]).
The present report describes the anti-tumor effect of TNP-470 on the
syngeneic rhabdomyosarcoma in rats. This poorly differentiated tumor has been
induced following irradiation [8]. Our study specifically focuses on the relation
between dosing/scheduling of TNP-470 and the size of the tumor at the start of the
treatments. Tumor growth delay and histological appearance as well as the profile of
the major side effects was assessed.
II. 1.2. Materials and methods
Male WAG/Rij rats, aged 12-14 weeks and weighing about 280 g were bred in
our conventional animal housing facility. The rats had free access to water and food
during the total experimental period. The syngeneic rat rhabdomyosarcoma was
implanted subcutaneously (s.c.) in the lower flank of anaesthetised animals using
tumor pieces of about 1 mm'. This experimental tumor model has been firmly
established in radiobiology research and described thoroughly in a vast number of
publications (f.g. [8-11]). Briefly, the rhabdomyosarcoma originated in the jaw
musculature of inbred WAG/Rij rats that received total body irradiations. From this
irradiation-induced tumor, a cell line was established using the classical procedures,
giving reproducibly growing tumors in WAG/Rij rats.
The TNP-470 was received from Takeda Chemical Industries (Japan). For
each experiment, the TNP-470 solution was freshly prepared in 10% cthanol and 5%
arabic gum in saline. Control rats were treated with the vehicle only. Volumes for
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injection varied between I and 1.5 ml (depending on the drug concentration and
animal weight). Animals were injected s.c. in the neck region distant from the tumor.
Several TNP-470 administration schedules and dosages were evaluated. Either 30
mg/kg or SO mg/kg were given 3 or 5 times, with 2 day intervals between the
successive injections. In the case of the 30 mg/kg dose, the effect of a single TNP-470
treatment was also evaluated.
Treatments started when tumors reached the predetermined volume, which
were cither < 3 cm', 3-7 cm' and >7 cm' and referred to as small, medium or large,
respectively. Measurements of the tumor volumes were regularly performed with a
calliper. The volume (V) was calculated according to the standard procedure for
ellipsoid growth : V = (a x b x c) x Jl/6 (a = length ; b = width ; c = thickness) expressed in cm'.
To enable an easy display of the anti-tumor effect, the curves representing the
measurements of TNP-470 treated tumors were normalised with respect to the control
(vehicle only treatment) tumor»; Starting volume« of the various TNP-470 groups
thus superimpose the control growth curve at the equivalent volume. This is indicated
in all graphs by an arrow. Student's t-test was used for comparison of the tumor
growth curves.
The histologicul characteristics of TNP-470 treated rhabdomyosarcomas were
examined and compared with tumor sections of vehicle only treated rats. The pieces
were selected from both the center and the periphery of the tumor separately. They
were fixed in Bouin followed by a 10% formalin solution and processed using the
routine histologic techniques. Hcmatoxylin-eosin and periodic acid stained sections
were evaluated by light microscopy.
The experimental procedures were approved by the "University of Leuven (KUL)
Animal Care and Use Committee" in compliance with European Guidelines.
II. 1.3. Results
The effect of TNP-470 on the growth of the s.c. transplanted
rhabclomyosarcoma was evaluated at different tumor starting sizes and drug doses.
The small (< 3 cm'), medium ( 3 - 7 cm') and large (> 7 cm*) sized tumors showed
different responses, with TNP-470 either slowing or even inhibiting tumor
progression.
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With small tumors the effect of the 5x50 mg/kg TNP-470 treatments was significuntly
more prominent than for the 5x30 mg/kg dosing (Figure 11.1.1 A). However, the
growth delay was similar for both treatments with the medium sized tumors (Figure
II.I.IB). The growth inhibitory effect of the 5x50 mg/kg treatment was also
demonstrated with rats bearing tumors larger than 7 cm' (Figure II.I.2A).
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The effect on tumor growth from 3x30 mg/kg was comparable to the delay
measured with the 5x30 mg/kg TNP-470 administrations (see above). These results
for both small and medium sized tumors are displayed in Figures II.I.1C and ID and
are to be compared with the data in Figures II. 1.1 A and IB. The growth inhibitory
effect of 3x3Omg/kg drug was not significant when tumors larger than 7cm' were
treated (Figure II. 1.2B).
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On histologic examination, the non-treated rhabdomyosarcomas are very
cellular. They consist of spindle cells, surrounding somewhat dilated vascular spaces.
The cells show obvious atypia ; mitoses are numerous. Necrosis is sparsely present in
the periphery of the tumors, but is more pronounced in the centre. With increase in
tumor volume, necrotic areas become relatively larger, especially in the central part of
very large tumors. After treatment with the repeated doses of TNP-470, necrosis is
much more prominent in the medium and large tumors in the central as well as in the
peripheral areas. This is illustrated in Figure II. 1.3 for a TNP-470 treatment of
3x3Omg/kg only, and is representative for the other schedules. In the small tumors,
this effect is also present, but less pronounced. In some of the very large tumors
(about 15 cm') little or no effect of TNP-470 treatment on the extension of necrosis is
seen. The diameter of the blood vessels is not altered by the TNP-470 administration.
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In a final set of experiments we studied the use of a single TNP-470 treatment
of 30 mg/kg. As can be deduced from Figure II. 1. 1C and 1D, a clear-cut reduction of
tumor growth was already obtained with this single TNP-470 treatment for rat
rhabdomyosarcomas with volumes smaller than 7cm'.
However, with most of these TNP-470 treatments also toxicitics were
observed. Overall, these were more severe with the 5x50 mg/kg than with the 5x30
mg/kg dosage and consisted of severe local skin damage at the site of the s.c. injection
and of body weight loss. The loss in body weight occurred from 2 days after the first
injection, and was between 10 and 30% for both dosages, being progressive
throughout the observation period. Lowering the total TNP-470 doses to 3x30 mg/kg
did not fully resolve the problem of both skin and body weight effects. However, most
of the animals started to recover their loss in body weight before the end of the
follow-up period. The vehicle-treated tumor-bearing rats always showed an increase
in body weight of 4-7% for the same time period as the TNP-470 series. The skin
7 0 Chapter II, I
damage was a local ulceration present during the series of s.c. injections in all drug
exprimcnts, with healing thereafter.
II. 1.4. Discussion
Inhibition of tumor angiogenesis has been recognized as a potential adjuvant
in the anticanccr treatment arsenal. The fumagillin analog TNP-470 (AGM-I470) has
retained special attention because of its strong inhibition of proliferation and
migration of endothelial cells in tumor systems. This endotheliostatic effect was
reflected in various laboratory in viVo biological models by a reduced growth rate of
the primary tumor or a decreased formation of metastasis (e.g. [2-4, 6,7,12]).
So far, however, data on the effect of TNP-470 are only available for very
small primary tumors (less than 1 cm'). The present report deals with several series of
experiments on the s.c. rat rhabdomyosarcoma with volumes between 1 and 10 cm' at
the start of the TNP-470 treatments.
Our results demonstrate that TNP-470 is also an active modulator of
rhabdomyosarcoma growth, even for relatively large-sized tumors. Indeed, with all
the drug-fractionation schedules tested, a substantial reduction or inhibition of growth
was seen. The overall examination of the stained tumor slices revealed the major
enlargement (factor 4-5 at least) of necrotic areas in TNP-470 as compared with
vehicle-treated medium and large sized tumors. There is ample literature information
on the effect of TNP-470 on the endothelium and the inhibition of angiogenesis (e.g.
16,7]). These observations might explain the presence of a decreased growth rate and
enlarged necrosis seen in the present rhabdomyosarcomas treated with TNP-470.
Interestingly, even a single TNP-470 dose of 30 mg/kg slowed the tumor growth. The
latter effect is important to quote, as it is measured in rats with a firmly developed
tumor load.
The reductions in growth capacity that were observed in the rat
rhabdomyosarcoma following TNP-470 treatments seem consistent with the
hypothesis that rapidly proliferating tumors are more angiogenesis-dependent [13].
Cell kinetic measurements with the rhabdomyosarcoma indeed showed a short cell
cycle time of about 20 hours [9]. Also, from our tumor growth curve for rats injected
with the vehicle only, a volume doubling time of 4-6 days can be deduced. These
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rapid tumor growth characteristics could partly explain the TNP-470 effect on the
evolution of s.c. implanted tumors whatever the size at the start of treatment.
A recently published clinical phase I study also cited the effectiveness of TNP-
470 with relatively large tumors as demonstrated in our study. Repeated TNP-470
administration affected in some patients (he pulmonary cervix carcinoma mclasiascs
with a volume of about 14 cm' (14). It is likely that such a promising therapeutic
approach will encourage the discovery of more potent and/or less toxic tumor
vasculature targeted compounds.
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Summary
Tumour-specific vascularisation may be therapeutically approached in two different
ways: by anti-angiogenic treatments specifically directed to dividing and migrating
cndothelial cells, or by agents that target principally the inadequate and ill-structured tumour
vasculaturc. Combretastatin A-4 phosphate (combreAp), a recently synthesized prodrug
(OXiGENE, Lund, Sweden), is a vascular targeting agent of the latter kind.
We evaluated the effect of a single intraperitoneal combreAp injection on the growth
of rhabdomyosarcomas syngencic in WAG/Rij rats. Different tumour volume groups, ranging
between 0.1 and 27 cm', were selected to assess the relationship between the size at treatment
time and the response to combreAp. A double combreAp treatment (2 x 25 mg/kg) was
investigated within the same overall aim: relation between growth delay and tumour size.
Our results show that (he systemic administration of combreAp induces a clear-cut
differential growth delay in the solid rat rhabdomyosarcomas: with large tumours (> 7 cm'),
an 18-fold stronger effect was measured than with smaller tumours (< 3 cm'). This is the
inverse of the volume-response seen with the conventional therapeutic approaches
(radiotherapy, chemotherapy or surgery). These combreAp anti-tumour responses were
observed without treatment limiting systemic toxicity in the rats. With clinical digital
subtraction angiography, using microsurgical cannulation of a major tumour draining vessel,
and with histopathology, we demonstrate that growth delay is related to an early (within 3-6
hours) and extensive break-down of tumour blood vessels. The experiments involving a
second injection also indicate a volume dependent effectivity of combreAp in reducing the
rcgrowlh rate of small or large rhabdomyosarcomas.
This significant differential volume-response obtained with 'selective' vascular
targeting, stronger in larger tumours than smaller ones, suggests the potential of broadening
the therapeutic window.
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IL2.1. Introduction
Maintenance and improvement of vasculature is critical for the continued
growth of solid tumours. These blood vessels represent therefore a target for potential
new anti-cancer therapies [for reviews, sec e.g. 1-6| Definitive damage will lead to an
avalanche of ischacmic tumour cell death and necrosis. As a consequence, inhibition
of angiogencsis and more recently specific vascular targeting arc being extensively
investigated [7-10].
Angiogenesis inhibition in solid tumours is defined as the prevention of new
blood vessel formation from the existing vascular bed [I, 7, H, II). The actions of
these drugs thus primarily consist of inhibiting growth and migration of the
cndothclial cell. Subsequent to such anti-angiogenic treatment, tumour growth that is
critically dependent on angiogencsis will be prevented.
Vascular targeting treatments, on the contrary, are based on the fact that
predominantly the already acquired tumour vasculalurc is selectively attacked [I, 12,
13]. This type of therapy takes advantage of the weaknesses of established tumour
endothelial cells and their supporting structures and induces collapse, thrombosis
and/or hemorrhage. Obviously, depending on the agent and the dose intensity selected
for this treatment, the proliferating endothelial cells of newly growing blood vessels
might serve as an additional target.
Selectively targeting the acquired tumour blood vessels may constitute a
potential tool, complementing traditional anticanccr therapy that is majorly directed
against the malignant cells themselves. Occlusion or collapse of the tumour vessels
inherently leads to ischaemic or hemorrhagic necrosis. The acute reduction of tumour
vasculature will initiate an immense loss of tumour cells because of nutrient
deprivation, and might thus result in stabilization or reduction of growth. This has
been demonstrated with hyperthermic treatment [14, 15], with flavonc acetic acid
injections! 13, 16], with tumour necrosis factor-a [13, 17] and with an anti-tumour
endothelial cell immunotoxin [18, 19]. Another vascular targeting approach, involving
tubulin-binding agents, recently gained increasing attention. As such, colchicine,
vinblastine and dolostatin have been tested for their effect on tumour growth through
anti-vascular activity [12, 20, 21]. Of particular interest is the novel compound
combretastatin A-4, derived from the South African tree Gwi^re/M/n ca#rum [22, 23].
The more soluble phosphated prodrug showed the potential to induce a similar extent
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of vascular shutdown and necrosis, but without the severe side-effects of the parent
compound [24-26]. These studies, as well as all other vascular targeting investigations
have, however, been restricted to only small-sized mouse tumours. They therefore
lack potentially useful information on the relation between tumour size and the
effectiveness of a selective vascular targeting compound.
The present study assessed the »n v/vo anti-tumour effect by vascular targeting
with combrctastatin A-4 phosphate prodrug (combreAp) in a broad range of tumour
volumes, using the syngeneic WAG/Rij rat rhabdomyosarcoma model. This tumour
grows subcutaneously (s.c.) in the flank region to much larger sizes than have been
described in the literature for mouse models. Such a growth capacity up to several
tens of cm' favours clinical relevance, as many cancer patients present with already
large tumour masses. In addition, we have tested a clinical imaging technique
consisting of digital subtraction angiography for its applicability to evaluate the anti-
vasculalurc and anti-tumour effects of combreAp in our rat tumour model.
The overall goal of our research was to determine the relation between tumour
volume and the vascular/anti-tumour effect of combreAp. Our investigations covered
(i) the extent of the anti-tumour activity in terms of growth delay, (ii) histo-
puthological examinations, and (iii) the visualisation of the effect of combreAp on
tumour vasculature with digital subtraction angiography. Using the latter (wo
methods, we also focussed on the time-relation between the combreAp injection and
the sequence of the major events involved in the development of tumour damage and
eventual regrowth. Finally, a double combreAp treatment was evaluated for its
additional tumour growth delay and the presence of a related size dependent
phenomenon.
II.2.2. Materials and methods
The in vivo tumour system used in the present project is a highly-reproducible
experimental syngeneic rhabdomyosarcoma in WAG/Rij rats (27). Briefly, the tumour
cell line has been derived from a radiation-induced tumour in the jaw musculature of
inbred WAG-Rij rats. Alternate subcutaneous (s.c.) tumour cell inoculation and
tumour piece transplantation are routinely used in our laboratory to maintain
qualitatively the characteristics of the rhabdomyosarcoma. The tumour shows a
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regular growth pattern without the development of mctastases. and has the property of
subcutaneous growth up to 40-50 cm* in the flank region of rats without causing any
obvious disturbance of the animals' health. Indeed, no anaemia, weight loss or change
in physical behaviour was recorded during the time of this growth. This allowed us to
investigate the effectiveness of combreAp in a large range of tumour sizes. It was,
however, decided to sacrifice rats bearing tumours larger than 40 cm' (or less if
adequate information is obtained earlier during growth) at any time during the follow-
up period. For the present experiments we transplanted tumour pieces of about 1 mm'
s.c. into the lower flank of adult rats (260 to 300 g). This technique avoids spread of
growth along the injection track, which often occurred after s.c. inoculation of 1-3 x
10* tumour cells, and allows adequate and reproducible tumour volume
measurements.
Preparation o/f/ie vascular rargering cowipoumf i«/uri»/i
The combretastatin A-4 prodrug (OXiGENE Inc., Lund, Sweden) was
dissolved in 0.9% saline immediately before use. The solution was injected
intraperitoneally (i.p.) in a volume of 0.5 ml. The control rats received an i.p. injection
of 0.5 ml 0.9% saline only.
de/ay measurements
Three orthogonal diameters were measured with a caliper and used to calculate
the volume of the tumour with the formula : a x b x c x n/6 = volume, expressed in
our study as cm'. Correction for skin thickness of 1 mm was applied at all the
measured diameters. To evaluate the relationship between tumour size and the
combreAp administration, 5 different tumour volume ranges were selected prior to
any treatment. These ranges were < 1 cm', 1-3 cm', 3-7 cm'. 7-14 cm' and > 14 cm',
referred to in our study as "very small", "small", "medium", "large" and "very large",
respectively.
After removal of the tumour from the animals, at selected time-intervals after
the combreAp injection, transsections were made of pre-determined tumour size
ranges. Either the whole segment (for small tumours) or half of the segment (medium
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to very large tumours) was fixed in 10% formaldehyde solution. Care was taken to
enable the evaluation of both the central and peripheral tumour area in the same slice.
Following paraffin embedding, 10 pm sections were stained with the haematoxylin-
eosin combination. All sections were screened independently, generally using a XI00
and a X4U0 magnification, by the principal investigator and the histopathologist. The
latter was blinded to the treatment protocol.
.vHr#/Va/ can/iu/af/un a/f/ie fu/nours/or rf/gito/ s«A/rac/i«n angiwgrap/i^
Spontaneously breathing anaesthetised rats (Fentanyl - Dehydroperidole
mixture 0.4 ml/100 g, i.p.) were placed in dorsal decubitus and pinned to a cork
operation table. Through transcutaneal and transsupcrficial fascia midline incision, the
encapsulated tumour was exposed. The wound was retracted, and the tumour vascular
pedicle was dissected under microsurgical viewing. The major feeding artery and vein
were followed by proceeding proximally up to the confluence site with the iliac artery
and iliac vein, respectively. Because the pedicle of the exposed tumour often appeared
kinked and occasionally compressed by vascular sheet bands, the sheet and the
adventitia of the vein were trimmed. Following the cannulation, a flush with 0,2 cc
pure heparin was made and the syringe with contrast medium was attached to allow
injection during imaging. An occlusive microvascular clamp was applied proximally
to prevent possible backfiow of contrast medium into the blood circulation. At the end
of the angiographic recording, the cannula was withdrawn and the operation wound
was closed with 4/0 Prolenc running suture. Only the large and very large tumours
were investigated in this way since the smaller ones had a narrow vascular pedicle
that made cannulation impossible.
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Ö/rar/ion angiograp/i.v
Following micro-dissection and cannulation of the major tumour draining
blood vessel, angiography of the tumour was initiated. For this purpose, I ml of
ioxaglate meglumine/ioxaglatc sodium (Hcxabrix) 200 mg I/ml, a water soluble low
osmolar ionic contrast agent, was injected. The animals remained anaesthetised to
obtain recordings without movement artifacts. Pulse mode X-ray image acquisition
was done at a fixed voltage of 70 kV with a Siemens Polytron apparatus, using a
constant image intensifier field. Scanning of the tumour vascularity was performed ui
3 frames per second during the injection. The images were stored and digital
subtraction of the body-background was performed to improve the analytical quality.
Selected images were printed on Agfa films. The tumour vasculaturc images were
offered for interpretation to two independent radiologists blinded to the study plun.
Number and size (numerical grading), location (peripheral; central) and gross
morphology (regular or irregular) of the blood vessels were the parameters used to
evaluate the anti-vasculaturc effects of combreAp.
The results presented in the growth delay graphs arc means with standard error
of the mean. Differences between groups were evaluated with Multiple Regression
Analysis.
Genera/ aspeefs
The overall number of tumours used to assess growth delays, tissue changes
and vascularity amounts to a total of about 320, including repeal experiments. The
research protocol was in accordance with the Ethical Committee for Animal Care and
Use of the University of Leuven (K.U.L.) and national guidelines.
II.2.3. Results
Systemic toxicity evaluations of a single i.p. combreAp injection clearly
indicated that doses above 50 mg/kg (MTD) resulted in severe weight loss. A
combreAp dose of 100 mg/kg resulted in 25% mortality in the rats. It was therefore
decided to use combreAp injections of 25 mg/kg or less in all experiments, as no
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significant signs of general toxicity were observed in both tumour-free and tumour-
bearing rats.
The subcutaneous (s.c.) growth of control tumours, evaluated between 0.1 cm*
and more than 40 cm', consistently occurred at a volume doubling rate of 2.5-3.5
days. The effect of combreAp on the growth rate of rhabdomyosarcomas was
evaluated with S pre-sclected tumour volume ranges. Each point of all the growth
curves represents the mean volume (cm') of at least 20 tumours. Using a single i.p.
injection of 25 mg/kg a distinct volume-dependent anti-tumour effect was seen
(Figure II.2.1). With tumours referred to as very small to medium (< 7 cm*), growth
delays of at most 5 days were seen (Figure II.2.1 .A, B and C). Tumours with a volume
at injection larger than 7 cm' responded well to the treatment, with growth delays
between 9 and 18 days (Figure II.2. I D and E). The slowing of tumour growth was
already measurable at 2 days after treatment. For the very large tumours, not only a
stabilisation in size but even a regression of tumour volume was detected (Figure
II.2. IE). Palpation of the control and treated tumours revealed, for all the changes in
volume, a consistently firm tumour mass that was later confirmed at transsection. To
enable a precise quantification of the growth delay relative to the treatment starting
volume, it was decided to interpolate the measured growth delay at 1.5 times the
increase in size. The results of these calculations are summarised in Table II.2.1. The
two extremes in the present study, i.e. no growth delay for very small tumours ve>rsus
a mean of 17.6 days delay with the very large tumours, clearly demonstrate the size-
dependency of the combrcAp effectiveness with this rhabdomyosarcoma tumour
model.
Differential tumour volume-response with combreAp 81
Table II.2.1. Rat rhabdomyosarcoma and cumbretasiatin A-4 phosphate (25 mg/kg i.p.)
Pre-determined
volume groups (cm*)
Very large (> 14)
Large (7-14)
Medium (3-7)
Small (1-3)
Very small (< 1)
Time lapse
change
control
3.4
2.6
2.5
2.4
2.9
for volume
(days)'"
CombreAp
21.0
12.1
7.0
4.8
2.9
Relative growth
delay (days)""
17.6
9.5
4.5
2.4
0
Statistical
significance for
growth changes'"
p < 0.0001
p< 0.0001
p < 0.002
p = 0.0044
-
(a) Time (days) necessary for tumours to increase I 5 » in volume.
(b) Time difference (day») between comhrc Ap-treated and control tumour* lo increase I J i in l i te .
(c) Significance level of the change in tumour growth between comhreAptrealed and control tumour* eitnnalrd
from the full growth curvet (tee Figures I and 2) using Multiple Regression Analysis.
When the single i.p. dose of combreAp was reduced to 10 mg/kg, a smaller
reduction in the growth rate was observed, still with a more marked effect at the larger
tumour volumes (data not shown). With large-sized rhabdomyosarcomas, 5 days
delay in growth was measured, as compared with 9.5 days when 25 mg/kg was used
with this tumour size. With medium sized tumours (3-7 cm*), 1.5 days growth delay
was obtained after injection of 10 mg/kg combreAp instead of 4.5 days as observed
with 25 mg/kg drug.
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Figure 11.2.1. Growi/i <»/ r/wMomvosairomai //?i/)/an/f<i s.c. w //i«/fanA: o/ WAC//?y rafs :
c«/i»r»>/ /«/«OMr.v f(7o.vf(/ £wnfa>/. /»roArn //n^) ant/ fo/nfcrM/)-fr?aff</ fumours fo/>e
/«// /I>II*). 77ic </i/)Vrf;i/ /w/ic/i </i's/>/av //i^ rMu/fs w/j/i f/i? vrrv 5ma// rumours f/./4),
f/.B). Mif</i'u»i (/.C). / « r ^ f /.D) «n</ vrrv / a r ^ (/.E) fu/noMrs. 7/i^ romfcreA/) </osa^f was 25
vrw «.v « .v/nx'«" '•/»• «yVcfi'on. V r^f/Va/ fcurs r^/>r«^n/ f/i^  5fan<iar</ error o/ f/»^
The digital subtraction angiographic images of control tumour-bearing rats
showed the relatively rich vasculanty of the large sized rhabdomyosarcomas (Figure
H.2.2.A). Vascularisation was always more intense in the periphery than in the centre
of the tumour, the latter being partially necrotic (see histopathological screening). The
majority of the blood vessels in these control tumours were large and showed a
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regular morphology. A striking effect of the treatment with 25 mg/kg combreAp on
the tumour vascularity was imaged.
B
Figure II.2.2. Ang/ogra/j/i/c imaj« (»WJ/I <//£/7a/ 5u^(racn'o/i o/ //if Jwdyfcic&grou/u/J <?/
/ar^e .Hiea" r/iafcaomvosarcomaj jfrotv/n^ s.c. i/i r/ie //an* O/ W/4C/Ä//' ra«. 77iev were
ra/u/om/v Je/ec/ea" ana" represewariVe /or //it /'mag/zig o/ /um««r vaicw/anVv /'/i c«n/ro/
'ai/iorma/' WooJ wM5e/j. fi, /mage o/>ra/'neJ a/ 6 /i««r5 a//er f/ie t«
"ig/lg). >4 i/ecrease /'n 5/je anJ /n nu/nier o/j/ie />/ooa* vewe/i >va5 «frjerve /^. C,
jcreening o/ /u/noMrj a/ i dVivs a//er f/ie c«m/»rey4/7 t'/iyVcfio/i revea/ea* very /»«or vajcu/ar/ry,
/>r«en/ on/y w //ie /»en/j/iera/ area. T/ie remai'/i/'ng veiJe/j /wJ a red*Mcet/ aVamefer a«a*
j/ioweJ a/i irregw/ar mor/?/io/ogy. D, y4/ /0 aavi a//er comArM/7 /rea/men/, c/wrac/er(5//c
/ea/wrej o/ n«w/y-/or7n«J ve«e/-mörp/io/ogv nrre iee/j. Com/rarea* IVI7/I //ie /mage.f o/>/ai««</
a/ r/ie J aavi »/me-/>i/erva/. a« i/icreaje i/i nwmfcer o/WooJ veweAi tvaj /7re5en/.
At 3 hours after drug administration, a slightly reduced number of vessels was
seen in the periphery and towards the center. These blood vessels showed an irregular
shape as well as a reduction in diameter. At 6 hours a clear decrease in number and
size of blood vessels was observed and they were found to be irregular (Figure
Ü.2.2.B). At both time-intervals, a back-pressure was present during the injection of
the contrast medium. Screening the rhabdomyosarcomas at 1 day after the combreAp
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treatment revealed similar pictures as those at 6 hours. Blood vessels were, however,
now present only in the peripheral area. The images obtained at 3 days after drug
injection showed that vascularity was absent in the major part of the tumour and that
few vessels remained at the periphery (Figure II.2.2.C). They had an irregular
morphology and reduced diameter.
The histopathological examination of control rhabdomyosarcomas showed for
all sizes a majorly cellular tumour with numerous actively dividing cells (Figure
II.2.3.A and B). Blood vessels were rather abundant and randomly located, showing a
normal morphology. Sections of medium to very large control tumours (> 3cm*)
revealed areas of necrosis dispersed in the centre as well as in the periphery. The
blood vessels adjacent to these necrotic tumour parts were dilated. After injection of a
single dose of 25 mg/kg combrcAp, the picture promptly changed. Apart from the
blood vessels present in the periphery of the tumour, dilatation and congestion were
observable at 3h post-injection of combreAp. Moreover, several small foci of fresh
necrosis were present in the potentially viable parts of the tumours. After 6 h, the
necrotic foci were larger and started to merge. After 1 day, the whole tumour showed
extensive necrosis, except for a very narrow rim of potentially viable tumour cells.
The blood vessels that were present in the peripheral rim showed no abnormalities.
Just beneath this rim, small hemorrhagic zones were seen. Vessel wall interruption
and cndothclial cell damage were present in the necrotic area. At 2 and 3 days after
combrcAp injection, the rim of potentially viable tumour was even thinner and the
hcmorrhagic/necrotic area practically occupied the whole tumour volume (Figure
II.2.3.C and D): at this time interval, no bleeding was present when the tumours were
transsectcd. Analysis of the rhabdomyosarcoma tumours with volumes less than 3 cm'
indicated that the combreAp-induced effects were quantitatively less than those
described for the larger tumours: the ratio of induced necrosis to the viable looking
areas was less than with the larger rhabdomyosarcomas. The time-scale for presenting
any vascular damage with subsequent necrosis was however again the same as
described in detail above.
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Figure II.2.3. Voicu/ar farge/mg <#«7 vW//i com&rey4/? ;n raf
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The strong anti-tumour effects observed in the large and very large tumours,
after the single combreAp injections and with three different techniques, were
however not permanent. Subsequent to the period of reduced growth rate, a renewed
increase in size was measured in these tumours, at a rate similar to the tumour growth
observed in the control groups (Figure II.2.1.A and B). This regrowth is also clearly
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blood vessels and their endothelial cells, with more specifically the inhibition of
tubulin polymerisation. Apoptotic death has been demonstrated /'« v/rro with normal
human umbilical vein endothelium [29]. More details about the action mechanisms of
combreAp specifically in tumour blood vessels remain to be unravelled, and further
discussion of this aspect is beyond the scope of the present paper.
Recently, using transplanted tumours in mice, several laboratories have shown
that a single administration of combreAp induced a vascular shutdown as soon as 6 to
12 h after injection, with subsequently the formation of hemorrhagic necrosis [24-26,
30]. To our knowledge, all of these reported in v/vo data involve the treatment of very
small rodent tumour models. It is obviously important to screen, when possible, the
activity of such a compound in larger tumours of any type. In radio- and
chemotherapy it is firmly documented that a differential anti-tumour effectivity exists,
and this for different reasons, with respect to tumour size at treatment time.
Our investigations, using the established rat rhabdomyosarcoma cancer model,
are intriguing in that they illustrate the dramatic change in growth pattern from
combreAp relative to the tumour volume at the time of treatment. With the very small
and small rhabdomyosarcomas, respectively no or a borderline significant growth
delay was measured. This result is similar to the published very small mouse tumour
data , wherewith also no growth delay was seen at a systemically non-toxic combreAp
dose [25, 26, 30]. However, as the rhabdomyosarcoma tumour volume at the time of
the combreAp injection was larger ( » 3 cm'), the growth delay became more
important. For instance, the difference in delay with the rhabdomyosarcoma between
the small (1-3 cm') to very small (< 1 cm') and the very large (> 14 cm') tumours is
respectively 8- and 17-fold. With the latter tumour size, even a significant shrinkage
was measured rapidly after the combreAp injection (see Figure II.2.2.B). This
"inverse" volume-response relation (compared with e.g. radio- or chemotherapy) could
be expected, if one accepts that the corollary presence of newly acquired blood
vessels increases with the size of the tumour. This implies at first glance that larger
tumours may have proportionately more ill-formed and eventually combreAp
sensitive vasculaturc than small tumours, that initially have their nutrient supply
through the peripheral and the co-opted host vasculature [6. 31 ]. A further and strong
impairment of the already inadequate blood supply due to combreAp activity will
^ _ Differential tumour volume-response with combccAp 89
consequently stop tumour growth and may lead to tumour growth retardation, as is
clearly demonstrated in the present study specifically with the tumours larger than 7
cm».
Digital subtraction angiography was performed with un iodinated contrusl-
medium and with image analysis, available as a standard in neuroradiology and
intervenlional radiology, to evaluate the overall blood vessel changes. The applied
intra-operative technique avoids the dilution of (he contrast medium in the total body
circulation, which occurred when we used injections in the tail vein. The angiogruphic
images obtained at 3 h after the combreAp injections already showed effects on (he
tumour vascularity. At later time-intervals (up to 3 days) reduction in vessel diameter,
changes in morphology and extensive loss of blood vessels within the tumour were
obvious. The histopathologic microscopy observations of tumour slices were in
agreement with these findings, with the first signs of vascular damage (dilation and
congestion) being clearly detectable at 3 h post-injection. At 6 h after the combreAp
treatment, evidence of damage of blood vessels and endothclium was detectable with
the microscopic analysis. An obvious deduction from the combination of the two
clinico-analytical approaches is the relation between the 'disappearance' of blood
vessels and the increase in necrosis, both phenomena clearly present 1 day after the
combreAp treatment. The early presence of tissue changes was histopathologically
also observed in the smaller rhabdomyosarcomas, similar to the reports on small
mouse tumour models which documented acute vascularity changes and blood flow
reductions [12, 24, 26]. Such an acute manifestation of necrosis has separately been
reported with experiments involving mouse tumours treated with flavonc acetic acid
(FAA) [20]. A strong reduction in tumour blood flow, indicative for vessel damage,
was measured within 4-6 hours after the FAA administration [ 16, 21, 33]. The overall
pattern of the combreAp-induccd necrosis, being preceded by vascular defects, also
resembles the anti-tumour effects observed with tumour necrosis factor-ct. Both
Baguley and colleagues [20] and Mahadevany rt a/. [33] discussed the tumour
necrosis factor-a involvement when analysing the anti-tumour effects of FAA as
measured in their biological systems. Anyhow, the straightforward relation between
the severity of vascular shutdown and the anti-tumour effect seems obvious. Indeed, a
significant growth delay was only obtained following a temporary clamping of tumour
blood supply for 12-14 hours, whereas 1-2 hours occlusion induced little tumour
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blood vessels and their cndothelial cells, with more specifically the inhibition of
tubulin polymerisation. Apoptotic death has been demonstrated /'« virro with normal
human umbilical vein endothelium [29]. More details about the action mechanisms of
combreAp specifically in tumour blood vessels remain to be unravelled, and further
discussion of this aspect is beyond the scope of the present paper.
Recently, using transplanted tumours in mice, several laboratories have shown
that a single administration of combreAp induced a vascular shutdown as soon as 6 to
12 h after injection, with subsequently the formation of hemorrhagic necrosis [24-26,
30], To our knowledge, all of these reported «« v/Vo data involve the treatment of very
small rodent tumour models. It is obviously important to screen, when possible, the
activity of such a compound in larger tumours of any type. In radio- and
chemotherapy it is firmly documented that a differential anti-tumour effectivity exists,
and this for different reasons, with respect to tumour size at treatment time.
Our investigations, using the established rat rhabdomyosarcoma cancer model,
arc intriguing in that they illustrate the dramatic change in growth pattern from
combreAp relative to the tumour volume at the time of treatment. With the very small
and small rhabdomyosarcomas, respectively no or a borderline significant growth
delay was measured. This result is similar to the published very small mouse tumour
data , wherewith also no growth delay was seen at a systemically non-toxic combreAp
dose [25, 26, 30]. However, as the rhabdomyosarcoma tumour volume at the time of
the combreAp injection was larger ( » 3 cm'), the growth delay became more
important. For instance, the difference in delay with the rhabdomyosarcoma between
the small (1-3 cm*) to very small (< 1 cm') and the very large (> 14 cm') tumours is
respectively 8- and 17-fold. With the latter tumour size, even a significant shrinkage
was measured rapidly after the combreAp injection (see Figure II.2.2.B). This
'inverse" volume-response relation (compared with e.g. radio- or chemotherapy) could
be expected, if one accepts that the corollary presence of newly acquired blood
vessels increases with the size of the tumour. This implies at first glance that larger
tumours may have proportionately more ill-formed and eventually combreAp
sensitive vasculalure than small tumours, that initially have their nutrient supply
through the peripheral and the co-opted host vasculaturc [6, 31 ]. A further and strong
impairment of the already inadequate blood supply due to combreAp activity will
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consequently stop tumour growth and may lead to tumour growth retardation, as is
clearly demonstrated in the present study specifically with the tumours larger than 7
cm*.
Digital subtraction angiography was performed with an iodinated contrust-
medium and with image analysis, available as a standard in ncuroradiology and
intcrventional radiology, to evaluate the overall blood vessel changes. The applied
intra-operative technique avoids the dilution of the contrast medium in (he total body
circulation, which occurred when we used injections in the tail vein. The angiographic
images obtained at 3 h after the combrcAp injections already showed effects on the
tumour vascularity. At later time-intervals (up to 3 days) reduction in vessel diameter,
changes in morphology and extensive loss of blood vessels within the tumour were
obvious. The histopathologic microscopy observations of tumour slices were in
agreement with these findings, with the first signs of vascular damage (dilation und
congestion) being clearly detectable at 3 h post-injection. At 6 h after the combreAp
treatment, evidence of damage of blood vessels and endothclium was detectable with
the microscopic analysis. An obvious deduction from the combination of the two
clinico-analytical approaches is the relation between the 'disappearance' of blood
vessels and the increase in necrosis, both phenomena clearly present I day after the
combreAp treatment. The early presence of tissue changes was histopathologically
also observed in the smaller rhabdomyosarcomas, similar to the reports on small
mouse tumour models which documented acute vascularity changes and blood flow
reductions [12, 24, 26]. Such an acute manifestation of necrosis has separately been
reported with experiments involving mouse tumours treated with flavonc acetic acid
(FAA) [20]. A strong reduction in tumour blood flow, indicative for vessel damage,
was measured within 4-6 hours after the FAA administration (16, 21, 33]. The overall
pattern of the combreAp-induccd necrosis, being preceded by vascular defects, also
resembles the anti-tumour effects observed with tumour necrosis factor-a. Both
Baguley and colleagues [20] and Mahadevany ?r a/. [33] discussed the tumour
necrosis factor-a involvement when analysing the anti-tumour effects of FAA as
measured in their biological systems. Anyhow, the straightforward relation between
the severity of vascular shutdown and the anti-tumour effect seems obvious. Indeed, a
significant growth delay was only obtained following a temporary clamping of tumour
blood supply for 12-14 hours, whereas 1-2 hours occlusion induced little tumour
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growth changes [34]. It seems clear that the suppression of rhabdomyosarcoma
tumour growth by combreAp is majorly the result of a selective targeting of the
acquired tumour neo-vasculature. This is consistent with the fact that the absolute
tumour volume, and inherently the absolute number of tumour cells depending on
these established ill-formed blood vessels for their survival, seems to be an important
parameter determining the growth delay after treatment. Also, larger tumours
inherently may have more newly formed blood vessels which can be abberant in
structure and functionality and thus more vulnerable for such agents. A correlation
between small and large rhabdomyosarcomas and their vasculature may be indirectly
dcducible from the comparison of our results obtained with anti-angiogenesis
treatment in the same tumour model [36J and the present combreAp data. With the use
of TNP-470, a fumagillin analogue and specific angiogenesis inhibitor, growth delays
were more pronounced in tumours smaller than 7 enr. This opposes, with regard to
tumour volume, to the effect seen with the combreAp administration. Both these
observations taken together may demonstrate the differential aspect of tumour size-
related vascular quality ( and quantity).
It could also be hypothesized that the combreAp finds activation through
hypoxia, present to a much greater extent in large tumours as compared with those
smaller than 3 cm'. It may be worthy to think about this possibility, since we earlier
showed with the same tumour model that only tumours larger than 4-5 cm', having a
sufficient amount of severe hypoxia / necrosis, could be colonised with anaerobic
bacteria |32). The possibility for such an inter-related activation will be investigated.
Finally, some direct cytotoxic effect of combreAp towards the tumour cell
population, as indicated in the recent literature for some tumour cell types [25, 30,
35], may have to be taken into account in our I/I vivo rhabdomyosarcoma studies.
The present data describing the influence of tumour size on the outcome of
vascular targeting treatment, may be compared with only a few other studies.
Indications for a similar size-response relationship have to our knowledge only been
suggested for hyperthcrmia and for FAA treatments [15, 16]. In some of these
experiments, the effect of treatment was also less with very small tumours as
compared with relatively larger ones. However, the use of these agents at their
respective anti-cancer effectivity was hampered by severe side-effects. The absence of
obvious systemic toxicity related to the combreAp dosage and injection site, used in
our investigations, are therefore an additional advantage. The rats maintained normal
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activity, with no evidence of bleeding, diarrhea, or skin lesions at the tumour
transplantation or injection site. The absence of normal tissue injury in parallel with
strong tumour cell kill has been quoted by other research groups using various mouse
tumour models [24-26. 30).
In view of the absence of systemic side-effects, the overall research with
combreAp encourages the use of such tumour vessel targeting drugs as a novel cancer
treatment modality, specifically for large tumours. With the present rhadomyosarcoma
tumour model, a clear-cut measurable 'inverse' tumour volume vrrsuj response
relation with combreAp injection is demonstrated. Also the double combreAp
treatment indicates this positive volume-dependent growth delay effect. The data
furthermore demonstrate (hat even tumours smaller than 3 cm* can be significantly
inhibited in growth with an appropriately scheduled repeal injection of comhrcAp.
This is at first surprising as well as promising since traditional anti-cancer therapies,
such as radiotherapy and chemotherapy, are less effective on large solid tumours than
on small ones [37, 38].
It is obvious that, since a single combrcAp treatment is not curative on its own,
a combined strategy with e.g. radiotherapy and/or chemothcrapcutic drugs will be
necessary to improve tumour control. Pilot experiments involving the mouse CaNT
tumour model, with either irradiation or with cis-Platinum in combination with
combreAp, provide a positive indication [30].
Corroborating the results described herein with the rhabdomyosarcoma tumour
model, it is conceivable that patients who present with large inoperable solid tumours
or who relapse after other treatments, may benefit from a vasculaturc targeting
treatment. At present phase I trials with combreAp treatments are ongoing in Europe
and the USA, of which the results are eagerly awaited.
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Summary
Interference with the tumor blood vessels through anti-angiogenesis or vascular
targeting can suppress tumor growth. Vascular targeting of solid tumors, using tubulin
compromizing agents, seems a promising and selective novel treatment. We aimed to evaluate
the potential (hypothesis-based) benefit from combinations of vascular targeting with
combrctastatin A-4 phosphate (combrcAp) and either ionizing radiation or anti-angiogenesis.
Rhabdomyosarcoma tumor pieces were inplanted subcutaneously (s.c.) in the flank
region of syngeneic adult WAG/Rij rats. Tumors were grown until different sizes, between
small (< 3 cm*) and large (7-14 cm'), and stratified for the different treatment groups.
CombrcAp was injected intrapcritoncally; injections of TNP-470 were s.c. in the neck area.
Localized single dose (8 Gy) irradiations of tumors were done under Nembutal anesthesia,
always I day prior a single combreAp (25 mg/kg) injection. The TNP-470 treatment (3 times
30 mg/kg in I week) started I day after a double (8 days interval between both) combreAp
administration. Tumor responses were evaluated by the growth delay assay and statistical
significancy of tumor growth changes was computed.
Large tumors responded better to combreAp treatment than did the smaller ones.
Combining irradiation with combreAp resulted in a tumor size-dependent growth delay. With
small and medium tumor volumes, a similar response was measured after the combination
treatment when compared with irradiation only. Large tumors however showed a strong (at
least additive) increase of the growth delay with the combined therapy. The difference in
tumor growth between the two treatment groups was very significant (p < 0.0001).
When TNP-470 was combined with combreAp, no significant lengthening of the growth
delay was present, irrespective of the tumor size.
The current data show a significant advantage from the combination of combreAp
with irradiation in rhabdomyosarcomas having a large size (7-14 cm*) at treatment. Such a
benefit in tumor response was not observed with the smaller tumors, seemingly because
irradiation as such was very effective. No significant gain in growth delay was observed when
TNP-470 was added to the combreAp treatment. This presumebly reflex only little
angiogencsis during the first week of rhabdomyosarcoma regrowth after the combreAp
treatment.
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111.1.1. Introduction
Tumors require blood vessels for nutrient and oxygen supply to maintain (heir
viability. In the first time-stage of growth, this demand is anticipated by the
cooptation of host vasculature. To continue lumoral expansion, the formation of
additional blood supply is a prerequisite (1.2). The presence of these morphologically
and functionally abnormal blood vessels makes vascular targeting an attractive
approach in anti-cancer treatment [reviewed by e\/j. 3, 4). Tubulin binding agents
were identified to exert anti-vascular activity in solid tumors, (hough not without
some morbidity |5, 6]. Recent experiments involving the combretaslatin A-4 family,
compounds that interfere with the tubulin polymerisation, provided evidence for m
vtvo anti-tumor effectivity at systcmically non-toxic doses |rj?. 7, 8]. It is at this point
relevant to state that the magnitude of effectiveness of the combrelastatin A-4
phosphate (combreAp) can be related to the tumor size. Tumor size has been
discussed to be an important determinant in the tumor response to a specific treatment
[e\g. 9, 10). Using specifically combreAp, an 'inverse' volume-response relation (wilh
respect to radio- or chemotherapy) has been demonstrated with a single injection, at
least in the rat rhabdomyosarcoma tumor model [ l l | . Longer growth delays were
measured with large tumors (> 7 cm') as compared with those that measured less than
3 cm' at the start of the treatment. Notwithstanding a major necrosis induction, this
vascular targeting treatment did not result in a complete tumor response (*.#. 7, 111.
To find an improvement of the anti-tumor response, we now examined the effect from
combinations of combreAp with two basically and mechanistically different treatment
modalities.
The first series of experiments combined combreAp vascular targeting with
ionizing radiation for treatment of rat rhabdomyosarcomas. We hypothesized to obtain
a (supra-)additive anti-tumor response with the combined direct (irradiation) and
indirect (combreAp) cytotoxic effect. It was assumed that the proliferating tumor
cells, predominantly present in the peripheral host vessel-irrigated region of the
tumor, should be most vulnerable for ionizing radiation. The combreAp on the other
hand should induce, as the result of collapse of the post-angiogenesis intra-tumoral
vascularity, a cascade of indirect tumor cell death including the killing of hypoxic,
radioresistant cells. Based on this hypothesis, we further assumed to obtain an
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important advantage with tumors having large sizes and inherently more hypoxic
areas at the start of the combination treatment.
In the second part of the investigations we assumed that the tumor regrowth
following the combreAp treatment would be parallelled by a renewed angiogenesis.
Blocking the latter process would than result in a further arrest of tumor growth.
Indeed the more established anti-angiogenesis compounds, including the synthetic
fumagillin analogue TNP-470, were demonstrated to interfere to a variable degree
with tumor growth [reviewed by e.g. 12, 13]. TNP-470 was therefore in the present
study given in conjunction with the combreAp treatment. Again we incorporated the
question of tumor size-dependent effectiveness of this combination strategy. The
selection of TNP-470 was related to our previous experience with this compound in
the rat rhabdomyosarcoma tumor model [14].
In general, the data presented thus aimed to demonstrate an improvement of
Ihc combreAp vascular targeting treatment from the combination with either ionizing
radiation or TNP-470 anti-angiogenesis and to eventually relate the results with the
tumor volume.
III.1.2. Materials and methods
/n vivo fu/«or moi/W
Male adult WAG/Rij rats, weighing at least 270 g, were used for all the
present experiments. The animals were housed 4 per cage and had food and water ad
/t'6irum. The syngeneic rhabdomyosarcoma, at its origin an X-ray induced jaw muscle
tumor [15], was implanted subcutaneously (s.c.) in the lower flank of lightly ether
anesthetized animals. Pieces of about 1 mm* were used in the sequential series for at
most 10-12 passages, whereafter transplantation was restarted from the frozen cell-
stocks.
Treatment was initiated when tumours reached the predetermined size: either
1-3 cm', 3-7 cm* or 7-14 cm*; these sizes are referred to respectively as small,
medium and large.
After the start of any treatment, rats were weighed regularly and the mean body
weights were compared with those for the appropriate single agent controls including
a batch of untreated tumor-bearing rats.
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All experimental conditions have been approved by the ethical committee of
the University of Lcuvcn, in compliance with the national guidelines on animal
research.
The vascular targeting compound combrctastatin A-4 phosphate (combrcAp)
was obtained from OXiGENE. Lund, Sweden, and stored at 4 °C. Immediately prior
intrapcritoneal (i.p.) injection, it was dissolved in 0.9 % saline. A dose of 25 mg/kg
was used, a selection based on our previous toxicity evaluation 111).
The angiogencsis inhibitor TNP-470, synthesized by Tukcdu Chemical
Industries, Japan, was kept at -20 °C. and solutions were freshly prepared before use
in 10 % cthanol/5 % arabic gum in saline. Injections of 30 mg/kg each were s.c. in (he
neck area of the rats; the dosage was based on previous TNP-470 experience in
WAG/Rijrats[14].
Local tumor irradiation, with the remainder of the body adequately shielded,
was done with a linear accelerator (Saturne 42, General Electrics) using a 18 megavolt
beam and a dose-rate of 3 Gy/min. Dosimetry was performed in treatment condition.
A perspex tissue-equivalent plate of 2.5 cm thickness was placed above the tumors.
To allow a correct positioning of the tumor, rats were anesthetized with sodium
pentobarbital (Ncmbutal, 0.1 ml/100g body weight).
7>eaf/nenf /?roioro/s and response eva/ua/ion
(7) Co/n/>rMp p/us /'on/'z/ng ra<//'af/ow:
CombreAp was given as a single i.p. injection (25 mg/kg) and combined with
a single radiation dose of 8 Gy, given 1 day prior the combrcAp.
(2) CbmZ?re/tp p/uj 77V/M 70:
For the different pre-selected tumor sizes, combreAp was injected i.p. (25
mg/kg) 2 times (days 0 and 8). The TNP-470 (30 mg/kg) was given s.c. 3 times
during 7 days, starting one day after the second combreAp injection (days 9, 12 and
15).
The response of rat rhabdomyosarcoma to the various treatments was evaluated by the
classical tumor growth assay. Using calipers, tumors were measured 2-3 times per
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week, and volumes were calculated as [(a x b x c) x 7t/6] where a, b and c are
orthogonal dimensions. Tumor growth delay time was derived from the mean growth
curves.
Computed analysis to differentiate between the treatment groups was
performed using 'Generalized Linear Models'based on the asymptotic chi-squared
distribution of the likelihood ratio statistics. Values of p < 0.05 were considered as
significant difference.
III. 1..V Results
Most of the combination experiments indicated the absence of a body weight
reduction when compared with the use of either agent alone. Only in the series
combining the double combreAp (2x 25 mg/kg i.p.) and the triple TNP-470 (3x 30
mg/kg s.c.) at most a body weight loss of 10-15 % was recorded. This reduction lasted
for about 2-3 weeks in some animals, before recovery in body weight was measured.
(1) CombreAp plus ionizing radiation effect:
Figure III. 1.1 (A, B and C) illustrates the growth pattern of rat rhabdomyo-
sarcoma treated with combreAp alone (25 mg/kg), single dose irradiation (8 Gy) alone
and combreAp combined with irradiation, including the growth in untreated
condition. The treatments were evaluated in tumors with the various pre-selected
volumes ranging between 1 and 14 cm', and these experiments were carried out two
times independently.
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These data demonstrate a clear-cut size-dependent strenghtening of the growth
delay as compared with radiotherapy alone. With small tumors (1 - 3 cm') at the start
of the treatment, no increase in growth delay was seen with this combination (Figure
DI. 1.1.A). The medium and the large tumors on the contrary showed respectively a
weak (3 days) or strong (10 days) enlargement of the growth delay (Figure III.l. 1 .B
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and 1 C respectively). The resulting growth delays and related significancy levels are
summarized in Table III. 1.1 .A for each tumor size and treatment.
Table III. 1.1. Growth delays with rat rhabdomyosarcomas for the various pre-selected tumor
volumes and Ihe different treatments
A)
B)
Singe dote irradiation (8 Gy) and combrcAp (1 x 25 mg/kg)
Volume (cm')
•mail (1-3)
medium (3-7)
large (7-14)
SD irr i d + combreAp
13.5 days (N.S.)»
l8days(N.S.)*
22 days «0.000 ! ) •
combreAp (2 * 25 mg/kg) and TNP-470 ami-angiogenesis ('
Volume (cm*;
small (1-3)
medium (3-7)
large (7-14)
combreAp + TNP-470
8days(N.S.)"
9 days (0 047) '*
l5days(N.S.)"
SD irrad. alone
13 days
15 days
12 days
1 x 30 mjg/kg)
combreAp alone
5 days
7 days
13 days
combreAp alone
5 days
6 days
8 days
TNP-470 alone
6 days
6 days
8 days
Qnv#l delays wsc daned al ihr fc\d of ire OIIV necessary m reach 8 x (he waning wtunc (and tunri). 4 x Ihe sarong volume
(medum u n n l and 3 x fr suing wiume (tijjr u n n ) far Ihc (eakd amis m»i« ihe ome b rcaii ihe same wiuine in camd
oondlni
SipilkaxyitfiilJnCTu:rpuw*diiiyluteuuihrttJK
N5. :r
(2) CombreAp p/us TNP-470 effect:
Rats bearing s.c. rhabdomyosarcoma tumors were treated twice with a
combreAp dose of 25 mg/kg. The time interval between the two injections was 8
days, a selection based on our previous studies with rat rhabdomyosarcoma. The
TNP-470 was injected s.c. three times in 7 days, with the first injection of 30 mg/kg at
1 day after the second combrcAp administration. Experiments were carried out in
duplicate. The results of these tumor size-related experiments are displayed in Figure
III. 1.2 (A: small, B: medium and C: large tumors).
The application of the TNP-470 after the combreAp introduced only a minor, non-
significantly. additional growth delay of 2 days, compared with that seen for
combrcAp alone. This additional growth delay was independent of the tumor size at
the start of the treatment (see Table HI. 1.1 B for details).
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111.1.4 Discussion
The introduction of anti-angiogenesis in the eighties , and more recently of
vascular targeting, provided new ways to attack solid tumor growth and its spread in
the body. Their mode of action involves a selective interference with blood vessel
constituents, and subsequently a cascade of tumor cell death.
In the perspectives of vascular targeting, modalities such as targeting tissue
factors, blocking antibodies to angiogenic factors orendothelium-related gene therapy
are being tested 116-18], Separately, the use of vascular targeting with tubulin
compromising compounds carries a substantial promise [19, 20]. Specifically with
combrcAp, a single injection of a non-toxic dose resulted in an extremely rapid and
extensive collapse of tumor vasculature. This effect and the resulting indirect anti-
tumor response have been demonstrated with several rodent tumor models [7, 8].
Whereas these detailed studies involved only small tumors ( « 3 cm'), we
demonstrated at least with a rat rhabdomyosarcoma tumor model that the extent of
growth delay depended on the size of the tumor at the time of combreAp injections:
i.e. the larger the tumor ( » 3 cm'), the firmer the response [11]. In comparison with
the standard radio- or chemotherapy, this clearly is a reverse size-dependent
responsiveness. It is therefore in our opinion important to introduce when possible the
volume-response relation into studies; moreover so since patients often present with
tumors much bigger than 2-3 cm'.
On the other hand, and for two decades already, anti-angiogenesis has also
been the topic of extensive anti-cancer research. The effectivity within the wide range
of angiogencsis inhibitors under investigation may be categorized between 'some
growth retardation' and tumor 'dormancy'. Also with TNP-470, a fumagillin analog
that inhibits proliferation and migration of endothelial cells and consequently unables
new vessel formation, in m-o activity has been demonstrated with a battery of tumor
models. Our earlier investigations in rat rhabdomyosarcoma with TNP-470 also
showed tumor growth retardation, with the effectivity depending on the
schedule/dosing used as well as the tumor volume at the start of the treatment [ 14].
Both these two different modes of vasculature-directed treatments, since not
curative on their own, have been combined in a few studies with tumor cell cytotoxic
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agents, e.g. cis-Platinum, Cyclophosphamidc, Taxol or ionizing radiation, and this
with variable success [8, 21-23].
The present in vivo investigations, using a rat rhabdomyosarcoma tumor
model, examined the effect from combining combrcAp cither with ionizing radiation
or with TNP-470 anti-angiogenic treatment.
(1) Ionizing radiation p/us combreAp:
The idea to apply irradiation before the combrcAp treatment was to avoid a
reduced radiation damage due to radioresistence from an enlarged hypoxic tumor cell
population. CombreAp indeed introduces necrosis, a process that is proceeded us well
as parallelled by hypoxia. as evidenced in rat rhabdomyosarcoma and other tumor
models [24, 25]. The selection of 8 Gy was based on the clinical use of such u fraction
size, as demonstrated for the relief of pain from skeletal mctastascs | r# . 26, 27|. Our
results with combreAp (25 mg/kg) given 1 day after the single irradiation demonstrate
a tumor size-dependent additional growth delay when compared with radiotherapy
given alone.The effectivity of the combined treatment was much more beneficial, at
least additive, in tumors larger than 7 cm' verm? those that were smaller at treatment
time, thus confirming our hypothesis. This differential overall response seen between
large and small tumors seems related to the stronger impact of the combreAp
treatment, and conversely, related to a lesser radiation effect because of the presence
of many more hypoxic cells in large tumors. The existence of severe hypoxia in large
tumors has been indicated previously in the rat rhabdomyosarcoma in a direct way
using the hypoxic marker NITP and indirectly with the degree of anaerobic bacterial
colonization with apathogenic C7<?5/r/'<fru/n [28]. On the other hand, the lack of a
positive change in growth delay in small tumors may be explained as the result of the
very efficient tumor cell killing from the irradiation as such. The induction of
combreAp related vessel damage would thus not substantially add (measurable in a
growth delay assay) to the tumor cell killing from irradiation. Our data differ from the
results obtained with the mouse adenocarcinoma CaNT tumor model by Chaplin er a/,
demonstrating a clear-cut gain in growth delay from combining irradiation with
combreAp [8]. In contrast however with our study, a fractionated irradiation schedule
was used in combination with a double combreAp injection. This difference may,
besides the fact that also carbogen breathing was concomittantly applied, offer some
explanation for the discrepancy. In addition, and of at least equal importance, the
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overall response to such a combined treatment will be related to the different
characteristics of each type of tumor cell: this means the sensitivity to irradiation with
at the same time the possibility of radiation-damaged cells to tolerate a prolonged
hypoxia condition as likely introduced by the combreAp treatment. The differential
effectivity will obviously also depend on the amount and the inherent quality of the
acquired tumor vessels in the various i« vivo models. The in vivo/in vi/ro mouse KHT
sarcoma experiments from Li ?/ a/ (29) also show evidence of enhanced tumor cell
kill when combreAp is combined with single dose irradiation, but the results are not
translated into growth delays and therefore unable a direct comparison with our data.
Whether this tumor-type independent improved response incorporates a
broadening of the therapeutic window remains a question. Based on the available
information in the literature about the combreAp activity and selectivity, combined
treatment limiting normal tissue reactions are not to be expected; the clinically
oriented question however deserves an answer with appropriate normal tissue in vivo
models.
(2) CombreAp p/us TNP-470:
We aimed to identify in rat rhabdomyosarcoma the possibility of an improved
response from combining combreAp with TNP-470, based on their distinctively
different vessel-related action mechanisms. We hypothesized that the use of TNP-470
after the combreAp injections, specifically during the time of tumor regrowth, may
result in increased tumor cell kill through the inhibition of the renewal of vascularity.
Proof of principle of anti-angiogenic activity being the major mechanism of TNP-470
anti-tumor activity has been discussed by several research groups [rg. 30].
Underlying our reasoning is (he fact (hat rat rhabdomyosarcoma regrowth was clearly
parallelled by angiogenesis. as evidenced with digital subtraction angiography [II].
The present experiment results obtained with the combreAp />/«$ TNP-470
combination show no statistically significant strengthening of the growth delay in rat
rhabdomyosarcoma as compared with the effect from combreAp alone. Independent
of tumor size, about 2 days of absolute extra growth delay was measured (see Table 1 -
B). The easy explanation for the very small effect from the TNP-470 may be found in
the possibility that not many new blood vessels were being formed at the time of the
TNP-470 application. This would obviously result in less vascular related anti-tumor
effects. Should we on the other hand think of a reduced accessibility of the TNP-470
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which was injected after the combrcAp? Possibly, but we hypothesized that mujorly
the acquired intra-tumor vasculature will be severely damaged by combrcAp, leaving
host vessels at the periphery of the tumor intact. This has been indicated in the nil
rhabdomyosarcoma using digital subtraction angiography and standard histopathology
techniques [ I I ] . Since vessel sprouting only can occur from these intact vessels in the
tumor periphery. TNP-470 should not find any obstruction to reach its target and
should thus do the job.
In conclusion, the present data and those from other groups (8, 29)
demonstrate a potential benefit from combining ionizing radiation with combreAp
treatments, but at the same time illustrate a tumor size and -type dependent
effectivity. Our results also indicate no significant improvement from the use of a
TNP-470 treatment given after the combrcAp injection.
The fact that the mechanisms of combreAp activity are not yet fully
understood, necessitates more experiment data involving different sequences,
treatment duration/fractionation/dosing as well as immunohistochcmical
measurements related to cndothelial cell growth factors and hypoxia.
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Summary
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a
promising strategy for hypoxia-specific tumour targeting. The present study shows that the
use of the vascular targeting compound combretastatin A-4 phosphate could significantly
(p<O.OOI) increase the number of C/asfr/'diM/n vegetative cells in rat rhabdomyosarcomas with
sizes between 0.2 cm' and 3 cm'. Furthermore, this study showed that administration of
mclronida/olc for a 9-day period was sufficient to eliminate systemically administered
C7o5/ru/;'um from the tumour. Moreover, previous C/05r/7</ii<m spore administration did not
effect tumour colonisation, regardless of the immune response status of the host.
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11L2.A.1. Introduction
The potential use of gene therapy as an oncologic treatment modality httbom
extensively addressed. Most viral and non-viral transfer systems developed so far are
however hampered in their use due to the lack of tumour specificity and low
transduction efficiencies (I). An innovative approach for tumour specific delivery of
therapeutic proteins is to use bacterial vector systems (2. 3, 4). Infections with
anaerobic bacteria can spontaneously occur in rodent as well as in human tumours [S,
6). Tumours can also be infected by systemic injections of spores of anaerobic
bacteria, as shown both in rodent tumours |7] and in cancer patients in clinical trials
|8).This is explained by the fact that rodent (e.g. 9) and most human [e.g. IO| solid
tumours have size-related hypoxic/necrotic regions. Hypoxie conditions arc normally
absent in healthy tissues and necrosis is never detected 110).
Recombinant DNA techniques and specific transformation protocols are
available to engineer C7os/rW/'nm to express and secrete proteins (hat have a potential
antitumoral effect [II , 12]. Administration of such recombinant C/rtf/nY/ium to a
tumour-bearing organism may thus likely result in a tumour-specific effect.
Using the rhabdomyosarcoma rat tumour model we have previously quantified
the specific colonisation of tumours with volumes larger than 3 cm' following
systemic administration of clostridial spores. Tumours with smaller size were
inefficiently colonised. Spores did not germinate in normal tissues [2],
Experiments were now set up in order to improve the colonisation capacity of
this bacterial-based vector system in much smaller tumours (<3 cm'). Such tumours
inherently have less hypoxia and little or no necrosis. It was previously shown in
several rodent tumour models that combrelaslalin A-4 phosphate (combrcAp),
injected at systemically non-toxic doses, induced a severe vascular shutdown within
3-6 hours resulting in the development of extensive necrosis at 1-3 days (e.g. 13, 14).
Based on this knowledge, administration of C/os/nd/um spores was combined with
combreAp administration and the effect on increase in bacterial colonisation was
analysed.
We further investigated the efficiency by which CVortrüftum could be removed
from a tumour-bearing organism following antibiotic treatment. This safety aspect is
of much importance in case adverse effects should occur. Finally, the extent of the
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host immune response and the possible hindrance on colonisation capacity of the
tumour with C7arfria7um after a first application was evaluated.
III.2.A.2. Materials and methods
in, ru/nowr modi/ and co/«nua//w«
C7<u/rü//um .v/wroj?enes used in this study was isolated in our laboratory and
identified following I6S rRNA sequence determination. This strain was cultivated in
an anaerobic incubator (Forma Scientific, model 1024) with palladium as a catalyst on
trypticasc-soy-agar medium (BioMörieux) enriched with 5% defribinated horse blood
for 10 days at 37°C. Spores were collected from the agar plates as described [2].
Male WAG/Rij rats with subcutaneously (s.c.) transplanted syngeneic
rhabdomyosarcomas were used as in vivo model [2]. The test tumours were divided
into groups of predetermined volume: < 1 cm\ 1-3 cm' and > 3 cm\ depending on the
type of experiments. Before and during the follow-up period, the rats were given food
and water arf //b/rum in a conventional housing facility. When tumours reached the
predetcmiined volume, 10* spores were systemically administered to the rats and
colonisation was analysed as described [2].
Vascu/ar /argefing compound
Freshly prepared solutions of combrctastatin A-4 phosphate (CombreAp;
OXiGENE, Lund, Sweden) were given i.p. as a 0.5 ml saline solution in a
concentration of 25 mgkg"'. 4 h after C7<mridiMm administration. This allowed the
distribution of the bacteria throughout the vascular network and, specifically, in the
tumours, prior to any possible tumour blood vessel damage. A number of tumour-
bearing rats received a sham-injection of saline only.
rrea/mrnr an«/ sufrs? ^ ucnf rumour ro/onisatfon
To test the effect of antibiotic therapy, metronidazole (Flagyl*) dissolved in
saline was injected intraperitoneally (i.p.) at 200mgkg' twice a day for up to 9 days,
starting at day 5 following spore administration. Control animals received the same
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volume of saline. Six hours after the last injection, bacterial colonisation was
determined [2|. Each experiment was repeated three times, each time with a minimum
of 3 to 5 animals per point.
The possibility of C/o5fnJium to colonise tumours in animals that hud been
treated with metronida/ole to eradicate previously administered clostridia was
investigated. Non-tumour bearing rats were therefore injected systcmically with 10*
spores. To control the distribution of bacteria in the body, liver and spleen were
removed from randomly selected rats at day 5 following injection und unulysed for the
presence of C7artri</iu;n spores (rcf. 2 for technique). All other animals were after
spore injection treated with metmnidazole according to the optimal schedule and time
(sec 'Results'). Five weeks after (he antibiotic treatment, tumours were implanted s.c.
in the flank of the treated animals. When the tumours reached a volume of at least 4
cm', clostridial spores were systcmically injected and five days later, colonisation was
evaluated. A control group of tumour-bearing WAG/Rij rats, which did not receive
pretreatment with clostridial spores and mctronidazole, were injected only once with a
suspension of 10* spores. Tumour specimen were microscopically inspected at the
time of removal. Quantification of C/asfm/ium-specific antibodies was assessed using
an ELISA-assay (Eurogenetics, Tessenderlo, Belgium). WAG/Rij rats with and
without tumour, not previously injected with C/ortrütium were used as a negative
control. During the course of the experiments body temperature and weight was
followed.
EL/SA assay
Blood samples were taken from each rat and the amount of C/oj/WJ/u/n-
specific antibodies in serum was estimated using an enzyme immunoassay. Therefore,
clostridial cell lysates were generated by sonication, and ISO ul of 100-fold dilutions
of the protein extracts were used to coat the solid phase in a 96-well microlitrc plate.
Following overnight incubation at 4°C, plates were washed three times with
phosphate-buffered saline (PBS). For signal detection, 125 ul of the isolated rat
antisera used as primary antibodies were diluted 1/2000 in PBS containing 7.5% BSA,
incubated for 45 min. at 37°C. 125 ul of horse radish peroxidase conjugated rabbit
anti-rat immunoglobulins (1/1000) was taken as secondary antibodies (Dakopatts). It
was subsequently added to the appropriate wells and incubated for 45 min. at 37°C.
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After each antibody incubation step, blots were washed five times with PBS + 0.1%
Twecn-80. For detection, lOOjil substrate was added to each well. The reaction was
stopped after 20 min. by adding 50 pi of 2N H2SO4 and (he colour change in the
plates was read at 450 nm. A standard curve was prepared by serially diluting a pool
of maximal rcsponders in PBS containing 7.5% bovine serum albumin, and ranged
from I to 1000 arbitrary units/ml. Samples and controls were added in duplicate to the
appropriate wells.
III.2.A.3. Results
(1) Improvement of clostridial tumour colonisation
In a first scries of experiments, rats bearing tumours with volumes larger than
3 cm* were injected systcmically with 10* C7osfm/»Mm spores. The tumours were
resected 4-5 days after (he injection and dilutions of the tumour homogenates were
prepared in saline. The analysis of bacterial growth in these larger tumours revealed
the presence of at least 10^  colony forming units (cfu) per g of tumour tissue (Figure
I, left panels).
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In a second series, 10* C7oy/Wa7u/n spores were injected in rats bearing tumours
measuring between 0.2 and 3 cm*. In contrast to the larger tumours, the number of
vegetative cells in these tumours was significantly lower (p<0.0001) (Figure 1, right
panels) and varied between 0 cfu and 10' cfu per g tissue, with exceptionally a tumour
containing 10* cfu per g tissue. When these small tumours were classified in volumes
between 1 and 3 cm' and volumes less than 1 cm', the differences in colonisation
were even more striking (Figure 2, left panels). In the very small tumours (< I cm*),
on average about 10°* cfu of C7oy/ru//H/n per g tissue were detected.
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In parallel with these investigations, rats bearing rhabdomyosarcomas of
closely matched sizes were treated with a single i.p. injection of combreAp at 4 h after
administration of the C/orfriV/iu/n spores. This resulted in a strongly improved
colonisation (Figure 2, right panels). Particularly, tumours smaller than 1 cm'
contained in most instances 10*-10^ cfu per g tissue. The bacterial colonisation of
combreAp-trcated tumours of 1 -3 cm' or < 1 cm' was significantly higher than the
colonisation of sham-treated tumours of a similar size (with p < 0.001 and p < 0.0001
respectively).
Gross examination of excised sham-treated small tumours always revealed a
firm, viable and wcll-vasculariscd tissue at transsection. Histopathological
examination demonstrated few, scattered foci of necrosis only in some tumours of 1-3
cm , whereas this was not observed in tumours < lcnr\ In tumours treated with
combreAp alone, a large core of necrosis with a rim of viable tumour tissue was
observed at 4-5 days post-injection (the standard time-interval for colonisation
measurements). When C/ojfri'di'imj spores were injected 4 h prior to the combreAp
treatment, most of the tumours became soft on palpation during the follow-up period.
When transscctcd for the colonisation study, these tumours showed some degree of
liquid necrosis. Also in these tumours, viable tissue was a rim surrounding the
nccrotic centre.
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(2) Removal of C/osfrü/iu/n from the tumour by antibiotic treatment
Experiments were designed to determine the effectiveness of an antibiotic
treatment specific for anaerobes in order to stop tumour colonisation, if desired. After
treatment with metronidazole, a decreasing number of cfu was measured in the
tumour as a function of treatment duration. In these treated animals, the number of
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cells before and after heating was not significantly different (data not shown), which
means that all the vegetative cells were killed. After 9 days no bacterial growth nor
presence of spores was detected in the tumours of metronidazole treated animals
(Figure 3). During this period, colonisation in tumours of animals that were not
treated with antibiotics remained high. These results clearly indicate that
metronidazole eradicates
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(3) Analysis of the occurrence of C/osrrü/ium-specific antibodies and effect on
tumour colonisation
An ELJSA assay was developed to quantify the amount of C7osrndju/n-
specific antibodies in serum of rats that were previously injected with
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spores and treated with metronida/olc before re-injcction. A comparison was made
both with animals receiving C7<urn'</ium spores only once and with animals that were
not treated at all. To obtain a sensitive assay, optimum concentrations of primary
serum antibody, HRP labeled second antibody and antigen were determined. A
maximum discrimination between the points in the standard curve could thus be
obtained. After a single injection of C7as/ri</»nm spores, an immune response was
induced but only a small amount of C/orfnV/ium-specific antibodies could be detected
(< SO AU). The majority (8/12) of animals that were injected twice with CTwrriV/ium
spores could be labeled as 'non-responders': the amount of C/orfriY/ium-spccific
antibodies was not different compared to the animals that received only one injection
of the spore suspension. In the other animals of this experimental group (4/12), un
increase (up to tenfold) of C/osfrü/i'um-specific antibodies in the serum could be
demonstrated. Interestingly, regardless of the immune response status, tumour
colonisation did occur to the same extent in animals that were previously injected with
a clostridial spore suspension compared to animals that were not treated before.
Again, spores as well as vegetative cells were present in the tumour as concluded
from the difference in c.f.u. before and after heat treatment and confirmed by
microscopical evaluation of the tumour suspensions. During the course of the
experiments, no change in body temperatures or body weights could be detected.
III.2.A.4. Discussion
It is a well established phenomenon that certain species of C/orfmftum can
selectively colonise hypoxic/necrotic regions of solid tumours |2, 3). It intrinsically
means that if a recombinant C7ojmdium is administered to a tumour-bearing subject
for therapeutic purposes, the mctabolically active cells that produce the therapeutic
proteins will be present only in the solid tumour. In addition to this tumour selectivity,
a major advantage of using an anaerobic bacterial vector system is the fact that the
therapeutic gene has not to be transduced into the genome of the tumour cell. Eventual
problems herewith associated such as a low transduction efficiency or the risk of
insertional mutagenesis can be avoided, since the anti-cancer gene will be expressed
and secreted from the bacteria.
However, one of the disadvantages of such type of vector system so far was
that only larger tumours (>3 cm') could become colonised with C/osrnV/ium. The
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latter finding would hamper the overall advantage of the proposed C/os/rid/M/n tumour
targeting system being of low value when considering both small tumours or tumours
not containing severe hypoxic/necrotic regions. The present investigations
demonstrated that a significant improvement of tumour colonisation in very small
tumours (<3 cm') could be obtained when the rats were injected with combreAp after
the administration of clostridial spores. The results of the histopathological analysis as
well as the gross appearance at the transscction of the tumour indicated the strong
relationship between the increased presence of C7o5fm//M//i and the level of necrosis
induced by the combrcAp.
Important considerations using 'classical' gene therapy vectors should be
made regarding the safely issues. The concern that viral vectors could recombine with
endogenous viruses remains. If the therapeutic gene would have unexpected major
side-effects, the recombinant virus can not be removed from the body and gene
expression can not be stopped. Furthermore, viruses are classified as hazardous agents
class 2 in the European list of infectious agents. In contrast, the apathogenic bacteria
used in our approach are classified as hazardous agents class 1 and sensitive to
antibiotics. Moreover, as demonstrated in our studies, complete removal of vegetative
C/«5/nV//wm cells, even from the tumour tissue, could be achieved after 9 days with
mclronidazolc, a standard antibiotic for anaerobic infection,. Metronidazole and other
electron-affinity drugs have also been used as hypoxic radiosensitizers in cancer
treatment, which suggests that these compounds have the ability to reach the hypoxic,
badly perfused tumour areas (15]. This indicates that their anti-bacterial effectivity is
not hindered by the absence of an adequate intratumoral vascular network.
Another important factor to be taken into consideration is an eventually
induced host immune response after a single or repeated administration of C7e«/r/dium
and its consequences on tumour colonisation. The results indicated the absence of
such an induced immune response in most rats. Moreover, even in those animals that
showed a tenfold increase in C/osfrü/jum-specific antibodies in the serum following a
second bacterial administration, colonisation of tumours was not affected. This is of
great importance, since it implies that long-term production of the therapeutic proteins
from the engineered C/(um</ium is possible in tumours.
Taken together, these findings illustrate the advantages of a vascular targeting
approach for use in C/ortnV/ium-guided tumour targeting systems. Furthermore, this
combined anti-cancer approach may also incorporate radiation therapy. Combining
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combrcAp with single dose irradiation irradiation seems to result in an increased
tumour-cell kill, as indicated by at least three research teams (Li ?r a/. 116), Chaplin rr
a/. [17] and Landuyt ?r a/. [18]) using rodent tumours. These strategics may be
exploited to improve both the selectivity to target the solid tumours, and the
subsequent production of the therapeutic protein into the extracellular
microenvironmenl of these tumours.
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Summary
Anaerobic bacteria selectively proliferate in and colonize the hypoxic/necrotic
regions of solid tumors. As a consequence, recombinant apathogenic clostridia can be used as
a selective vector system in an enzyme/prodrug approach for the treatment of cancer. To test
this hypothesis, the £;c/i«nc/iia co/i cytosine deaminase coding sequence was fused in-frame
to the clostridia] clostripain promoter and signal sequence and cloned in the pKNT19 shuttle
plasmid to transform C/ortru/ium üctfo6i/fv/icum.
Significant levels of functional cytosine deaminase were detected in lysates and
supcrnalunts of the recombinant clostridia as measured by thin layer chromatography analysis.
More importantly, for the first time the in vivo applicability of recombinant C/otfrn/iu/n as a
tumor specific vector for the local secretion of cytosine deaminase in the tumor was
demonstrated by the administration of the engineered C70jrn<//H/n to WAG/Rij rats bearing
subcutaneously implanted syngeneic rhabdomyosarcomas. Four days after the recombinant
bacteria were injected, enzyme activity was detected in the tumors but not in normal tissues.
These results demonstrate the potential use of recombinant C. ac«ro6ur>7icum as a
tumor-specific delivery system for the transfer of therapeutic genes to solid tumors.
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1IL2.B.1. Introduction
Despite the improvement of conventional radio- and chemotherapy, lengthy
survival rates and prognosis remain poor for many cancer patients. This led to a strong
interest in the investigation of anti-cancer protocols based on gene therapy. Herein,
the use of suicide genes has been put forward to create artificial differences in
sensitivity between normal and malignant cells, with specifically the CDase/S-FC
suicide gene/prodrug system being well investigated. The major hurdle, however,
remains the tumor-specific transfer of the gene encoding (he therapeutic protein.
A fundamental difference between normal and tumor tissue is the presence of
extensive hypoxia, responsible for e.g. resistance to radiotherapy and chemotherapy.
Hypoxia can however also be appreciated as an opportunity for tumor selective
therapy (1). Apathogenic clostridia have been proven to selectively proliferate in the
hypoxic/necrotic regions of solid tumors and the potential use of C7orfm/;um as an
anti-tumor agent has been indicated earlier in clinical studies. With the current
availability of recombinant DNA technology for clostridia and the possibility to
transform C7arm'<//'um, the use of these strictly anaerobic bacteria has attracted
renewed interest. As such, recombinant apathogenic clostridia may be used as a
selective vector system in an enzyme/prodrug approach for the treatment of cancer.
In the present report, we describe the development of recombinant C. acero/wry/ZcHm
strains secreting high amounts of cytosinc dcaminase (CDase) in medium. The £. co/i
CDase was therefore placed under transcriptional control of the C nirfo/yf/cum
clostripain promotor, preceded by the clostripain signal sequence, and cloned in a
stable E. co/i-C/orfnYtium shuttle vector. We also document the expression and
secretion of functional enzyme at the tumor site, when recombinant clostridia were
administered to rhabdomyosarcoma-bearing WAG/Rij rats. The use of vascular
targeting treatment with Combretastatin A-4 phosphate in combination with the
suicide gene transfer system enabled a dose intensification of CDase activity.
HI.2.B.2. Materials and methods
fiarrma/ sfrains, p&umüfr, D/V/l manipulation; anrf franjr/brmarion proc«/wre»
C. ac£/0bt4f>7«cu/n DSM792 and NI4082 were cultivated in 2xYT medium or
RCM (supplemented with erythromycin when needed) at 37°C in an anaerobic
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cabinet. Transformation procedures and DNA manipulations were carried out
essentially as described*. The E. co/i/C. acefofcufy/zcMm shuttle plasmid pKNT19 was
used as a cloning vector. The £. co// CDase gene (coJA) was present on the pSDl 12
plasmid, kindly provided by S. Danielsen. The clostripain regulatory sequence was
available on CI60-23, a gift from Weisheimer Malz (Andernach, Germany).
Mutations were carried out using the 'Altered Sites™ in v/rro Mutagenesis kit'
(Promcga). An EcoRI site (oligonucleotide 5'-
ATTATCCTTGGATTGAATTCCTGGA-TTTGCATA-3) was introduced four
codons upstream of the signal sequence cleavage site of the clostripain regulatory
sequence. The resulting 1.04 kb //i/idIII/£coRI fragment was cloned in pBluescript,
leading to pBsclosEcoRI. A Seal site was introduced two codons downstream of the
GTG initiation codon of the co</A-cDNA with oligo 5'-
GCGTTATTCGACACAGTACTCCTCCACATGC-3'. pBsclosEcoRI was digested
with Ea>RI, treated with Klenow polymcrase, digested with ÄamHI and treated with
alkaline phosphatase prior to »>i-/rame fusion with the 1.5 kb Scal/ßaraHI fragment
containing the codA-cDNA. Finally, the closcodA-fragment was isolated by
W</idIIl/fl<miHI digestion and inserted into the ßa»iHI/«//idIH digested pKNT19
shuttle vector.
<m</ arfiw/y m«ajrureme/i/ o/cy/osjne Jeaimnase in vi/ro
Detection of CDase was performed using Western blot analysis with mAb
16D8F2'\ For quantification of CDase activity, bacteria were sampled at various
stages of growth. To 45 pi of Tris.HCl (pH 7.5) buffered lysates and supernatants, 5-
FC (15mM) was added and the solution was incubated for 24 h at 37 °C. Five pi
aliquots of the samples and 5-FC/5-FU controls were then applied to tic plates (Silica
gel 60 F:v», Merck) that were developed in 8 6 * butanol in water. Sections of the
plates that contained the 5-FU UV-absorbing spots (254 nm) were cut out and 5-FU
was extracted with incthanol. The extract was dried in a vacuum centrifuge (Hetovac)
and the residue was resuspended in 50 ul of mcthanol. A 10 pi aliquot was then added
to ISX) pi HCI 0.1 M and the concentration of 5-FU was assayed
spcctrophotomctrically at OD;,**™ This approach made quantitative monitoring of
CDase activity possible without the need of radioactive substrates. Before incubation
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with S-FC. the pH of the buffered reaction mixture was controlled and proven to be
pH 7.2-7.4, for all samples taken at different stages dunng growth.
/n
WAG/Rij rats with subcutancously implanted rhabdomyosarcomas of 6 to 20
cm' were used. Rccombinant C. acrro/jury/'Vu/n DSM792 and N14O82 spores were
administered intratumorally. Injection of C. art/ofrufy/iVum having no or the empty
vector, was used as a control. Four to five days following injection, tumors and
normal tissues excised and grinded to look microscopically for the presence of
C/oj/rutf/M/n vegetative cells following Gram-staining. CDasc activity in tumors was
measured following homogenisation of the tumor (-350 mg) in 450 ul of PBS
containing I ugml ' aprotinin, 30 ugml' phcnylmcthylsulfonyl fluoride and 5 inM
EDTA. Following incubation for 24 hours at 37 °C with 15 mM 5-FC. 50 pi aliquots
were taken, quenched in mcthanol and applied on Silicagcl 60 F;vi sheets (hat were
developed in 86% butanol/water. After drying, 5-FU spots were visualized under
short-wave UV illumination.
III.2.B.3. Results and discussion
(1) /n w'fro analysis of recombinant CDase activity in C7os/n</<um
The recombinant constructs in E. co/i were quality-controlled by DNA
sequence analysis and Western blotting. pKNT19closcodA was subsequently
electroporaled into C. amobim/zcM/w DSM792 and NI4082. After Western blotting of
proteins present in supcrnatants and lysates of early-logarithmic growth phase
recombinant C/orfnY/ium cultures, mAb 16D8F2 strongly reacted with a protein of
about 52 kDa, which corresponds to £. co// CDase. No CDasc could be detected in
supcrnatants or lysates of plasmid-free C. ac r^ofe«r>7icM/n cultures, or in cultures
carrying the empty pKNTI9 plasmid alone. The functionality of the clostripain
regulatory sequences preceding the CDase coding sequence was herewith evidenced,
not only for its expression but also for the secretion of this large protein by
C/orti-ü/zum. Our results parallel the observation that shuttle vectors based on the
replicon of the fiaci//uj plasmid pIM13 showed structural and segregational stability.
We previously demonstrated this with the £. co/z-C ac^/o/wfy/Vcu/n pKNT19 and
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pIMPl shuttle vectors, developed for the secretion of the anti-tumor and
radiosensitizing agent tumor necrosis factor alpha (TNFa). Significant amounts of
biologically active TNFa were measured in both lysates and supematants of
recombinant clostridia [2].
Because of the potential importance of CDase and 5-FC/5-FU conversion in
antitumor therapy, we focused on the expression and secretion of CDase by
C7<Mrn'rf/M/M at various stages of growth. Maximum enzyme activity in lysates (1084.5
± 189.5 pmol 5-FC converted to 5-FU min' ml ' cell lysate) was obtained as the
bacteria reached the stationary growth phase (OD6oonm~l-5) (Fig. 1A). This activity
level was maintained within the follow-up period of 20 hours (data not shown). In
supematants of recombinant C. ace/ofcM/y/icum NI4082, the CDase activity reached a
maximum (701.9 ± 104.3 pmol 5-FC converted into 5-FU min"' ml ' supematants) at
the early-logarithmic growth phase at ODooonm-1-2 (Fig. IB). Subsequently, CDase
activity decreased. This might be a consequence of the acidification of the culture
medium resulting in denaturation of CDase. Experiments with the recombinant C.
ac*ftf/>wf>7/cum DSM792 strain resulted in similar CDase activity patterns in both
lysates and supematants (data not shown). When high levels of active CDase could be
delivered at the tumor site, this would result in significant amounts of 5-FU in the
tumor, which could lead to tumor control by 5-FU without systemic toxicity.
Interestingly, it has been reported that 5-FU at the tumor site does not return rapidly
into the systemic circulation, offering the opportunity for the therapeutic agent to
exert locally its antineoplastic effects [3].
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(2) Detection of functional cytosine deaminase in vivo
The results of the <>i vivo observations are summarised in Table I. Gram-
staining revealed the presence of vegetative C/05/rüftum cells in tumor specimen, but
not in samples of liver or spleen. CDase activity was present only in tumors injected
with recombinant bacteria. As expected, no functional enzyme was present in tumors
injected with plasmid-free bacteria, in tumors treated with bacteria carrying the empty
piasmid or in the normal tissues (liver, spleen) that were investigated. Animals,
concomitantly treated with CombreAp, showed higher incidence of CDase positive
tumours (100% versus 58%). Moreover, the level of active CDase in these tumor
specimens was considerably higher (mean conversion efficiency of 5-FC to 5-FU
-11%) as compared to tumours not treated with CombreAp (mean conversion
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efficiency of 5-FC to 5-FU -3%). We already showed that targeting the tumor
vasculature in rhabdomyosarcoma bearing WAG/Rij rats using CombreAp resulted in
extensive necrosis, observed already at 4 days post-injection [4]. The present results
with rccombinanl clostridia confirmed the hypothesis that combining the
administration of clostridia with CombreAp treatment should result in an increased
therapeutic dose intensity. This should obviously also be expected in combinations
with other strategies that induce tumor necrosis, such as radiotherapy or
chemotherapy. The engineered C/osfm/iu/n strains can thus be considered as J/I sir«
'cell factories', that produce and secrete anti-tumor therapeutics specifically at the
tumor site, restricting activity to the tumor being targeted. As a consequence, this
strategy holds promise for circumventing the limited therapeutic window of 5-FU
treatment.
Table 1. Overview of the in vivo experiments with clostridia recombinant for CDase
Strain
NI4()82/pKNTI9closcodA
NI4082/pKNTI9
DSM792/pKNT 19closcod A
DSM792/pKNTI 9closcodA
DSM792/pKNT19
Tissue
tumor
liver
spleen
tumor
tumor
liver
spleen
tumor
liver
spleen
tumor
tumor
CombreAp* Presence''
Cdase
yes
no
no
No
+ yes
+ no
+ no
yes
no
no
+ no
no
Incidence (%)
10/18(55)
0/5 (0)
0/5 (0)
0/6(0)
9/9(100)
0/5 (0)
0/5 (0)
4/6 (66)
0/3(0)
0/3(0)
0/4 (0)
0/6(0)
CDase
lever
+
NA"
NA
NA
++
NA
NA
+
NA
NA
NA
NA
* single i.p. administration, 25 mg kg'
* presence of CDase was evaluated using tic-analysis, measuring conversion of 5-PC to 5-FU
* +, low; ++, moderate-high
* NA : not applicable
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To show that the conversion of 5-FC to 5-FU was a consequence of the CDasc
present in (he tumor and was not due to the metabolic activity of the C/turnY/ium
during the incubation, metronida/ole (SO ug ml') was added (o rhabdomyosarcomu
tumor homogenates prior to the incubation to kill all bacteria. No difference in the 5-
FC/S-FU conversion pattern was observed whether or not mctronidazole was added.
Moreover. CDase activity was also detected when only supcrnatants of tumor
homogenates were incubated with 5-FC. Conversion efficiencies of 5-FC to 5-FU
after incubation with supematants were similar as obtained after incubation with the
whole tumor homogenates. Taken together, this clearly indicates that the CDase
activity, recovered from the intratumoral tissue, originates from active enzyme that is
secreted by metabolically active recombinant clostridia during the m vivo colonization
of the tumor.
Separated from its anti-ncoplastic effects, 5-FU also sensitizes tumor cells to
irradiation, and significant improvements in tumor response can therefore be
anticipated when the approach described in the present manuscript would be
combined with radiotherapy. We recently showed that sufficient 5-FU should be
available if the conversion efficiency from 5-FC is 1-3%, enabling sensilization
enhancement ratios of 1.1 to 1.2 with daily 2 Gy fractioned radiotherapy [5). Based on
the obtained conversion efficiencies both in virro and /'n vivo using the plasmids
discussed above, it is reasonable to expect that clinically significant radiosensiti/.ing
effects can be achieved using the recombinant clostridia.
Besides its exquisite tumor selectivity, the application of the clostridial
delivery vehicle is very safe. It elicits only a minor host immune response and the
clostridial cells can be removed from the body at any time by the administration of
metronidazole.
Overall, the present in viVo/ün w'fro investigations provide strong evidence for
the potential use of apathogenic clostridia, genetically engineered to express cytosine
deaminase in anticancer therapy.
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Summary
Purpose: To reduce functional MRI susceptibility distortion at the air/tissue interphase in
animal experiments.
Materials and Methods: We investigated the applicability of a body-adaptable flexible mold
consisting of a fast setting alginate. This technique was implemented for subcutaneous
growing tumors in rats and for the brains of monkeys.
Results: The Tj*-wcighted GE-EPI data obtained with body-adapted mold showed a reduction
of susceptibility artefacts and improved image quality. With both rat tumor and monkey brain,
an optimized match with the anatomical Tl images was possible.
Conclusion: The present mold methodology is a rapid, easy and inexpensive way to reduce
magnetic susceptibility during animal GE-EPI.
Animal fMRI using a body-«dap«cd mold 139
IV. 1.1. Introduction
Functional MRI techniques that are based on the paramagnetic properties of
oxygen, i.e. the blood oxygen level dependent (BOLD) endogenous contrast, rely on
Tj* effects [*.g. 1.2]. Gradient-echo, echo planar imaging (GE-EP1) acquisitions arc
implemented to achieve high temporal resolution and optimal visualization of the
BOLD effect within the whole organ/body.
In our research groups, we have 2 major applications for the BOLD effect: (i)
investigations in rats with subcutancously growing tumors, aiming to non-invasivcly
define the tumors that may respond to hypoxia modulators; and (ii) the study of the
brain function, performed in monkeys. These GE-EPl studies highlighted a well
known difficulty: signal loss and image distortions due to magnetic field
inhomogeneity specifically at the air/tissue interface. Magnetic susceptibility
distortion could be reduced after shimming, but the results remained unsatisfactory in
the pilot experiments.
The present study reports a practical procedure that involves a body-adapted alginatc
mold. This mold was tested first in the GE-EPI acquisitions for rat tumors and later on
in imaging monkey brains, with (he results showing improved image quality.
IV.1.2. Materials and methods
One set of experiments was performed with male adult WAG/Rij rats,
weighting 280-300 g. Rhabdomyosarcoma tumors were implanted subcutancously at
the lower flank region as 1 mm' pieces and had grown to a size of 3-14 cm' at the
time of the present functional MRI study. To avoid movement, the rats were
anesthetized with 0.1 ml/100 g Nembutal® injected intraperitoneally a few minutes
prior the imaging. They were positioned supine within a home made cylindrical
resonator coil of 14 cm diameter.
A separate investigation involved the use of Macaque monkeys. The brains were
imaged in awake animals, positioned supine in the magnet. They were specifically
trained to behave and feel at ease and thus allowing an adequate imaging.
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Imaging was performed using a whole body 1.5 T MR scanner (Magnetom
Vision, Siemens; Erlangen, Germany), without and with the body-adapted mold.
The imaging session started with the acquisition of a scout sequence in 3 directions,
followed by a multi-angle projection (MAP) shim and the functional MRI acquisition
with a scries of single shot T2*-weighted GE-EPI images (TE 39 ms).
Anatomical images were obtained using T|-weighted spin echo measurements.
The anaesthetized animals were placed supine in a flexible plastic recipient, to
allow a correct mold application and an easy insertion in the cylindrical coil. A mold
of about 1.5 cm thickness was applied securely around the tumors and the major part
of the body up to the claviculac. The mold material consisted of a fast setting alginate
powder Xanlalgin® Select (Bayer Dental, Leverkusen, Germany), which after mixing
with tepid water became a viscous mass that stiffened gently in less than 2 minutes.
The mold remained flexible and did not interfere with the breathing capacity of the
animals. The mold could be removed rapidly from the body without any difficulty.
• a/way
The initially viscous mold was positioned on the upper part of the head and allowed to
stiffen before the insertion of the animal into the magnet.
Dato
Images of the tumor-bearing rat and of the monkey brain without and with
mold, obtained after careful shimming, were printed together with the anatomical
images. Quality and global confidence was appreciated on images with the mold not
being visible.
IV. 1.3. Results
Images of the rats that were acquired without the use of any covering mold
showed major susceptibility artefacts. These problems are demonstrated by
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representative images from sagittal sections of two different rats at the level of the
tumor (Fig. IB and 2A). The folded upper surface and the edgy tumor massa, as well
as loss of tumor/body volume, are visible. Without the alginate mold, mapping the
GE-EPI data to the Ti-weighted anatomical MR images (sec for example in Fig. IB
verm; 1A) was very difficult, as was also the identification of the location of the
tumor. Classical MAP shimming resulted in a minor amelioration of the image
quality.
With the use of the body-adapted mold and after applying MAP shimming, GE-EPI
image improvement was obvious: easily appreciated were the flattening of the base of
the sagittal image and an increase in the body diameter parallel with the phase
encoded dorso-ventral direction (Fig. 1C and 2B). The Tj'-weightcd images of the
rats with the mold more closely resembled the whole body volume and to some extent
the anatomy obtained with the T|-weighted spin echo scanning (Fig.ID and 2C). It
became possible to un-ambigously locate the tumor and to describe the shape of the
lesion.
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Figure 1: /*<wiW <4 i.v r/i? sajf/f/a/ 7/ ana/omica/ inui^ o /a raf af f/ir /*vW o/rn* fumor
fl. C ««(/ /)) «na* f/if »IW/I / « » r <^<fc/ o/ J/i«- moW on 7-»ri'|f/i/«</ imaj?inj? (A vrrii«
5<i^ifw/ G£-£/*/ rj*-»ri'j?'iW i>mi^«, (fi) H-ir/iour ana* (C) H-«A I/I^ a/^ina/f moW; f/
/<H'«/i<>« a/i</ if.v lolumf />rr5«nrr</ in /wnW C corrr/ar? H-irn »n* anafomica/ image J/IOHTI in
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Figure 2: Sa£/7ra/ C£-£/ ' / 7";* /ma^ej o///i<? ra/ ZWy a/ //i* /*vW o/f/i* rumor fa« arrotv),
a/ia" (B) iv/'f/i f/ie fcoJv-oaa/'/^ moW fsom« i/ice />05/7/on f/iroM /^i /M/n«r). 77M" 7"/-
anarom/ca/ /magf rs aaVferf /or compamo« (O. /n //if />r«<rnce o/ f/ie »wW, //«*
am/ac«
tv/r/iour a/u/ tv/7/i //it a/^/na/e moW.
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The use of a 2 cm thick mold always resulted in an improved brain
delineation, as can be appreciated from the example in figure 3. A transverse GE-EPI
image through the brain of a monkey, prior to the use of the mold, is shown in figure
3A. From the comparison with the anatomical image taken at the same level of the
brain (Fig. 3C), an important deviation along the phase encoded direction is obvious.
Following the positioning of the flexible mold material, an almost perfect match of
the contour of the brain has been obtained (Fig. 3B).
F i g u r e 3 : (A) GE-EP/ f /wmrrsa/ «c/i'on ofc/ain^J »'ir/iou; ana" (Ä) GE-EP/
«if fnc Slime /occifion a.v (/A), wi'f/t feoa'v-aa'apf«/ mo/</ a/>p/»>d on fn* 5M/*rior part o /
monit^v rmwiMiw. (C) rrannvraa/ 7"/-Hri^n*</ s^c/ion </«/>icrin; /A* aiuuomy
//if monilrv />rni'/i f«im* /ot'ci/ion a$ J4 J. 77I^ />rain confour Zias <*«i Jf/in^a/f J H'
.w/h»'«rr in /Mnrl C o/«f HOS /n^n /xis/^J on/o f^J ana* fß). /f is
eia//v rt/on^ /n^ />n«w^ rnc<>ci?</ </«'rrc/M>»i. i.«. /«wn /ron/ fo tacA m rAu a/lima/
arc mi«/i
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IV.1.4. Discussion
One of the shortcomings with GE sequences for in vivo whole body functional
MRI, with BOLD endogenous contrast, is the major geometric distortion and
susceptibility artifacts related to the air/tissue interface.
The present data describe a practical and inexpensive method by which this important
source of distortion and susceptibility can be reduced. The body-adapted alginate
mold increases the accuracy to delineate regions of intensity changes and the
quantification of these changes. This technique has been successfully used in a larger
series of investigations which evaluated modulation of tumor oxygcnation [3j. The
application of this type of mold also improves the image quality and the delineation of
the anatomical structures to be investigated, such as indicated with the monkey brain.
A dedicated BOLD and MION functional MRI study using the mold material, more
broadly demonstrates the necessity to obtain high quality images to assess motion-
related brain function in monkeys [4].
In summary, the impact of the susceptibility-reducing mold procedure as seen with the
rodent tumor model as well as with the monkey brain analysis is obvious. It is a rapid
and easy technique that introduces an objective decrease of magnetic susceptibility, a
result that will contribute to the basic research in functional imaging.
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Summary
To evaluate the feasibility of functional magnetic resonance imaging (fMRI) at 1.5
Tcsla, exploiting 'blood oxygenation level-dependent" (BOLD) contrast, for detecting
changes in whole tumour oxygenation induced by carbogen (5 % CO2 + 95 % O2) inhalation
of the host.
Adult WAG/Rij rats with rhabdomyosarcomas growing subcutaneously in the lower
flank, were imaged when tumours reached sizes between I cm' and 11 cm' (n=12). Air and
carbogen were alternatively supplied at 2 l/min using a snouth mask. Imaging was done on a
1.5 T MR scanner using a Tj* weighted GE-EPI sequence. Analysis of the whole tumour EPI
images was based on statistical parametric maps; voxels with and without signal intensity
changes (SIC) were recorded. Significance thresholds were set at p < 0.05, corrected for
multiple comparisons.
In continuous air breathing condition, 3/12 tumours showed significant negative SIC
and I tumour had a clcarcut positive SIC. The remaining tumours showed very little or no
change. When switching to carbogen breathing, the SIC were significantly positive in 10/12
tumours. Negative SIC were present in 4 tumours, of which three were simultaneously
characterised by positive SIC. The overall analysis indicated that 6 of the 12 tumours could
be considered as strong positive respondent to carbogen.
Our research demonstrates the applicability of fMRI GE-EPI at 1.5 T to study ole
tumour oxygenation non-invasively. The observed negative SIC during air condition may
reflect the presence of transient hypoxia during these measurements. Selection of tumours on
the basis of their individual response to carbogen is possible, indicating a role of such non-
invasive measurements for using tailor-made treatments.
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IV J.I . Introduction
The inappropriate vascular remodeling and the related hypoxia arc critical
issues for survival and certainly growth of tumours.as well as for the presence of
radio- and chemotherapy resistance; tumours with high oxygenaiion status on average
responded more favourably than those that were poorly oxygenated [e.g. 1-3). This
knowledge has led to the introduction and evaluation of agents that may have the
potential to promote the oxygenation status of the tumour. Agents such as carbogen (S
% CO2 + 95 % O2) and nicotinamidc have been shown to selectively improve tumour
oxygenation, both with rodent and human tumours (4-6). Subsequently, the
combination of such agents specifically with radiotherapy demonstrated the potential
benefit of positive tumour oxygenation changes |7-IO).
Research has in parallel also focussed on the measurement of hypoxia levels in
tumours, using a battery of different techniques [11-15]. A drawback is their
invasiveness and the absence of whole tumour information. Although improving the
understanding of the physiology and biology of different tumour types, such
techniques on their own do not meet the requirements to enable f.i. non-invasive
repeated oxygenation measurements, before and during treatments, in relatively short
time. They neither allow the assessment of anatomically difficult and deep seated
tumours. The availability of a non-invasive total body imaging technique could thus
positively guide oxygenation modulating treatments that aim to improve tumour
control and patient survival.
One potential candidate principle, extensively used in functional MRI to assess
brain activity triggered with external stimuli, involves the endogenous blood
oxygenation level-dependent (BOLD) contrast [16-181. The BOLD contrast relates to
the endogenous change of paramagnetic dcoxyhcmoglobine that is translated in
variation of MR signals. The method thus likely offers a non-invasive and clinically
applicable tool to detect changes in tumour oxygenation from different treatments
without the need to inject contrast agents, nor to disturb the tumour
microenvironment. Tumour oxygenation data were therefrom collected using fMRI
applying a gradient-recalled echo (GRE) technique, specifically in function of
responses to various gas breathing [19-22]. Two important limitations remain. The
measurements have been performed with single slice techniques and they often
involved magnetic field strenghts above 4 T, exept some limited experience with both
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animal and patient pilot studies [23-26]; extrapolation of these results to lower field
strength systems is not straightforward.
The major objective of our investigation was to evaluate the application of
BOLD contrast fMRI at a clinical whole body 1.5 T using a fast EPI sequence, as a
non-invasive tool to determine changes in tumour oxygenation from carbogen
breathing of the host. The relationship between carbogen responses and tumour
volume was also adressed. Finally, the question was raised whether the proposed
analysis allowed for clearcut selection of carbogen responsive tumours.
IV.2.2. Materials and methods
/n Wvo /mm/Mr
Male adult WAG/Rij rats, with a body weight of about 270 g, were implanted
subcutancously (s.c.) in the lower flank region with a 1 mm' piece of syngeneic
rhabdomyosarcoma (Rl tumour). At the time of the fMRI study their volume was
estimated using a calliper, correcting for the thickness of the skin. The experiments
were planned to incorporate various tumour sizes ranging between 0.1 and 14 cm'.
i / «r imaging
The rats were anaesthetised with 0.1 ml/100 g Nembutal® (SANOfi, Brussels,
Belgium) injected intrapcritoncally a few minutes prior to imaging. To reduce
susceptibility artefacts, the animals were placed supine in a flexible plastic recipient,
and a mould of about 1.5 cm thickness was applied around the tumours and the major
part of the body. This mould consists of the fast setting alginate powder Xantalgin®
(Bayer Dental, Leverkusen, Germany), remaining flexible and not interfering with the
breathing capacity of the animals; it could be removed rapidly from the body without
difficulty 127],
Throughout the measurements, the animals were breathing air or carbogen
(95% Oi, 5% COj) at a flow rate of 2 1/min through a small snout mask.
These animal-based experiments were in agreement with the Ethical
Committee for Animal Care and Use of the K.U.Leuven (Belgium) and the national
guidelines.
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The fMRI studies were performed on a whole body 1.5 Tesla MR scanner
(Magnetom Vision, Siemens, Erlangen, Germany), equipped with a gradient system
achieving 25 mT/m in 300 jis. A home made cylindrical coil of 14 cm diameter was
used as antenna.
The imaging sessions consisted of the acquisition of scout images, followed by
shimming and fMRI acquisitions. For the fMRI acquisitions, series of sagittal T2*
weighted echo planar imaging (EPI) images were acquired through the entire animal.
The parameters for the single shot Ti* weighted EPI sequence used were: TE 39 ms,
echo spacing 0.8 ms, band width 1950 Hz/pixel, field of view 288 x 384 mm, matrix
% x 128, slice thickness 3 mm, interstice gap 1 mm.
Two series, each consisting of 120 measurements of 16 slices and each lasting 8 min,
were obtained sequentially. During the first series air was continuously delivered,
while during the second series air and carbogen were delivered alternatively (i.e. one
min of air / five min of carbogen / two min of air).
ana/ysis
The images were transferred to a work station (Silicon Graphics), corrected for
motion and spacially smoothed by convoluting the data using a Gaussian imput
function with a full-width at '/i maximum. Statistical parametric maps (SPM) were
computed using SPM96 [28,29). The evaluation of the T2* images was always done
with reference to the mean baseline signal intensity (obtained for air condition during
the first min of the imaging) of every individual tumour screening. The different
conditions were modeled with a box car function convolved with the hemodynamic
response function implemented as a delayed Gaussian function [30] in the context of
the general linear model, as employed by SPM96. Global changes were adjusted for
by proportional scaling, and low-frequency confounding effects were removed by an
appropriate high pass filter. Specific effects were tested by applying appropriate linear
contrasts to the parameter estimates for each condition, resulting in a t statistic for
each voxel. These statistics constitute an SPM. Significance thresholds were set at p <
0.05, corrected for multiple comparisons.
Using a mouse-controlled cursor, the borders of the tumours were manually
traced on the T2* weighed EPI images by the same experienced radiologist (R.H.).
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The number of voxels within the defined tumour volumes was counted, and a MR
determined tumour volume was calculated by multiplying the number of voxels with
their dimensions ( 3 x 3 x 4 mm); the MR determined tumour volume was compared
with the calliper-method using linear regression.
Voxels showing a statistically significant increase or decrease in signal
intensity during air breathing were counted. The relative degree of signal intensity
changes (SIC) during air condition, compared to the baseline signal intensity, was
calculated for each of the voxels showing changes above the significance threshold.
By summing up all the negative SIC and separately all the positive SIC, two areas-
undcr-thc-curves (AUC's) were calculated; these AUC's were normalized by dividing
them by the total number of voxels within the MR defined tumour volume.
The same type of analysis was applied for the EPI images obtained during the
intermittent carbogen breathing condition. These analyses also were performed for all
tumours.
The results obtained during the air or the carbogen breathing condition were
compared using a paired non-parametric statistical test (Wilcoxon's signed rank test);
p-vulucs <0.05 were considered significant.
IV.2.3. Results
The comparison of the tumour sizes (n = 12), as either obtained from the T2*
weighted images or with the calliper, is shown in Figure 1. The MR determined
volumes of the 12 rat rhabdomyosarcomas under investigation ranged from 1.62 to
10.37 cm*. Using the calliper method, the volume of the tumours measured just before
the fMRl study ranged from 0.9 to 8.9 cm'. An optimal linear fit was obtained
between both methods of measuring volume by using the following function: MR
volume = 0.8451 x calipcr volume + 0.3982 (R = 0.84). The MR defined tumour
volumes were used throughout the further analysis of all fMRI images. Figure 2
displays a representative image of the rat tumour signal intensity evaluation, both
during air breathing (Figure 2A) and during the carbogen breathing condition (Figure
2B).
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Table 1 gives an overview of the absolute number of voxels that showed
positive, negative or zero signal intensity changes (SIC) either during the continuous
air breathing condition or during the switch to carbogen. Figure 3, A and B,
summarizes the voxel-based measurements (percentages deduced from the absolute
values presented in Table 1). During the prolonged air breathing, voxels with negative
SIC were present in some tumours (Figure 3 A), clearly seen in 6 of the 12 tumours:
about or less than 10 % of the total voxel number in 4 tumours, 27 % and 43 % in 2
other tumours (Table 1). The number of voxels that remained without SIC dominated
the picture for the various tumours. In comparison with the results during air
breathing, a significantly (p = 0.022) lower percentage of voxels showing zero SIC
was found during the carbogen breathing (Figure 3 B). This was parallelled by a non-
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significant (p = 0.907) decrease in voxels with negative SIC, and by a highly
significant (p = 0.002) increase in percentage of voxels with a positive SIC. In 4
tumours for which voxels with negative SIC were recorded during air breathing (< 7
% - 43 %), no negative SIC were observed during the carbogen condition (Table 1). A
negative change of signal intensity of 22 % and 56 % was observed in 2 tumours, and
5-9 % in 2 others, when the rats breathed carbogen (Table I). For those tumours that
were responsive to carbogen, the change in the EPI Ti* signal intensity was very
rapid, most often reaching the highest value within 1 minute after the switch from air
to carbogen (data not shown).
Table 1. Tumour responses during air or carbogen breathing of the rats; analysis on
the basis of voxel numbers (T2* weighted images)
MR
volume
(cm*)
1.62
1.8
2.52
3.17
3.6
4J2
4.97
6.8
7.42
7.99
8.42
10J7
Total
number of
voxels
45
50
70
88
101
120
138
189
206
222
234
288
1751
negative
0
0
0
9
I I
51
37
0
0
16
5
17
146
AIR condition
(responding voxels)
zero
45
50
67
7«
«9
69
/O/
/«9
206
206
m
27/
1569
positive
0
0
3
1
1
0
0
0
0
0
31
0
36
CARBOGEN condHloa
(responding voxels)
negative
1
I I
1
2
12
2
0
42
0
1
0
5
77
zero
JO
J2
*J
W
«7
89
/06
/¥7
/90
//2
2 »
2/2
1338
positive
14
7
24
2
2
29
32
0
16
109
30
71
336
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A Air breathing condition B Carbogen breathing condition
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Figure 4 (A and B) shows the variation in AUC for SIC, present for air
breathing and, although to a lesser extent, also for carbogen breathing conditions. No
correlation was apparent between the AUC for SIC and the various tumour volumes
thai were analysed.
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Overall, in comparison with the air breathing condition (Figure 4 A), a much
larger AUC for the positive signal changes is found during the carbogen breathing
(Figure 4 B). As also can be read from Figure 3 B, in 3 tumours a clearcut AUC of
negative SIC is present. With these three tumours (sizes at imaging = 1.8 cm'; 3.6 cm'
and 6.8 cm' respectively), the benefit of using carbogen to improve the oxygenation
status is nihil.
Figure 5 displays, only for the carbogen breathing condition, the percentage of
voxels showing positive SIC compared with the AUC for degree of positive SIC
within the responding voxels for the remaining 9 tumours individually (main aim of
our investigation). The product of the reponding voxels and their respective AUC,
calculated for each tumour separately, indicates that only 6 of the 12 tumours were
very significant (p«0.05) responsive to the carbogen application (insert Figure 5,
relative unit for response).
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IV.2.4. Discussion
In choosing a MR scanning technique for fMRI. spatial resolution, acquisition
speed (i.e. temporal resolution) and signal-to-noise ratio (SNR) play an important
role. Optimizing one factor will be at the cost of the other two. Echo planar imaging
allows rapid acquisition of a single slice. Repeated measurements of the same slice
require a time interval of at least 2s. In the present study, however, this lime window
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was used for the measurement of adjacent slices. Disadvantages of the technique are
the relatively low spatial resolution and the sensitivity to susceptibility artefacts. The
large acquisition band width needed for the rapid sampling results in a poor SNR.
Susceptibility artefacts are caused by field inhomogcneity at air/tissue interfaces,
gradient non-linearity and chemical shift. Using a body-adapted mould, significant
improvement of image quality has been obtained by decreasing the magnetic
susceptibilily at the air/body interface boundary of an animal [27], However, this
correction is not perfect, and may explain the non-optimal correlation (R=0.84)
between the tumour volumes determined by the calliper method with those measured
on the MRI GE-EPI-images, with the former being the most secure volume approach.
The low SNR is compensated by repeated measurements and analysis using statistical
methods.
Studies on fMRI of tumours published until now used single slice ORE
sequences at high Held strength [e.g. 19-21]. The in-plane spatial resolution and SNR
during these experiments is better than what can be obtained with the GE -EPI
technique that we describe. Applying the GRE technique, however, we could not
visualize an effect of carbogen inhalation as attempted in at least 5 tumour bearing
rats, wheras GE-EPI images did show a response in all the tumours that were analysed
An obvious limitation of GRE images is that the single section may not be
representative for the entire tumour. EPI sequences allow however to examine the
entire body/tumour in a multi-slice fashion, and may therefore provide a more
comprehensive evaluation of the tumour response to carbogen breathing. The limited
spatial resolution of GE-EPI introduces a problem of signal averaging within each
voxel, and thus a very detailed mapping of tumour oxygenation is not feasible, which
counterbalances somewhat the gain of temporal resolution obtainable with this
imaging procedure. However, every technique used to estimate tumour oxygenation
suffers to some extent from the problem of signal averaging; furthermore, none of the
thus far applied methodologies, including microelectrode measurements, allows
evaluation of the entire tumour.
During the application of the body-adapted mould and the subsequent BOLD
contrast fMRI , the animals were immobilised with an anaesthetic. Possible subtle
effects of the Nembutal* anaethesia on the effectivity of carbogen breathing and
160 Chapter IV.2
consequently also on the oxygenation of the s.c. growing rhabdomyosarcomas can not
be excluded. However, no straightforward agreement on such a bias can be deduced
from the literature involving s.c. tumour models. Some blood flow reducing or
hypoxia inducing effect from this anaesthetic has been reported, but it was
insignificant or not at all different from the s.c. tumour condition during physical
restraint without any sedation [31-33]. Moreover, all of these published data involved
tumours much smaller than I cm'. With our study, the s.c. rhabdomyosarcomas were
much larger at the time of the imaging; and thus inherent to the natural process of
hypoxia development during tumour growth, any slight additional hypoxia from the
use of the pcntobarbital likely will become proportionately of lesser influence
anyway. The moulding should not affect the tumour oxygenation condition since it
remains flexible, thus allowing the normal breathing of the animals.
The present fMRI data for rat rhabdomyosarcoma show that when carbogen
was administered to the rats bearing the rhabdomyosarcoma, a rapid change (less than
1 minute to reach the maximum) in T2* weighted signal intensity was observed in
most tumours, independent of the tumor size (graphical pixel-by-pixel data-analysis
not shown). With BOLD contrast GE-EPI fMRI, increases in T2* weighted signal
intensity are related to decreases in deoxyhemoglobin, and therefore indicative for
improved oxygenation in the tissue under investigation. Inversely, decreases in T2*
weighted signal intensity arc related to increases in deoxyhemoglobin and thus likely
reflective for tissue hypoxia induction. Other research teams investigated oxygenation
changes under different gass breathing conditions in a variety of tumor systems [19-
21 ]. The carbogen-induced changes of tumour oxygenation published for these other
tumor types with different techniques were, when present, also recorded rapid in time
and to a significant extent.
The second observation in our study was the large intertumour variability as
well as an important intratumour difference in SIC when the rats breathed carbogen.
Separate from the major presence of tumour parts with zero changes, in most tumours
positive signal intensity changes were observed (indicating improved oxygenation).
However, also negative changes in intensity (indicating reduced oxygenation) were
seen both in separate as well as in the same tumours. This was true when analyzing
both the number of responding voxels, and the changes of the signal intensity within
these voxels (AUC).
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The proportion of voxels with zero SIC (see Table 1) should be interpreted as
the simultaneous presence of oxygenated tumour parts and areas of necrosis,
proportionately depending on the tumour size at measurement. A correlation between
the at random distribution/extent of necrosis and the tumour volume in rat
rhabdomyosarcomas has been indicated previously by histopathological evaluation of
hematoxylin-eosin stained sections of tumours of the present size-range investigated
[34]. On the other hand, sufficient hemoglobin saturation with oxygen at the time of
imaging could also explain the absence of a carbogen effect in some tumour parts.
This information correlates with the heterogeneous response to carbogen breathing
seen in our fMRI studies (present work) and the GRE-MRI studies of others [e.g. 20-
22]. Already in this perspective of heterogeneity, the possibility to analyse the whole
tumour in a short time is an attractive and necessary feature to quantitatc the variable
effects of oxygenation modifying compounds.
The increases in signal intensity observed with MR spcctroscopic imaging of
s.c. R323OAC rat mammary adenocarcinomas (volumes of about 0.5 cm') have been
discussed as the result of improved blood oxygen concentration and oxygen diffusion
[35]. Such relationships may likely explain the carbogcn-induccd positive changes in
T2* weighted BOLD contrast images as measured in the present investigation with
s.c. rat rhabdomyosarcomas. Also other studies illustrate that the amelioration of
tumour oxygenation is highly related to the blood pO2 increases. With near infrared
spectroscopy, van der Sanden and colleagues demonstrated a clearcut improvement of
the oxyhemoglobin concentration in tumour blood, when the mice breathed carbogen
at any CO2 content between 1 % and 5 % [36]. These measurements were performed
on a xenografted human glioma, when tumour size was on average 0.5 cm'.
Obviously, the balance between the rate of oxygen consumption of tumour and
stromal cells and the oxygen diffusion during carbogen application will impact on the
overall analysis outcome. The latter will therefore and in the first place depend on the
tumour type, inplantation site, and its changing general morphology as well as quality
of vascularity during growth.
Furthermore, yet not really surprising, carbogen also induced prominent
negative signal intensity changes in 3 rhabdomyosarcomas, independent of tumour
size. In at least three studies involving GRE-MRI of different tumours, researchers
demonstrated a transient decrease in signal intensity or no response during carbogen
breathing [21,23,37]. Also with MRS, such negative as well as positive SIC from
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carbogen inhalation compared to air breathing (control condition) have been seen[ 19].
These observations strcnghten the biological reality of this phenomenon. This
heterogeneity within a single tumour was attributed by Al Hallaq and colleagues to an
intratumoral 'steal effect' [19]. They suggested that this could be due to redistribution
of blood flow within the tumours. In a patient study, the steal effect seemed the most
obvious explanation for the reduced GRE-MRI signal during the carbogen breathing
as observed in two different tumour types [23]. To our opinion, it could be the result
of the intratumoral change in balance between the vasodilating effect from the CCh
partner and the vasoconstriction effect from the O: partner in the carbogen. It should
be noted that the breathing of 100 % oxygen either had no effect on the oxy- to
dcoxyhcmoglobin ratio, or reduced (he oxyhemoglobin concentration in the tumour
blood circulation as the result of vasoconstriction, as indicated through two different
studies [36,38]. These 'seemingly conflicting' phenomena may well be the result of a
similar physiological response from the intratumoral vasculature, partly controlled to
a thusfar unknown extent of the microvessel maturity and configuration.
Finally, also with the prolonged air-only condition heterogeneity was
appreciated, with tumours showing some positivity in SIC and others with definite
evidence of negative SIC. The presence of voxels with negative signal intensity
during 8 minutes of air breathing (identical box car function analysis as with the
carbogen response analysis), as seen strongly in 3 rhabdomyosarcoma tumours and
slightly in 3 others, could indicate the occurence of areas with acute-type transient
tumour hypoxia at the time of the MRI multislice measurements. This type of hypoxia
is a relatively well-known physiological behavior that is the result of sequential
opening and closure of tumour microregional vessels [39,40]. These intermittent
changes of (he oxygenation status in tumours may thus relate to a transient reduction
in crythrocytc tlux, with subscqently alterations in oxygen diffusion and consumption
rate [sec for discussion e.g. 41,42]. The time course of transient changes in blood flow
within a rat mammary adenocarcinoma has been documented using Fourier analysis,
and shown to be much stronger present in the tumour as compared with muscle [43].
The overall scenery indicates the appropriateness of imaging the whole tumour
for the translation of oxygenation changes. Other methods appreciated until now as
'standard' (such as Eppendorf pOj microelectrode or biopsy-related hypoxia
immunohistochemistry) enable a certain yet limited level of knowledge about the
oxygenation condition in tumours, and only however for those that can be reached.
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The fMRI data obtained with GE-EPI and presented here-in, being non-invasive and
short in time, should permit the study of tumour oxygenalion also during the treatment
phase. Several recent small-scaled clinical studies, using either microeleetrode pOj
measurements or perfusion MRI, reported the importance to evaluate tumour
characteristics before and during the course of radiochemo- or radiation-only therapy
[*.g. 44-46].
Our initial results with the rat rhabdomyosarcoma tumour model provide good
evidence for the feasibility to image tumour oxygcnation using the BOLD fMRI with
GE-EPI operating at 1.5 Tesla. Significant inter- and intratumoral heterogeneity in
changes in T2*. reflecting changes in intratumoral oxygcnation status from the
carbogen breathing, were observed. The imaging and analysis methodology enabled
the selection of tumours that reacted favourably (or the opposite) to the carbogen
breathing of the hosts. The fMRI methodology also allowed to indicate the
spontaneous presence of transient hypoxia, as evidenced by the analysis of
intratumoral signal intensity fluctuations that occurred during continuous (8 minutes)
air breathing of the rats. The proposed total body fMRI methodology involving a
clinical applicable magnetic Held strength and fast whole tumour screening should
help to select for differential oxygen-improvement related treatments.
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V.l. Introductory notes
Expanded vascularization is a prerequisite for continued growth of solid tumours. This
important biological event seems mainly regulated through the 'parallel' development of
hypoxia, in combination with oncogenic transformation and cell survival selection. Both
experimental laboratory and clinical evidence have been supplied for the existence of these
tumour characteristics, globally referred to as a highly specific micro-environment. Many
published data point at the influence of these characteristics on classical therapy and their
association with increased malignancy, metastasis and ultimately prognosis. These include the
development of bio-reductive compounds, selective drug-delivery systems, both vessel- and
hypoxia-specific gene therapy systems, and anti-angiogenesis and vascular targeting. In
parallel, becoming aware of this potential for therapy, researchers aimed to identify the intra-
tumoural vessel network and oxygenation status using biopsy- or microprobe-based
technologies and non-invasive nuclear medicine or radiology imaging.
The broad background of these important tumour micro-environment aspects is
presented in Chapter I.I. and sets the scene of the present thesis research.
The investigations were guided by several working hypotheses and questions in
relation to the tumour micro-environment (see Chapter 1.2). Briefly, they related to
(i) Anti-ungiogcncsis and vascular targeting are (wo different approaches, for which
the efficacy in general and more specifically the impact of tumour volume was
investigated;
(ii) Since these treatments on their own were not expected to eradicate the whole
tumour, whatever its size, vascular targeting was combined with radiotherapy or with
anti-angiogencsis;
(iii) The poor intra-tumoural oxygenation condition was previously exploited (by our
research group) to establish an anaerobe bacteria-based therapeutic protein transfer
system. Tumour volume-related quality and safety of this selective transfer system,
and specifically the further improvement of colonization and protein expression from
the combination with vascular targeting, were evaluated;
- (iiii) Finally, based on the potential to modulate the intra-tumoural hypoxic condition,
a fast and whole body functional MR imaging methodology was investigated for its
feasibility to select tumours for a specific oxygenation treatment.
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Assessment of the hypotheses and questions (Chapter II. 1 to Chapter IV.2), and
eventual inter-comparison of the various tumour micro-environment-related research, was
done with the rat rhabdomyosarcoma (Rl). This tumour originated in the jaw musculature of
inbred WAG/Rij rats that received a total body irradiation, and has been established in vi/ro
and in vivo (subcutaneous implantation) for radiobiological investigations since three decades
[1, 2]. Cell kinetic measurements showed a cell cycle duration of about 20 hours, and
correspondingly a volume doubling time of 3-5 days [3]. The rhabdomyosarcoma tumour
consists of spindle cells, showing atypia and numerous mitoses (see Figure V. 1).
Figure V.I: /te/»r»?nfafive im<j£* (x/00) o/ /jarajjfn-emfcwft/«/ non-fmw«/ Wia/>aVvnv0sarc0/na
; naimafory/in/rarin 5/ai/iin;.
More detailed description using histology and digital subtraction angiography can be found in
the description of research results of Chapter II. 1 and II.2.
V.2. Tumour blood vessel-based treatment efficacy in relation with tumour volume
The first part of the present prc-clinical studies elaborated the activity of anti-
angiogenesis (using the fumagillin analogue TNP-470) and vascular targeting (using the
tubulin-interfering combretastatin A-4 phosphate (combreAp)). specifically investigating
effects in a broad range of tumour sizes.
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Although surely not a general rule for all anti-angiogenic compounds, and although growth
delay was definitely longer with small tumours, a transient growth inhibition after repeat
subcutaneous injections of TNP-470 was present with tumours having a volume even up to 7
cm' at treatment start (see Chapter II.1). One plausible explanation of this result may be
offered by the relation between the relatively rapid tumour growth and accompanying
angiogenesis. Most if not all anti-angiogenic compounds show activity against very small
tumours (often very much less than 0.5 cm*) only, a growth period during which additional
blood vessel formation may be more important for these tumour types. This possibility has
however been questioned by Beecken and colleagues, demonstrating about equal effectivity in
both poorly vasculari/.cd and highly vascularized human bladder carcinoma cell lines growing
in severe combined immune deficient (SCID) mice [4]. TNP-470 has been shown to be a
strong cytostatic agent with both human and rat endothelial cells [5]. Additionally, TNP-470
showed activity in a broad range of tumour types, both primary lesions and metastasis. The
compound was therefore one of the first to enter a clinical phase I trial, and was in several
.phase II-III trials (ejr review Jfi.O Very rrr^ntlv however thf dny» has JW.P withdrawn .fenrp
clinical application. This likely is the consequence of side effects, narrowing the therapeutic
window. Severe skin reactions at the site of the repeated subcutaneous injections were
observed in our rat study, as was a transient drop in the body weight (10-15 %) at the doses
used.
Obviously, drug activity in relation to the tumour type and the site of growth, including
quality and quantity of angiogenesis as well as the phase of the angiogenic cascade with
which the drug interferes, all need attention when comparing various published data-sets. Yet,
bused on the volume aspect in our study and taking into account the relatively short doubling
time of rodent tumours including xenografts as compared with the temporal evolution of
human cancer, the lack of important anti-angiogenic activity in clinical studies is not fully
surprising, as very large tumours are involved in human phase MI studies.
Opposed to the results with TNP-470 anti-angiogenesis is the intra-tumoural activity
of the vascular targeting compound combreAp. It is our conviction that a distinction should be
made between newly sprouting vessels and the already established yet immature micro-
circulation. Indeed, not only is proliferation and migration of endothelial cells necessary to
expand vasculari/alion. but of equal importance is the perfect establishment of the endothelial
cell cytoskcleton for adequate function within the blood vessel wall. This characteristic
(together with the necessity of support cells such as pcricytes) could make the difference in
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response to agents that specifically target endothelium, as during tumour growth more vessels
become established and thus dividing endothelial cells are not exclusively the vulnerable
element. Using digital subtraction angiography we were able to visualize the acute and
dramatic reduction in the intra-tumoural vascular network evolving in a short time after
combreAp treatment. The parallel process of necrosis formation in about the total tumour
volume confirmed the idea to kill tumour cells indirectly by cutting off the supply of
proliferation nutrients (see Chapter II.2). More severe overall intra-tumoural changes from
the use of a single intra-peritoneal combreAp injection were anticipated in our studies
involving large rat rhabdomyosarcoma tumours as compared to small ones. It does however
seem that the effectivity of combreAp differs somewhat among tumour types, with for
example the mouse KHT sarcoma [7] and the WAG/Rij rat rhabdomyosarcoma (present thesis
research) showing more intra-tumoural damage than the mouse C3H mammary carcinoma [8|
or the rat BT4An glioma [9].
Notwithstanding the presence or absence of a difference in morphological outcome, a very
important observation with the WAG/Rij rat rhabdomyosarcoma was a clear-cut 'inverse'
effectivity of combreAp as compared with the tumour volume-dependent efficacy obtained in
general, as well as with the same tumour model, with radiotherapy (sec Figure V.2, A wrai«
B) or chemotherapy.
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Indeed with larger tumors (>6 cm') a much stronger effect in terms of growth delay was
measured, including some regression shortly after the combreAp treatment (see Chapter II.2,
Figure II.2.1), whereas with the very small tumours no significant growth delay was present.
Absence of clear-cut growth delays was also observed with the different rodent tumour
studies published until now (always involving volumes less than 1 cm*). A similar finding of
tumour volume-related increase in combreAp efficacy has been presented by D.W. Siemann
(invited lecture, ESTRO workshop on The Biology of Radiation Oncology, June 2001,
Fulgstf, Denmark) using the KHT mouse sarcoma model. In this study, 2-3 logs less cell
survival was measured with tumours of 1.5-2 g than with those of only 0.1-0.5 g following a
single intrapcritoneal injection with combreAp. Our results, and likely those with the KHT
sarcoma, strongly suggests a relationship between combreAp activity and the quantity of ill-
formed blood vessels established in the larger tumours as compared with the smaller ones.
The importance of deficient blood vessel maturation during the establishment of a functional
intra-tumoural vascularity has been nicely documented by Benjamin and colleagues [10]and
Morikawa and colleagues [ M J. These data, demonstrating the control of tumour blood vessel
sprouting and maturation through the complex involvement of pericytes, vascular endothelial
growth factor and angiopoietins, may help to explain the selectivity of vascular targeting with
combreAp and analogues. The information certainly invites further research to exploit the
difference between normal host vasculature and the aberrant tumour vessels, a difference that
may allow improved anti-cancer therapies.
Of equal potential to explain the 'inverse' tumour size-related effect could be the growing
imbalance of viable hypoxic tumour cells in regions with ill-formed vasculature, a fraction
that becomes proportionately larger with increase in tumour size, compared with well-
oxygenated cells in regions with mature blood vessels. Adding to this explanation is the fact
that the combreAp activity not only is directed at endothelium, but seemingly also exerts a
cylostatic activity towards tumour cells (12, 13]. This has recently been further investigated
and clearly demonstrated by us (Angiogenesis Laboratory. Univ. Hosp. Maastricht) with i/i
vi'/rr> research involving various human tumour cell lines as well as the Rl
rhabdomyosarcoma cells [14]. In fact, using the 'H-thymidine incorporation assay, the anti-
proliferativc activity of combreAp was 20-30 times stronger in the human breast (Hs578T)
and colon carcinoma (LS174T) cell lines as compared with human umbilical vein endothelial
cells. A similar difference of sensitivity was measured in favour of the Rl rhabdomyosarcoma
cells as compared with rat heart endothelial cells in these investigations.
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Though indications for an anti-angiogenic activity were present in some published research
papers on combreAp vascular targeting, we provided direct evidence that such a component
plays a role in the overall anti-tumour activity [14]. Indeed, not only inhibition of endothelial
cell migration (HUVEC) but also reduced sprouting (BCE) was measured after combreAp
application at drug doses that did not interfere with the cell growth (no inhibition of the
proliferative activity). Yet, should this activity be most important, the small-sized
rhabdomyosarcoma tumours would show a significant growth delay, as was observed with the
larger tumours (differential staining of newly formed vessels versus all blood vessels can help
to further clarify this item). This deduction is also based on the TNP-470 results, where
important growth delays were measured for small rhabdomyosarcoma tumours; yet, we
should bear in mind that a different anti-angiogenic pathway is involved (combreAp
interfering with the tubulin polymerisation, while TNP-470 inhibits mclhionyl
aminopeptidase-2 activity), and drug-scheduling for both agents was different as well.
Elevated interstitial fluid pressure (IFP) is a known obstacle for the effective drug delivery in
solid tumours. The importance to investigate IFP is further highlighted by a recent publication
from Milosevic and colleagues, which illustrates that IFP may serve as a significant
independent prognostic factor in cervix cancer patients 115]. Part of the research recently
published by Eikesdal and colleagues [16], using (he subcutaneous implanted BT4An rat
glioma, was to assess whether and how the IFP was affected by combreAp and whether such
information could add to the understanding of the differential efficacy of the drug in large
versus small tumours. Our underlying hypothesis was the occurrence of a strong IFP
reduction by virtue of the fact that combreAp induces intra-iumoural vascular collapse and
vessel number decrease. However, independent of tumour size (range 3-19 cm*), no effect
from a single combreAp treatment on the IFP was measured in this rat glioma tumour model.
This could eventually reflect the following: the combrcAp-induccd vascular damage,
including vessel permeability changes, could improve diffusion of drug into tumour tissues,
which however is counter-balanced by a 'renewed' increase of the IFP from increased vessel
leakage. The lack of IFP changes may be explained on the basis of a lesser efficacy of
combreAp in the rat glioma (see [9]); however, in the referred study only very small tumours
were analysed. At some point of this complex pattern of changes in IFP, it may be of interest
to think of self-trapping of combreAp in larger tumours. An extended presence of low doses
of combreAp could be more endothelial as well as tumour cell cytostatic than a brief exposure
(evidence for the latter can be found through published /« wrro results). More extensive
evaluation in different tumour models including eventually rat rhabdomyosarcoma, is for sure
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necessary tu enable a conclusion about the impact of IFP changes on the overall tumou
response after combreAp treatments. The importance of such studies is accentuated b
ongoing studies on combinations with chemotherapeutic drugs.
The discovery of several mechanisms firmly associated with the tumour-selective bloa
vessel targeting capacity (in the first place), has evolved into small scale clinical research
Currently a limited number of phase MB clinical studies in the United States and the Unite
Kingdom examine the impact of combreAp on tumour physiology as well as genera
compliance and normal organ function. Reports at scientific meetings have provided som
encouraging data about the tumour-selective vascular-mediated effects for various tumou
types and locations, specifically involving dynamic magnetic resonance imaging of tumou
pcrfusion (Rustin G. «r a/, proceedings of the first International Conference on Translations
Research, 2001, Lugano, Switzerland). Very recently, data about these clinical phase I studie
have been published, indicating the potent efficacy of repeated cycles of combreAp in th<
treatment of patients with advanced cancer at doses which did not induce limiting acute sid<
wftfleoK, 117' •Tb»*..ppi\rQaf:be«-use .^J«w*yftlual'* i^iroQi''"»no''.»onnnp'Mtisau'*^fAfccr'iifenr
combreAp treatments indicate vascularity-related anti-tumour activity at doses that do not
induce systemic toxicity.
Taking into account the substantial efficacy demonstrated in our (and others) pre-clinical
research, as well as the small scale clinical study, and with the necessary caution in mind, the
use of such a vascular targeting agent may be beneficial in the first place to de-bulk large
tumours. Secondly, vascular targeting may help to improve overall outcome when combined
with specifically selected treatment strategies, such as a triple combination using irradiation
and either chemotherapy or a hypoxia-based therapy.
The fact that combreAp induces a strong anti-tumour effect at doses below the MID,
generated the search for novel agents with stronger anti-tumour activity. One example is the
tubulin-binding agent ZD6I26, for which recent data show major selective tumour vascular
damage with subsequent hemorrhagic necrosis in both primary and metastatic mouse tumour
models, using cither a single or repeat injections [18, 19]. However, to which extent the
application of this compound results in a broader therapeutic window when compared with
combreAp or AC-7700 remains to be firmly documented.
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V J . CombreAp vascular targeting combined with different anti-cancer treatments
Following the single combreAp injection, after which only a peripheral viable rim of
cells remained, tumours either continued to grow (small sized ones) or re-grew after a certain
time delay (large rhabdomyosarcomas). This was documented with histological analysis for
large tumours as peripheral thickenings or nodular outgrowths. With the small
rhabdomyosarcomas however, the continuing growth was translated as a broad expansion of
the peripheral viable rim. Treatment with a second combreAp injection of these small or large
tumours at a selected stage of (re)-growth, resulted in an additional growth delay, however
without eradication (see Chapter II.2). The failure to fully destroy the tumour, even after a
double combreAp treatment, requires this vascular targeting treatment to be combined with
other anti-cancer therapies such as radiotherapy.
Since the tumour consists not only of hypoxic tumour cells but at least also of oxygenated
proliferating cells, it is obvious to combine radiotherapy with combreAp. The hypothesis is
that irradiation given first would kill (he oxygenated cells, leaving the hypoxic cells to die as
the consequence of vascular targeting induced vessel collapse (see Chapter III.1.1). Our data
support this elegant idea, as they show an increased growth delay with the rat
rhabdomyosarcoma tumour model. Interestingly, these results demonstrate that again the
additional anti-tumour effect was more pronounced with large tumours than with the small
ones. When combreAp was given before or simultaneous with irradiation, no additional
growth delay was observed ; this may be explained on the basis of an increase in (he hypoxic
micro-environment and thus a larger radioresistant cell population. Others have published
similar findings (no enhanced efficacy when combreAp was given before irradiation) with for
example a subcutaneous mouse mammary carcinoma (20). Yet, the proposed theory docs not
seem to fit the overall response of all tumour types. For example with the mouse KHT
sarcoma tumour model also an enhanced efficacy (reduced tumour cell surviving fraction)
was seen when combreAp was given before or simultaneous with a single irradiation [7, 20|.
These opposing data arc difficult to explain unless we assume an important interplay from
intermittent acute hypoxia.
When combinations of cytotoxic or cytostatic compounds with ionising radiation are tested
for their efficacy, it is usual to consider the presence of a broader therapeutic window as
compared with either agent given alone. The published data from Murata and colleagues
demonstrate the absence of any increase in radiation-induced acute mouse skin damage
178 Chapter V
following the combination with combreAp [20]. To further evaluate the important issue of
potential increases of radiation-induced normal tissue damage when combreAp is
administered in combination with irradiation, we used a mouse gastro-intestinal model. The
novel non-invasive methodology that was applied in our experiments specifically assesses the
small bowel injury reflected by a reduction of citrulline concentration in plasma, thus offering
an estimate of the intensity of induced functional damage (Lutgens L e/ a/, proceedings
ESTRO meeting, September 2000, Istanbul, Turkey; and [21]). Citrulline is a nitrogen end-
product of glutaminc metabolism in small bowel mucosa. Combining a single injection of
combreAp with total body irradiation at doses from 2 Gy up to 12 Gy did not change the
plasma citrulline concentration as compared with the measurements for irradiation only (sec
Figure V.3).
Plasma Citrulline concentration
intervention: 100 mg/kg CombreAp
0 3 4 6 8 10 12
whole body radiation dote (Gy)
Combretastatine
l
Rao, - 0,4746
Raq • 0,6393
Total Population
Rao, -0 ,5133
Figure V.3; ßrihi iV/urfrarinx f/if /«cA o/a ma/or c/ian^f /n gatfro-inrrtfi/Ki/ damage,
<wirenrnjfion i/i /»/asmi, in mice fr«i/«/ wi'f/i /ofa/ ixx/v i/Tad/ödon »W/nou/ (0) or
Within the limitations of the selected dosing, sequence and time interval as used in the present
investigation, there seems to be a therapeutic gain, specifically when large tumours are
considered for such a combination (Landuyt W r/ a/, proceedings ESTRO workshop on
Biology of Radiation Oncology, June 2001, Fulgsö, Denmark). However, in view of the
recently published data on the endothelial cell-involvement with early occuring irradiation
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effects in normal mouse intestine [22] and accepting that radiation-damaged normal
endothelial cells may become vulnerable for combreAp activity, further research certainly is
necessary to determine the most favourable treatment criteria in such combinations, including
late effect evaluation. Radiation-induced damage to endothelial cells at clinically relevant
doses was demonstrated as early as the 1980's, and the impact of a vascular component in the
development of late treatment complications in normal tissues co-determines the therapeutic
window.
Our studies combining TNP-470 with combreAp were based on the hypothesis that the
further expansion (observed with small tumours) or the re-growth (with larger tumours) after
the combreAp treatments should be accompanied by renewed angiogenesis (see Chapter
III.1.2). The fact that no significant additional growth delay has been observed when TNP-
470 was administered during the period of tumour growth could possibly be explained by
either an insufficient delivery of the anti-angiogenic drug and/or by a too short duration of
TNP-470 application. This contrasts the combination of repeated TNP-470 intrapcritoncal
injections with hypcricin-based photodynamic therapy (PDT), which resulted in a
significantly longer growth delay of the murine RIF-1 fibrosarcoma tumour when comparing
with the result of either agent alone [23]. Ongoing dedicated studies on differential expression
of genes in tumour versus normal endothelial cells [24] will certainly aid in defining more
efficient combination therapies, for example involving agents interfering with the
extracellular matrix modeling process. For sure, also the combination of vascular targeting
with agents that interfere with endothelial cell growth simultaneously through several
pathways, such as the recently developed angincx [25] deserves further exploration.
Experiments investigating the use of combreAp to further advance the novel anaerobe
bacteria-based therapeutic protein transfer to the tumour micro-environment showed a clear-
cut beneficial outcome (see Chapter III.2). The introduction of the vascular targeting
compound was based on the finding of an increase in anoxia and necrosis. This condition
should hypothetical I y favour the C/as/ru/tum growth and subsequently the expression of the
transferred therapeutical protein in the tumour micro-environment. A first part of our research
dealt with the evaluation of improving the tumour colonisation with apathogenic anaerobe
clostridia (specifically in tumours less than 3 cm*). These small tumours were poorly or not at
all colonised with bacteria following spore administration only. CombreAp was injected 4
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hours after the systemic administration of C/os/rü/iu/n spores, then yielding a bacterial
colonisation level almost equal to the one observed with large tumours. The difference m
bacterial colonisation between combreAp-treated and non-treated tumours was highly
significant, even for tumours much smaller than 1 cm' (p < 0.0001). Of equal importance in
those experiments were the results that indicated absence of C/o5/nV//«m-specific antibodies
in serum of the treated tumour-bearing rats. The lack of induced immune response allows
repeated administration with similar colonization, even if a clinical reason necessitates an
intermittent arrest of the bacterial application.
The second scries of investigations was carried out to define, separately from the colonisation,
the potential improvement of the intra-tumoural expression of the stable therapeutic cDNA
construct from the use of a single combreAp treatment. These experiments involved the £.
cw/i-cytosine deaminase (CDase). This enzyme converts the non-toxic prodrug 5-
Fluorocytosinc (5-FC) to the cytotoxic 5-Fluorouracil (5-FU), cloned in-frame with the
clostripain promoter into a £. co/i/C. acf/ofcMf>'/'c«'" shuttle vector. The results clearly
«jd.vi'*.<r A\»ÄWIV>' V'A*" I'lte pAwmÄi <w »eiY <ts expression of CDase in aff the combreAp-treated
tumours. A significantly improved intra-tumoural conversion efficiency of 5-FC to 5-FU was
measured (thin layer chromatography), as compared to tumours not treated with combreAp.
As expected, based on previous research of our group [26], no proliferating bacteria nor 5-FU
were detectable in normal tissues of the combination-treated tumour-bearing rats. Further
indication for the in vivo anti-tumoural efficacy from this novel combination strategy has been
offered by Liu and colleagues [27]. In their study using a mouse squamous cell carcinoma, a
stronger growth delay was measured with the C. sporogenes CDase-5-FC system as compared
with daily systemic 5-FU injection at MTD for 5 days. Combining a vascular targeting
compound with the bacterial enzymc-prodrug system may, apart from the advantages
presented and discussed in the thesis research (Chapter III.2), improve the anti-tumour
efficacy of the 5-FU. Grosios and colleagues [28] indeed demonstrated the enhanced anti-
tumour effect in a mouse colon adenocarcinoma from the combination of combreAp with
systemic 5-FU treatment.
Our data and the results of research colleagues from the Stanford University School of
Medicine (USA) taken together demonstrate the potential of the novel anti-cancer strategy,
likely to gain benefit from combination with radiotherapy. Indeed, (i) the chemotherapeutic
compound 5-FU is known to 'sensitize' cells for improved ionising radiation efficacy, as
demonstrated in many publications (e.g. review [29]). Furthermore, because 5-FU has a high
diffusion capacity and because continuous infusion is shown to be the most effective delivery
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system, the anaerobe bacteria-based CDase-5-FC treatment strategy with 5-FU production
selectively in the tumour micro-environment should permit a beneficial therapeutic window;
and (ii) the use of a radiation-inducible promotor of the highly conserved SOS-repair system
of £. co/i (e.g. recA gene) further enhances the tumour-selectivity of these anaerobe
recombinant bacteria (e.g. [30, 31]). Indeed, this should limit the expression of a therapeutic
protein only within the defined, irradiated, tumour volume and in a time-dependent way. This
procedure should moreover result in reduced or absent normal tissue reactions which are seen
with the classical combination of systemically given 5-FU with radiotherapy.
Other developments in the bacteria-based transfer of therapeutic proteins are offered by the
use of e.g. ßj/jdofcacrer/'um /ong«m [32] or attenuated Sa/mo/ir/Za Typhimurium, engineered
to express CDase in the tumour micro-environment (e.g. [33]). High tumour to normal tissue
ratios were observed in their pre-clinical investigations with mice and large animals, us well
as in our rat study [34]. Our study moreover indicates that an optimal 'therapeutic bacteria
dose' can be defined and that the tumour-colonizing recombinant 5a/mon?//<i (VNP20047)
produced 5-FU selectively in the tumours and not in any normal tissues. These data, together
with published results from combining X-ray irradiation (5-15 Gy single dose) with
attenuated Sa//no/iW/a (VNP20009), non-recombinant for CDase, thus indicate the potential
gain that may be obtained from the combination of recombinant bacteria and irradiation [35].
Even more so in the attenuated Sa/monW/a setting, the introduction of a radiation-inducible
promoter will advance the spatial control and allow the temporal switch for therapeutic
protein expression.
V.4. Non-invasive imaging of intra-tumoural oxygenation
Hypoxia- and blood vessel-related treatments necessitate a firm knowledge of (i) the
tumour micro-environment, (ii) the potential modulation of these parameters and (iii) the
temporal follow-up of induced changes. The modulation of the intra-tumoural oxygen tension
when applying for example cither carbogen breathing or recombinant EPO administration,
does increase the sensitivity of tumour cells to e.g. radiotherapy, but not equally with all
tumours. The end-result of individual tumour screening should therefore enable tailored
therapy combinations, and a reduction of the chances of treatment failure, while also avoiding
unnecessary addition of treatment.
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It is well known that heterogeneity of oxygenation is present in all tumour types. Evidence
has been provided using for example the Eppendorf polarographic needle electrodes w
measure pO2 or antibody-based staining of hypoxic cells in pre-clinical and patient studio
These studies also indicated that unfortunately the heterogeneity was also often strongl'
present within the individual tumours, whatever the type or the site of growth. Thr
heterogeneity has also been observed in the subcutaneous implanted rat rhabdomyosarcom'
using immunohistochemical staining and fibre-optic microprobe pCh measurements (Oxylite
Oxford Optronix.UK). A global and fast picture may allow a more optimal tumou
stratification for such individualized treatment. Functional MRI using the BOLF
methodology provides a complete non-invasive screening with both spatial and tempori
tumour physiology information.
The application of EPI sequences in T2*-weighted functional MRI allows us to examine tfr
entire tumour and body in a multi-slice way, and thus provides a comprehensive evaluation d
responses to external stimuli. However, the optimal balance between spatial and tempor*!
resolution remains a ueiicaie item wncn using ine 12'-weigmeu imaging in e n . opaiial
resolution is reduced by geometric distortion and susceptibility artefacts related to the air-
tissue interface. We demonstrated that a practical and rapid mold technique, using a fast
setting alginatc, objectively reduced these problems (see Chapter IV.l). Indeed, improved
T2*-wcighted image quality and delineation of anatomical structures under investigation was
obvious. Separately from the rat tumour study, the objective improvement of image quality
was also seen in the larger-animal study of brain function after external stimuli, a result that
indicates its broader applicability in this radiological analysis.
Subsequently, the results of a separate series of experiments using BOLD fMRI with GE-EPI
(TE39) operating at 1.5 Tesla (see Chapter IV.2), and incorporating the mold technique,
provided good evidence for the feasibility to image tumour oxygenation changes from
carbogen breathing of the host. Changes in intensity of the T2* weighted images were very
rapidly seen after the start of the carbogen breathing. The data indicate that the quantity of
hypoxia modulation was not dependent on the tumour size; inter-, but also intra-tumoural
variability was found. An additional advantage of our method is the possibility to detect
paradoxical responses to carbogen breathing instantaneously within an individual tumour. The
combined analysis of the tumour volume showing intensity changes (voxel number) together
with the change in intensity within the responding voxels allowed the selection of those
tumours that significantly reacted favourably.
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Our functional MR measurements involved a clinical apparatus (1.5 T) and therefore the
present application can be considered feasible in terms of patient translation. The BOLD MR
methodology has very recently been demonstrated to be a valuable tool to study tumour
oxygenation status and modulation in a patient group which involved different tumour types
and sites of growth [36]. Though this was a single slice evaluation using T2*-weighted
gradient-echo imaging on a 1.9 Tesla scanner, the data also indicated inter-tumour variability
of carbogen response even for tumours of the same type and similar location. Some tumours
showed a high signal intensity change, while for others this was very small. Similar
observations were made in pre-clinical rodent tumour models by the same research group as
well as other teams using the gradient-echo single slice MR technique.
Not unimportantly, the recent introduction of stronger magnetic fields (well above 2 T) in
clinical radiology may broaden the applicability of the fast whole body BOLD fMRI. Indeed,
their use should improve resolution (smaller voxel and increased signal-to-noise performance)
and thus the modelling of physiological oxygenation changes.
Since the methodology is completely non-invasive, changes can be evaluated in time. This is
very important, as some recently published small-scale clinical studies using dynamic MRI
indicated the necessity to evaluate tumour micro-environment before and during the course of
treatment.
Temporal information in addition to established parameters of tumour response may, whilst
gaining prediction of the result of the ongoing treatment, ultimately guide treatment.
V.5. Perspectives
Treatment resistance is, apart from intrinsic cellular characteristics, to an important extent due
to the physiologic and biochemical heterogeneity within tumours. Presently, strong interest in
morphological and functional parameters that define the difference between tumour and
normal tissue vasculature and its relationship with the oxygenation status of tumours evolves
into the use of this information for treatment selection and prognosis evaluation.
Throughout the discussion parts of the present thesis research, the potential benefit from using
the proposed novel approaches in clinical oncology has been indicated. It is at the same time
however realized that several shortcomings still remain to be resolved to optimize such
strategies. Also research about the complementary information on tumour oxygenation and its
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relation with the vascularity, which can be gained by using different invasive and non-
invasive techniques, needs much more in-depth documentation for various tumour types.
The prc-clinical studies demonstrated the disruption of the intra-tumoural blood supply, either
through anti-angiogenesis or vascular targeting methodologies, which significantly resulted in
tumour cell loss. It was clearly shown in the present thesis research that the combreAp
vascular targeting activity was stronger against larger rat rhabdomyosarcoma tumours as
compared with small ones. Although this very interesting aspect (the reverse efficacy as
observed with for example radiotherapy) has been reported to some extent with the mouse
KHT sarcoma model by D.W. Siemann (invited lecture, ESTRO Radiobiology Workshop,
June 2001, Fulgso, Denmark), more information is necessary to explain and to firmly
establish this characteristic with other tumour models. Already, the issue of large tumours
being attractive for the combreAp vascular targeting activity can be deduced to some extent
from the phase I study, data that have been reported very recently [17]. The knowledge about
tumour size involvement in vascular targeting treatment will become even more important
when combination therapies are introduced.
Combining the tubulin-intcrfcring compounds such as combreAp, which are active at doses
below MTD, with radio- or chemotherapy or anti-angiogenesis seems promising. But this
aspect needs more prc-clinical elaboration before such strategies can safely enter clinical
trials. Published results and data offered by the present thesis research indicate an increased
anti-tumour effect with single dose combinations. Based on these results, the combination of
vascular targeting with ionizing radiation, both fractionated and at clinically relevant doses,
can provide a broader therapeutic window but only when the appropriate scheduling is used.
The latter has to delicately take into account the different changes in oxygenation resulting
from both treatments in order to avoid a reduced efficacy of either agent. The fact that such
fractionation combinations can be advantageous towards tumour cell death has been indicated
very recently by a mouse KHT sarcoma study of Siemann and Rojiani [181. Injecting the
novel vascular targeting compound ZD6126 twice during a 10-fraction radiation treatment,
the authors measured a significantly increased growth delay (with very small tumours at
treatment start) as compared with ionising radiation only. Again, such an improvement may
be tumour type dependent, as it may relate to differences in oxygenation changes during
radiotherapy. Indeed, we did not find a change in the radiation-induced growth delay of the
small rat rhabdotnyosarcoma when fractionated radiation treatment was combined with the
vascular targeting combreAp (abstract 354, proceedings ESTRO meeting, Istanbul. September
2000). The increase in local tumour control from the combined combreAp and fractionated
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irradiation had borderline significance in comparison with radiotherapy alone in the C3H
mouse mammary carcinoma study of Murata and colleagues (abstract 3S3, proceedings
ESTRO meeting, Istanbul, September 2000).
Furthermore the combination of blood vessel targeting modalities with the classical therapies
necessitates the study of normal tissue responses (c/r. supra: general discussion). The
involvement of blood vessel damage induced by ionizing radiation has been well recognized
to play a major role in the development of consequential as well as late occurring normal
tissue defects. The recently published data on intestinal crypt damage in mice demonstrate the
involvement of radiation-induced endothelial lesions also in the evolution of this acute dose-
limiting side effect [22]. Absence of an increased radiation-induced acute (e.g. gut) and late
(e.g. lung) normal tissue effect has been suggested by us (c/r. supra Chapter V) and by
Horsman and colleagues (presentation at ESTRO meeting, Prague, September 2002). Yet,
these studies involved single dose treatments only, as well as a single time interval between
both agents. Therefore, results from experiments including fractionation and prolonged drug
use, including different sequencing, are of major importance for safety and eventual
establishment of the therapeutic window. Of interest in (his context arc (he results published
by Park and colleagues, describing the increased mitogen activated protein kinusc-dcpcnclcni
VEGF expression in glioblastoma cells but also in primary astrocylcs and (his following
exposure (o a radiation dose of 2 Gy [37]. The understanding of gene expression changes that
occur after irradiation, such as VEGF, will further improve the combined use of radiotherapy
with either vascular targeting or anti-angiogenesis or even the triple combination.
An additional hypothesis that deserves stringent research is the combination of vascular
targeting with biorcductive compounds. The latter may indeed kill tumour cells in transient
hypoxic condition that is induced by the vascular targeting activity. Although normal tissue
toxicity could limit the applicability, as reported by Lash and colleagues (38) when however
DMXAA was combined with various bioreductive drugs, the type of combination remains
attractive and should be examined with the tubulin-interfering systcmically less toxic
compounds such as combreAp. Such a treatment may circumvent the reduced efficacy of
classical therapies that is the result of hypoxia-relatcd resistance and changes to a more
malignant phenotype (the latter problems are nicely reviewed by e.g. [39)).
As indicated in the general discussion, several directions to improve the bacteria-based
therapeutic gene transfer need experimental evidence. One of these involves the non-invasive
assessment of the intra-tumoural expression of the transferred active protein. Regarding the
CDase-5-FC strategy, the non-invasive '*F MRS is the most attractive methodology. The
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potential utility has already been demonstrated in other treatment conditions both in vitro and
in vivo; for instance to measure the 5-FU metabolism following the systemic injection of the
chcmothcrapeutic drug, or to evaluate the conversion of 5-FC to 5-FU by the CDase (e.g. [40-
42]). The parallel evaluation of the 5-FC conversion and the growth changes in tumour
bearing rodents is under investigation by us.
Due to the ongoing development of tumour vessel-based therapies and due to the need for
non-invasive screening of individual tumours before, during and after any therapy, the
refinement of functional and contrast-based dynamic MRI and PET is a pre-requisite in
oncology. Specifically the evaluation of the complementary information that may be gained
on tumour micro-environmental characteristics and their modulation when using different
methods of analysis will enable treatment guidance and reduce the chances of failure. This
could be possible by relating for example the oxygenation and metabolic condition with the
vascular function and with the proliferation characteristics for an individual tumour and for
different tumour types. These aspects have been indicated to some extent in the literature, as
weJJ jc$anlix£' j.te JJATOGW .ra\LTOs?rc»iTO«TiTiwrr( v'er.#. i'-f?-45j7 as in relationship with the MRI
evaluation of vascular targeting effects [46, 47]. The bottom line: a close-to-ideal concept for
the future planning is to further evaluate the efficacy of novel anti-tumour strategies using
stringently documented and complementary non-invasive imaging methodologies.
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Samenvatting
De intense ccldclingsactivitcit inherent aan de groei van tumoren noodzaakt een
afdoende en constante beschikbaarhcid van voedingsstoffen en zuurstof. Initieel zorgen
gcc(K>ptcerdc en nahegelegen vaatstructuren voor deze aanvoer, maar al snel ontstaat een on-
evenwicht met dc tumoruitbreiding wat resulteert in hypoxische regio's. Via de produetie van
hypoxic-gcmcdieerdc angiogene factoren wordt de ontwikkeling van nieuwe bloedvaten uit
dc bestaande vasculatuur geinduceerd. Op deze wijze kunnen tumorcellen overleven en kan
het proces van cclproliferatie voortgaan of hervatten. Juist deze verschillende belangrijke
stappen in dc vicieuse cirkcl van lokale tumorexpansie zijn het aanknopingspunt voor nieuwe
methoden in bchandcling en diagnose van vaste tumoren.
Ook hcl ondcrzoekswerk beschrcven in de voorliggende thesis relateerd gebruikt
karaktcristicken van de tumoralc micro-omgeving voor het testen van gerichte therapie en
diagnose.
In hoofdstuk I.I worden specifieke parameters van de tumorale micro-omgeving
gcdefinieerd.
In de ccrstc plaats en voornamelijk in relatie met het gepresenteerde onderzoek, zijn een
auntal aspecten van tumorale vaat-gcrichte bchandelingen in het kort geschetst. Steunend op
dc tot hicrtoc gekende actiemechanismen wordt onderscheid gemaakt tusscn 'anti-
ungiogenese' en 'vascular targeting'. Produkten met anti-angiogene eigenschappen
verhinderen de vorming van nieuwe bloedvaten, terwijl vascular targeting Stoffen selectief de
bestaande, siecht ontwikkclde, intra-tumoralc bloedvaten beschädigen en vernietigen.
Naast dc cnkclvoudigc tumorbehandeling met zulk een produkt, wordt de potentiele
vcrruiming van het therapeutisch venster via een combinatic met een klassieke
behandclingsmethode (bijvoorbccld radiothcrapie) in het kort besproken.
Vcrdcr wordt het belang en het evalucren van hypoxie in vaste tumoren uitgelegd in functie
van tumor evolutic en bchandcling. Vooral wordt aandacht besteed aan invasieve versus niet-
invasicve mclhixlcn om hypoxie in kaart te brengen.
Aansluitcnd worden dc bclangrijkstc bchandelingsmogelijkheden gericht op de intra-tumorale
hypoxic. zoals het toedienen van bioreductieve produkten. bondig voorgestcld. Specifiek
wordt dc achtcrgrond voor het gebruik van anaerobe apathogene clostridia als transfersysteem
van cen therapeutisch proteine naar dc tumorale micro-omgeving uitgelegd. Tevens wordt de
Samenvaiting en lijst van publicaties 193
mogelijkheid van hypoxie modulatie door gebruik van bijvoorbeeld een zuurstofrijk gas of
een vasodilatator belicht.
Tot slot worden in hoofdstuk 1.2 de doelstellingen met inhoudelijke hypothesen voor het
thesisonderzoek geschetst.
Hoofdstuk II beschrijft de resultaten van /n v/vo cxperimenten ener/.ijds met de
angiogenese-inhibitor TNP-470 en anderzijds met de vascular targeting stof combrctastatin A-
4 fosfaat. Ondermeer omwille van het verschil in specifieke actie voor beide bloedval-gcrichle
behandelingen is het zeer belangrijk hun effecten in tumoren van verschillende grootte te
onderzoeken.Voor dit onderzoek werd de syngene WAG/Rij rat rhabdomyosarcoma tumor
(Rl cellijn) gebruikt, waarbij longitudinaal voor de verschillende experimenten een
onderhuidse inplanting van 1 mm' stukje weefsel in de abdominale flank gebcurdc. Tumor
volumina varierend tussen 0.1 cm* en meer dan 20 cm* werden bcoogd, en als volgt
ingedeeld: <1 cm* (zeer klein), 1-3 cm' (klein), 3-7 (medium), 7-14 cm' (groot) en >14 cm'
(zeer groot).
Een significante groeivertraging (p< 0.01) werd gemctcn na het ondcrhuids tocdicnen (om de
twee dagen, 5x) van de maximum tolereerbarc dosis TNP-470 bij tumoren kleiner dan 7 cm'
(hoofdstuk II.1). Er was geen verschil in groeivertraging voor de kleine tumoren tegenovcr
dc medium grocp. Bij de tumoren groter dan 7 cm' werd een groeivertraging slcchts
vastgesteld wanneer de TNP-470 dosering gepaard ging met een ernstigc lokale huidlacsic op
de plaats van de onderhuidse inspuiting alsmede systemischc toxiciteit onderdc vorm van een
blijvend gewichtsverlies van ruim 15 %. Een lagere dosering minder frequent gegeven
(minimale en transiente toxiciteit), induceerde groeivertraging cnkcl bij rhabdomyosarcoma
tumoren kleiner dan 7 cm'. Rechtstreeks vergelijk met gcpublicccrdc rcsultatcn en dus met
andere in vivo tumor modellen is niet mogelijk, aangezien deze prc-klinischc studies cnkel bij
tumoren kleiner dan 1 cm' werden uitgevoerd. TNP-470 bleek evenwel in dezc studies zeer
aktief te zijn bij zowel pnmaire tumoren (syngene en humane xenografts) als bij mctastascn.
Ook klinische studies (fase I tot III) toonden belangrijke anti-tumorale effecten door
toedienen van TNP-470. Recent werd het klinisch gebruik van dezc angiogenese remmer
echter stopgezet, waarschijnlijk omwille van een ongunstige balans tussen intra-tumorale
activiteit en ernstige nevenwerkingen (c^-. jupra onzc Studie).
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In hoofdstuk II.2 worden de resultaten beschreven van de in vivo experimenter! met ha
onderhuids groeiend rat rhabdomyosarcoom na behandeling met de vascular targeting stof
combretastatin A-4 fosfaat (combreAp), een intracellulair tubuline-interfererend molecule.
Het toepassen van vascular targeting als anti-kanker behandeling is op zieh een gekendc
strategic. Vooral hyperthermie, en ook fotodynamische therapie, zijn niet enkel rechtstreeks
tumor ecldodend maar zijn tevens gekenmerkt door het aanbrengen van bloedvatschade
Bclangrijkc bcrpcrkingen van deze modaliteiten zijn (i) dat alleen oppervlakkige tumoren (of
intra-opcratief bcrcikbarc tumoren) kunnen worden behandeld, en (ii) het afwezig zijn van
selectieve activiteit in het tumorweefsel. Het gebruik van producten die systemisch worden
tocgediend en sclcctief de tumorvaten beschädigen, zoals combreAp, kunnen een brederc
tocpassing kennen.
Na cen einmalige intrapcritoncalc inspuiting van combreAp aan 1/3 MTD is een snelle en
stcrkc vcrmindcring van het aantal blocdvaten zowel histologisch als angiografisch
gcdocumcntcerd. Deze emstig vaatschadc wcrd gevolgd door een uitgebreide
necroscvorming, ongcacht het tumorvolume op het ogenblik van de combreAp inspuiting. De
door combreAp aangcbrachte intra-tumorale vaatschadc en necrose kan best worden
vcrgelckcn met de resultaten na gebruik van tumor necrosis factor alfa (TNFct). Een
belangrijk vcrschil cvenwel is de afwezigheid van systemische toxiciteit bij een combreAp
dosering met toch een sterk anti-lumoraal effect.
Deze stevigc combreAp-gcinduceerde schade werd echter niet vertaald in een algemene
groeivertraging of rcgrcssie van de bchandclde tumoren. Bij zeer kleine en kleine tumoren
(<3 cm*) werd geen significantc verandering in de groeisnelheid gemeten; de grotere tumoren
(vooral deze >7 cm') vertoonden een zeer significante groeivertraging (p=0.001). Deze tumor
volumc-ufhankclijke rcsultaten zijn precies het omgekeerde van de resultaten na radio- of
Chemotherapie. Bij deze laatste behandelingsmodaliteiten zijn grotere tumoren veel slechterof
nict bchandclbaar vcrgclcken met de kleine, en dit vooral door de ontwikkeling van in-
efficientc vasculatuur en daannee gepaard gaande hypoxie. Het feit dat grotere tumoren
vatbaarder zijn voor combreAp op basis van een belangrijker aantal siecht gevormdc
bloedvatcn kan ccn uitleg zijn voor deze omgekeerde resultaten in vcrgelijking met radio- en
Chemotherapie. Mogelijks zijn in grotere tumoren een grotere proportie tumorcellen
afhankclijk van elk intra-tumoraal blocdvat, of zijn veranderingen in interstitiele druk mede
de oorzaak van deze resultaten. Andere vcronderstellingen die de volume-respons relatie
medc kunnen verklaren zijn gerelateerd aan een hypoxie-gemedieerde verandering van de
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combreAp activiteit of aan een direct cytostatisch effect van de stof voor de tumorale cellen.
Vergelijkingen met literatuurgegevens betreffende tumor groeivertraging of tumorcontrole na
combreAp behandeling zijn niet evident, want in zowat alle bekende studies werden allcen
zeer kleine tumoren onderzocht.
Het gebruik van een dubbele combreAp toediening (met 1 week interval) resulteerde, zij het
minder duidelijk dan bij de einmalige toediening, eveneens in een tumorvolume-afhankelijke
effect. Grotere tumoren waren ook hier vatbaarder voor combreAp dan kleinere. Een
bijkomende bevinding was dat kleine tumoren dus ook een groeivertraging vertoonden na een
herhalingsbehandeling met een gelijke dosis combreAp.
Hoofdstuk III toont de resultaten van verschillende reekscn cxperimentcn wuarbij
combreAp werd gecombineerd met een andere vorm van anti-kanker behandeling.
Zoals duidelijk is uit dc gegevens beschreven in hoofdstuk II.2, inducccrt combreAp als
monotherapie niet een algemcne necrose en is er dus gcen tumor cradicatic. Aan dc rand van
de rhabdomyosarcoma tumoren blevcn een aantal tumorcellen overleven, en is hcrgroci vanuit
die regio's dan ook logisch.
De combinatie met ioniserende straling is uiteraard de ccrste kcu/.c. Dit houdt verband met dc
hypothese dat cellen in de buitenste schil van de tumor voldocndc van /uursiol en
voedingsmiddelen zijn voorzien, en dus stralingsgcvoelig zijn. Dc resultaten wijzcn op ccn
duidelijk tumor volume-afhankelijk effect (hoofdstuk III.l): bij grotc tumorcn (>7 cm') wcrd
een belangrijke bijkomende groeivertraging gemcten in vcrgclijking met de vrij effectieve
bestraling alleen. Kleinere tumoren (<3 cm') vertoonden een nict-significantc of afwe/.ige
verandering van dc groeisnelhcid. In al deze experimenten werd dc einmalige bestraling ccrsi
gegeven, om intra-tumorale inductie van hypoxie door combreAp (en dus stralingsrcsistcntic)
te vermijden. Het gebruik van combreAp vooraf aan dc bestraling, of zelfs gclijktijdig
gegeven, leidde niet tot een vcrlengde groeivertraging
Tijdens de hergroei van de rhabdomyosarcoma tumoren was cr een duidelijkc loename van
het aantal bloedvaten (vooral perifeer), zoals in beeld gebracht met de digitale subtractic
angiografie techniek (zie hoofdstuk II.2). Het verhinderen van deze revascularizatie zou
moeten leiden tot een afremming van de tumorgroei. Op basis van deze hypothese wcrd 1 dag
na combreAp de angiogenese remmer TNP-470 gedurende I week dricmaal loegediend. Deze
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reeks experimenten (hoofdstuk III.l) wees op een zeer beperkte bijkomende gToeivertraging,
ongeacht het tumor volume bij de start van de behandelingen. Mogelijks is de afwezigheid
van een duidelijk effect het gevolg van een nog to geringe hergroei van de vasculatuur bij de
meesle tumoren gedurende de eerste week na de combreAp toediening.
De combinatie van combreAp met een nieuwe recent ontwikkelde anti-kanker strategic met
name het gcbruik van anaerobe apathogenc clostridia met selectieve transfer van
therapeutische protemen naar vaste tumoren, werd eveneens onderzocht (hoofdstuk III.2.A
en B). Ondcr andere binnen onze onderzoeksgroep werd dit bacterieel systeem met
C7o5rru//M/n op punt gesteld voor transfer van het suicide gen cytosine deaminase (CDase) en
het cytokine tumor necrosis factor (TNF) a. Met deze combinatie werd een verbreding van
hel bacterieel systeem-gerelateerd therapeutisch venster beoogd op basis van intra-tumorale
kolonisatic verbetering. De hypothese was dat combreAp necrose induceert, ook in zeer
kleine tumoren, waardoor de kolonisatie en potentieel ook de prote'ine expressie wordt
gcoptimalisecrd. Daarnaast werd binnen het kader van therapeutische optimalisatic ook
gckeken naar mogclijke 1/1 v/vo toxische effecten. Het gebruik van combreAp resulteerde in
een uitstckende C7o.vrm//um kolonisatie van alle tumoren, ook de zeer kleine, equivalent aan
dc kolonisatic gemcten in grotc tumoren niet behandeld met combreAp. In een parallelle reeks
experimenten werd de afwezigheid van een duidelijke immuunreactie aangetoond: niet-
significante C/ar/rit/iu/n-specifieke antilichaam conccntratie in serum van dc proefdieren en
gcen stijging van de rectale temperatuur. Tevens werd aangetoond dat, indien nodig, de
clostridia kunnen worden verwijderd met een specifiek antibioticum zoals metronidazole. De
verdcre evaluatie van een mogelijke winst door het combineren van combreAp met het
anaerobe bacterie transfer systeem gebeurde door het meten van de intratumorale expressie
van het CDase. Dit enzyme zorgt voor de omzetting van het schimmelwerend 5-
Fluorocytosine (5-FC) tot het cytotoxisch 5-Fluorouracyl (5-FU). De combinatie van
combreAp met de clostridia recombinant voor het CDase resulteerde in een stabiele en sterk
verbeterde proteine expressie in alle onderzochte tumoren. De CDase expressie was, zoals
gcanticipecrd werd. afwezig in al de onderzochte normale weefscls van de met dcze
combinatie thcrapie behandelde tumordragende proefdieren.
Het is nuttig de rcsultatcn bekomen met de bloedvat gerichte behandelingen. al dan
niet in combinatie met een klassieke anti-kanker thcrapie, in iedere tumor longitudinaal te
kunnen volgcn. Het is eveneens noodzakclijk dat een selectie van tumoren kan gebeuren voor
Samenvauing en IIJSI van publicaties 197
een optimaal gebniik van bijvoorbeeld het anaerobe bacterie-gemedieerde therapeutisch
proteine transfer systeem. Een snelle en degelijke selectic van tumoren die potentieel in
aanmerking kunnen komen voor hypoxie-modulerende Stoffen zoals hyperoxische gassen en
vasoactieve produkten is eveneens gewenst. In dit kadcr is het gebruik van een niet-invasieve
sreening techniek zoals magnetische resonantie beeldvorming (MRI), welke zowel snel als
volledig tumor-omvattend is, zeer belangrijk. In hoofdstuk IV wordt een specifieke
loepassing van MRI, gesteund op "blood oxygen level dependent" (BOLD) endogeen
contrast, voor het evalueren van tumor hypoxie en de modulatie hiervan met carbogcengas
(95 % O2 + 5 % CO2) onderzocht. Dit onderzock gebeurde met een in de klinische radiologie
gcbruikt apparaat, een totaal lichaam 1,5 Tesla MRscanner.
Het toepassen van snelle sequenties (hoge temporale rcsolutic), zoals mogclijk met echo
planar imaging (EPI), resulteert echter in een verlies van spatialc rcsolutic. Dc bckomen
suboptimale kwaliteit van de T2*gewogen beeiden is ook het resultaat van geometrische
distortie ten gevolge van susceptibilitcits-artcfactcn, zoals die kunnen ontstaan op luchl-
weefsel overgangen. Door gebruik te maken van ccn socpcl blijvend alginaat, dat over het te
evalueren lichaamsdeel werd aangebracht, kon een ohjccticvc vcrbctcring van dc
beeldkwaliteit worden bckomen (hoofdstuk IV.1). Dezc gegevens toncn duidclijk dc winst
voor functionele MRI (fMRI) door gebruik tc maken van zulk een alginaat in zowcl
oncologisch als neurologisch onderzock bij proefdiercn.
In een aparte reeks experimenten werd dc haalbaarhcid en gcvoclighcid van dc fMRI techniek
getest bij WAG/Rij ratten met het onderhuids rhabdomyosarcoom (hoofdstuk IV.2). Met
deze methode werden meerderc sneden gemaakt doorhcen het vollcdigc volume van dc
individuele tumoren, terwijl de proefdieren of met lucht of met carbogcen werden beademd.
De evaluatie van de voxelintensiteit, als vertaling van dc BOLD veranderingen ten gcvolgc
van carbogeen beademing, was voor alle tumoren mogclijk doorhcen het gansc volume. Dc
läge signaal-ruis ratio werd gecompenseerd door het snelle opecnvolgcnd hcrhalcn van dc
metingen en door analyse van deze metingen met een aangepast statistisch pakket (SPM96).
De Ti'gewogen beeiden toonden verschillen in intcnsileitsvcrandcringen ten gcvolgc van
carbogeen, zowel binnen dezelfde tumor als tussen de verschillcndc tumoren (ook dcze met
een vergelijkbaar volume). De verandering in intensiteit was zeer akuul na dc start van de
carbogeen beademing. maar echter niet voor alle tumoren even sterk. Tcvens had het gebruik
van carbogeen bij enkele tumoren een negatief effect (vcrmindering in signaalintcnsitcit), wat
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kan worden tocgeschreven aan een 'stelen van zuurstof binnen de tumor of binnen he
omliggende weefsel. Op basis van de gecombineerde metingen van (i) het volume, aanta
voxels, van intensiteitsvcranderingen en (ii) de grootte van deze intensiteitsveranderinj
kunnen individuele tumoren met een globaal positief antwoord op carbogeen beademinj
worden uitgczocht. De niet-invasieve fMRI methode blijkt een snelle evaluering van di
modulatie van hypoxie toe te laten, en dit voor het totale tumorvolume.
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